<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus - Madsen, KS - 2019 | Cochrane Library</title> <meta content="Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus - Madsen, KS - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012368.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus - Madsen, KS - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012368.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012368.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus" name="citation_title"/> <meta content="Kasper S Madsen" name="citation_author"/> <meta content="University of Copenhagen" name="citation_author_institution"/> <meta content="kasperstaberg@gmail.com" name="citation_author_email"/> <meta content="Pernille Kähler" name="citation_author"/> <meta content="Faculty of Health and Medical Sciences" name="citation_author_institution"/> <meta content="Lise Katrine Aronsen Kähler" name="citation_author"/> <meta content="University of Copenhagen" name="citation_author_institution"/> <meta content="Sten Madsbad" name="citation_author"/> <meta content="Hvidovre Hospital, University of Copenhagen" name="citation_author_institution"/> <meta content="Filip Gnesin" name="citation_author"/> <meta content="Department 7652, Rigshospitalet" name="citation_author_institution"/> <meta content="Maria‐Inti Metzendorf" name="citation_author"/> <meta content="Institute of General Practice, Medical Faculty of the Heinrich‐Heine‐University Düsseldorf" name="citation_author_institution"/> <meta content="Bernd Richter" name="citation_author"/> <meta content="Institute of General Practice, Medical Faculty of the Heinrich‐Heine‐University Düsseldorf" name="citation_author_institution"/> <meta content="Bianca Hemmingsen" name="citation_author"/> <meta content="Institute of General Practice, Medical Faculty of the Heinrich‐Heine‐University Düsseldorf" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD012368.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/04/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012368.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012368.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012368.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Diabetes Mellitus, Type 2 [*drug therapy]; Drug Therapy, Combination; Hypoglycemia [chemically induced]; Hypoglycemic Agents [*therapeutic use]; Metformin [*therapeutic use]; Sulfonylurea Compounds [*therapeutic use]; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012368.pub2&amp;doi=10.1002/14651858.CD012368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ytRBD0EW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012368\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012368\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012368\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012368\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","fr","fa","es","zh_HANS","ru","ms","de"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012368.pub2",title:"Metformin and second\\u2010 or third\\u2010generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus",firstPublishedDate:"Apr 18, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Metabolic and Endocrine Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012368.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012368.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012368.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012368.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012368.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012368.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012368.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012368.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012368.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012368.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11733 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012368.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/full#CD012368-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/full#CD012368-sec-0240"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/full#CD012368-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/full#CD012368-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/full#CD012368-sec-0036"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/full#CD012368-sec-0037"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/full#CD012368-sec-0076"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/full#CD012368-sec-0234"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/appendices#CD012368-sec-0245"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/table_n/CD012368StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/table_n/CD012368StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/information#CD012368-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Kasper S Madsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/information#CD012368-cr-0003">Pernille Kähler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/information#CD012368-cr-0004">Lise Katrine Aronsen Kähler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/information#CD012368-cr-0005">Sten Madsbad</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/information#CD012368-cr-0006">Filip Gnesin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/information#CD012368-cr-0007">Maria‐Inti Metzendorf</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/information#CD012368-cr-0008">Bernd Richter</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012368.pub2/information#CD012368-cr-0009">Bianca Hemmingsen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/information/en#CD012368-sec-0269">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 April 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012368.pub2">https://doi.org/10.1002/14651858.CD012368.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012368-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012368-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012368-abs-0011">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012368-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012368-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012368-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012368-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012368-abs-0001" lang="en"> <section id="CD012368-sec-0001"> <h3 class="title" id="CD012368-sec-0001">Background</h3> <p>The number of people with type 2 diabetes mellitus (T2DM) is increasing worldwide. The combination of metformin and sulphonylurea (M+S) is a widely used treatment. Whether M+S shows better or worse effects in comparison with other antidiabetic medications for people with T2DM is still controversial. </p> </section> <section id="CD012368-sec-0002"> <h3 class="title" id="CD012368-sec-0002">Objectives</h3> <p>To assess the effects of metformin and sulphonylurea (second‐ or third‐generation) combination therapy for adults with type 2 diabetes mellitus. </p> </section> <section id="CD012368-sec-0003"> <h3 class="title" id="CD012368-sec-0003">Search methods</h3> <p>We updated the search of a recent systematic review from the Agency for Healthcare Research and Quality (AHRQ). The updated search included CENTRAL, MEDLINE, Embase, ClinicalTrials.gov and WHO ICTRP. The date of the last search was March 2018. We searched manufacturers' websites and reference lists of included trials, systematic reviews, meta‐analyses and health technology assessment reports. We asked investigators of the included trials for information about additional trials. </p> </section> <section id="CD012368-sec-0004"> <h3 class="title" id="CD012368-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) randomising participants 18 years old or more with T2DM to M+S compared with metformin plus another glucose‐lowering intervention or metformin monotherapy with a treatment duration of 52 weeks or more. </p> </section> <section id="CD012368-sec-0005"> <h3 class="title" id="CD012368-sec-0005">Data collection and analysis</h3> <p>Two review authors read all abstracts and full‐text articles and records, assessed risk of bias and extracted outcome data independently. We used a random‐effects model to perform meta‐analysis, and calculated risk ratios (RRs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes, using 95% confidence intervals (CIs) for effect estimates. We assessed the certainty of the evidence using the GRADE instrument. </p> </section> <section id="CD012368-sec-0006"> <h3 class="title" id="CD012368-sec-0006">Main results</h3> <p>We included 32 RCTs randomising 28,746 people. Treatment duration ranged between one to four years. We judged none of these trials as low risk of bias for all 'Risk of bias' domains. Most important events per person were all‐cause and cardiovascular mortality, serious adverse events (SAE), non‐fatal stroke (NFS), non‐fatal myocardial infarction (MI) and microvascular complications. Most important comparisons were as follows: </p> <p>Five trials compared M+S (N = 1194) with metformin plus a glucagon‐like peptide 1 analogue (N = 1675): all‐cause mortality was 11/1057 (1%) versus 11/1537 (0.7%), risk ratio (RR) 1.15 (95% confidence interval (CI) 0.49 to 2.67); 3 trials; 2594 participants; low‐certainty evidence; cardiovascular mortality 1/307 (0.3%) versus 1/302 (0.3%), low‐certainty evidence; serious adverse events (SAE) 128/1057 (12.1%) versus 194/1537 (12.6%), RR 0.90 (95% CI 0.73 to 1.11); 3 trials; 2594 participants; very low‐certainty evidence; non‐fatal myocardial infarction (MI) 2/549 (0.4%) versus 6/1026 (0.6%), RR 0.57 (95% CI 0.12 to 2.82); 2 trials; 1575 participants; very low‐certainty evidence. </p> <p>Nine trials compared M+S (N = 5414) with metformin plus a dipeptidyl‐peptidase 4 inhibitor (N = 6346): all‐cause mortality was 33/5387 (0.6%) versus 26/6307 (0.4%), RR 1.32 (95% CI 0.76 to 2.28); 9 trials; 11,694 participants; low‐certainty evidence; cardiovascular mortality 11/2989 (0.4%) versus 9/3885 (0.2%), RR 1.54 (95% CI 0.63 to 3.79); 6 trials; 6874 participants; low‐certainty evidence; SAE 735/5387 (13.6%) versus 779/6307 (12.4%), RR 1.07 (95% CI 0.97 to 1.18); 9 trials; 11,694 participants; very low‐certainty evidence; NFS 14/2098 (0.7%) versus 8/2995 (0.3%), RR 2.21 (95% CI 0.74 to 6.58); 4 trials; 5093 participants; very low‐certainty evidence; non‐fatal MI 15/2989 (0.5%) versus 13/3885 (0.3%), RR 1.45 (95% CI 0.69 to 3.07); 6 trials; 6874 participants; very low‐certainty evidence; one trial in 64 participants reported no microvascular complications were observed (very low‐certainty evidence). </p> <p>Eleven trials compared M+S (N = 3626) with metformin plus a thiazolidinedione (N = 3685): all‐cause mortality was 123/3300 (3.7%) versus 114/3354 (3.4%), RR 1.09 (95% CI 0.85 to 1.40); 6 trials; 6654 participants; low‐certainty evidence; cardiovascular mortality 37/2946 (1.3%) versus 41/2994 (1.4%), RR 0.78 (95% CI 0.36 to 1.67); 4 trials; 5940 participants; low‐certainty evidence; SAE 666/3300 (20.2%) versus 671/3354 (20%), RR 1.01 (95% CI 0.93 to 1.11); 6 trials; 6654 participants; very low‐certainty evidence; NFS 20/1540 (1.3%) versus 16/1583 (1%), RR 1.29 (95% CI 0.67 to 2.47); P = 0.45; 2 trials; 3123 participants; very low‐certainty evidence; non‐fatal MI 25/1841 (1.4%) versus 21/1877 (1.1%), RR 1.21 (95% CI 0.68 to 2.14); P = 0.51; 3 trials; 3718 participants; very low‐certainty evidence; three trials (3123 participants) reported no microvascular complications (very low‐certainty evidence). </p> <p>Three trials compared M+S (N = 462) with metformin plus a glinide (N = 476): one person died in each intervention group (3 trials; 874 participants; low‐certainty evidence); no cardiovascular mortality (2 trials; 446 participants; low‐certainty evidence); SAE 34/424 (8%) versus 27/450 (6%), RR 1.68 (95% CI 0.54 to 5.21); P = 0.37; 3 trials; 874 participants; low‐certainty evidence; no NFS (1 trial; 233 participants; very low‐certainty evidence); non‐fatal MI 2/215 (0.9%) participants in the M+S group; 2 trials; 446 participants; low‐certainty evidence; no microvascular complications (1 trial; 233 participants; low‐certainty evidence). </p> <p>Four trials compared M+S (N = 2109) with metformin plus a sodium‐glucose co‐transporter 2 inhibitor (N = 3032): all‐cause mortality was 13/2107 (0.6%) versus 19/3027 (0.6%), RR 0.96 (95% CI 0.44 to 2.09); 4 trials; 5134 participants; very low‐certainty evidence; cardiovascular mortality 4/1327 (0.3%) versus 6/2262 (0.3%), RR 1.22 (95% CI 0.33 to 4.41); 3 trials; 3589 participants; very low‐certainty evidence; SAE 315/2107 (15.5%) versus 375/3027 (12.4%), RR 1.02 (95% CI 0.76 to 1.37); 4 trials; 5134 participants; very low‐certainty evidence; NFS 3/919 (0.3%) versus 7/1856 (0.4%), RR 0.87 (95% CI 0.22 to 3.34); 2 trials; 2775 participants; very low‐certainty evidence; non‐fatal MI 7/890 (0.8%) versus 8/1374 (0.6%), RR 1.43 (95% CI 0.49 to 4.18; 2 trials); 2264 participants; very low‐certainty evidence; amputation of lower extremity 1/437 (0.2%) versus 1/888 (0.1%); very low‐certainty evidence. </p> <p>Trials reported more hypoglycaemic episodes with M+S combination compared to all other metformin‐antidiabetic agent combinations. Results for M+S versus metformin monotherapy were inconclusive. There were no RCTs comparing M+S with metformin plus insulin. We identified nine ongoing trials and two trials are awaiting assessment. Together these trials will include approximately 16,631 participants. </p> </section> <section id="CD012368-sec-0007"> <h3 class="title" id="CD012368-sec-0007">Authors' conclusions</h3> <p>There is inconclusive evidence whether M+S combination therapy compared with metformin plus another glucose‐lowering intervention results in benefit or harm for most patient‐important outcomes (mortality, SAEs, macrovascular and microvascular complications) with the exception of hypoglycaemia (more harm for M+S combination). No RCT reported on health‐related quality of life. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012368-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012368-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012368-abs-0012">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012368-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012368-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012368-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012368-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012368-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012368-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012368-abs-0005" lang="en"> <h3>Metformin and sulphonylurea combination therapy for adults with type 2 diabetes mellitus</h3> <p><b>Review question</b> </p> <p>We wanted to investigate the effects of the combination of the antidiabetic medications metformin plus sulphonylurea compared with other antidiabetic interventions in people with type 2 diabetes. </p> <p><b>Background</b> </p> <p>Many people with type 2 diabetes are treated with several types of glucose‐lowering drugs such as 'sulphonylureas' (for example glibenclamide or glyburide, glipizide and gliclazide). These medications lower blood glucose by stimulating the secretion of insulin in the body, thereby increasing insulin levels in the blood. Another antidiabetic agent, metformin lowers blood glucose by improving the body's ability to make insulin work better (insulin sensitivity). The combination of metformin plus sulphonylurea is widely used. We wanted to investigate the effects of metformin plus sulphonylurea on patient‐important outcomes such as complications of diabetes (for example kidney and eye disease, heart attacks, strokes), death from any cause, health‐related quality of life and side effects of the medications. </p> <p><b>Study characteristics</b> </p> <p>We found 32 randomised controlled studies (clinical trials where people are randomly put into one of two or more treatment groups), which allocated 28,746 people with type 2 diabetes to either metformin plus sulphonylurea or a comparator group. The comparator groups consisted of the following types of antidiabetic medications in addition to metformin: five studies with glucagon‐like peptide 1 analogues, nine studies with dipeptidyl‐peptidase 4 inhibitors, 11 studies with thiazolidinediones, three studies with glinides and four studies with sodium‐glucose co‐transporter 2 inhibitors. </p> <p>Participants of the studies were treated for between one and four years. There were big differences between people taking part in the studies, especially with regard to age, how long people had diabetes and whether diabetes complications were present at the start of the study. </p> <p>This evidence is up to date as of March 2018.</p> <p><b>Key results</b> </p> <p>Data on patient‐important outcomes were few, and data were sparse for all comparisons of metformin plus sulphonylurea with other antidiabetic medications. The available data did not show firm differences between metformin plus sulphonylurea and other combinations of metformin with antidiabetic drugs or metformin only for most patient‐important outcomes. There were more events with low blood sugar (hypoglycaemic episodes) with metformin plus sulphonylurea combination treatment compared to all other combinations of metformin with another antidiabetic compound. </p> <p>We did not identify studies reporting on health‐related quality of life. We identified nine ongoing studies and two yet unpublished studies are awaiting assessment. Together these studies will include around 16,631 participants. Once results are published these studies could significantly influence the findings of our review. </p> <p><b>Certainty of the evidence</b> </p> <p>All included studies had deficiencies in the way they were conducted or how study authors reported the results. For individual comparisons of the antidiabetic medications the number of participants was often small, resulting in a high risk of random error (play of chance). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012368-sec-0240" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012368-sec-0240">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012368-sec-0332">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012368-sec-0240"></div> <h3 class="title" id="CD012368-sec-0241">Implications for practice</h3> <section id="CD012368-sec-0241"> <p>There is no firm evidence whether metformin plus sulphonylurea combination compared with metformin plus another glucose‐lowering agent or metformin monotherapy increases benefit or harm for most patient‐important outcomes (all‐cause mortality, serious adverse events, macrovascular complications (cardiovascular mortality, non‐fatal myocardial infarction, non‐fatal stroke) and microvascular complications (amputation of lower extremity, blindness or severe vision loss, end‐stage renal disease)). There were more reported hypoglycaemic episodes with metformin plus sulphonylurea combination in comparison to all other metformin‐antidiabetic agent combinations. The risk of hypoglycaemia increases with low glucose level targets which may not apply to the majority of elderly people with diabetes. There were no trials comparing metformin plus sulphonylurea with metformin plus insulin. We identified nine ongoing trials and two trials are awaiting assessment. Together these trials will include around 16,631 participants and could have an impact on the findings of our review. </p> </section> <h3 class="title" id="CD012368-sec-0242">Implications for research</h3> <section id="CD012368-sec-0242"> <p>It remains to be clarified whether there are any substantial beneficial or harmful effects of metformin plus sulphonylurea in people with type 2 diabetes mellitus. Several ongoing trials with around 15,147 participants are investigating this topic and each trial will provide data on one or more outcomes of interest for our review. Trial completion dates are estimated between 2018 and 2021. Furthermore two trials with 1484 participants investigating metformin plus sulphonylurea compared with metformin plus SGLT‐2 inhibitors are awaiting assessment. Future long‐term randomised controlled trials should focus on patient‐important outcomes (especially mortality, health‐related quality of life, serious adverse events, macrovascular and microvascular complications). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012368-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012368-sec-0029"></div> <div class="table" id="CD012368-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy compared with metformin plus another antidiabetic drug for adults with type 2 diabetes mellitus</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy compared with metformin plus another antidiabetic drug for adults with type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient:</b> people with type 2 diabetes mellitus </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> metformin + sulphonylurea </p> <p><b>Comparison:</b> metformin plus another antidiabetic drug </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Metformin + antidiabetic drug</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Metformin + sulphonylurea</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No. of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>All‐cause mortality (N)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + GLP1‐A<br/> Follow‐up: 2‐3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> (4 to 19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.15</b> (0.49 to 2.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2594 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>a1</sup> </p> <p><b>Low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + DPP4‐I<br/> Follow‐up: 1‐3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> (3 to 9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.32</b> (0.76 to 2.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,694 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + thiazolidinedione<br/> Follow‐up: 1‐5.5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> (29 to 48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.09</b> (0.85 to 1.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6654 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>c1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + nateglinide</p> <p>Follow‐up: 1‐2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>874 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>d1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participant died in each intervention group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + SGLT2‐I<br/> Follow‐up: 2‐4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> (3 to 13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> (0.44 to 2.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5134 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>e1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Cardiovascular mortality (N)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + GLP1‐A<br/> Follow‐up: 2‐3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>609 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/307 (0.3%) participants died due to cardiovascular disease in the M+S group compared with 1/302 (0.3%) participants in the M + GLP1‐A group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + DPP4‐I<br/> Follow‐up: 1‐3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> (1 to 9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.54</b> (0.63 to 3.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6874 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + thiazolidinedione<br/> Follow‐up: 1‐5.5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> (5 to 23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> (0.36 to 1.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5940 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>c2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + nateglinide</p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>446 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>d2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No cardiovascular death was reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + SGLT2‐I<br/> Follow‐up: 2‐4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> (1 to 12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.22</b> (0.33 to 4.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3589 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>e2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Serious adverse events (N)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + GLP1‐A<br/> Follow‐up: 2‐3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>114 per 1000</b> (92 to 140) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> (0.73 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2594 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + DPP4‐I<br/> Follow‐up: 1‐3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>124 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b> (120 to 146) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.07</b> (0.97 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,694 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + thiazolidinedione<br/> Follow‐up: 1‐5.5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b> (186 to 222) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> (0.93 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6654 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>c3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + nateglinide</p> <p>Follow‐up:</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>101 per 1000</b> (32 to 313) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.68</b> (0.54 to 5.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>874 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>d3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + SGLT2‐I<br/> Follow‐up: 2‐4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>124 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> (94 to 170) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> (0.76 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5134 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>e3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Non‐fatal stroke (N)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + GLP1‐A</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b><sup>a4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + DPP4‐I<br/> Follow‐up: 1‐2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> (2 to 18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.21</b> (0.74 to 6.58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5093 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + thiazolidinedione<br/> Follow‐up: 1‐4.8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> (7 to 25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.29</b> (0.67 to 2.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3123 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>c4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + nateglinide</p> <p>Follow‐up: 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>d4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No non‐fatal stroke was reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + SGLT2‐I<br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> (1 to 13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> (0.22 to 3.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2775 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>e4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction (N)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + GLP1‐A<br/> Follow‐up: 2‐3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> (1 to 16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.57</b> (0.12 to 2.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1575 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + DPP4‐I<br/> Follow‐up: 1‐3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> (2 to 10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.45</b> (0.69 to 3.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6874 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>b5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + thiazolidinedione<br/> Follow‐up: 1‐4.8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> (8 to 24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b> (0.68 to 2.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3718 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>c5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + nateglinide</p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>446 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>d5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 1 trial 2/101 (2%) participants had a non‐fatal myocardial infarction in the M+S group compared with 0/112 participant in the metformin plus nateglinide group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + SGLT2‐I<br/> Follow‐up: 2‐4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> (3 to 24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.43</b> (0.49 to 4.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2264 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>e5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Microvascular complications (N), definition: end‐stage renal disease, blindness or severe vision loss, amputation of lower extremity</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + GLP1‐A</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b><sup>a6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + DPP4‐I<br/> Follow‐up: 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 1 trial no participants had a lower‐extremity amputation, developed blindness or severe vision loss, or end‐stage renal disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + thiazolidinedione<br/> Follow‐up: 1‐4.8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3123 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>c6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials (3123 participants) reported that no participants had a lower‐extremity amputation<br/> 1 trial (95 participants) reported that no participants developed blindness or severe vision loss, or end‐stage renal disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + nateglinide</p> <p>Follow‐up: 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>d6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No microvascular complications were reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + SGLT2‐I<br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1325 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>e6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 1 trial 1/437 (0.2%) participants had an amputation of the lower extremity in the M+S group compared with 1/888 (0.1%) in the M + SGLT2‐I group </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI) </p> <p><b>CI:</b> confidence interval; <b>DPP4‐I</b> : dipeptidyl peptidase‐4 inhibitor; <b>GLP1‐A:</b> glucagon‐like peptide 1 analogue; <b>HbA1c</b> : glycosylated haemoglobin A1c; <b>M:</b> metformin; <b>M+S:</b> metformin + sulphonylurea; <b>N:</b> number; <b>N/R</b> : not reported; <b>RR:</b> risk ratio; <b>SGLT2‐I</b> : sodium‐glucose co‐transporter 2 inhibitor; <b>T</b>: thiazolidinedione </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>All‐cause mortality</b><br/> <sup>a1</sup>Downgraded by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials) ‐ see <a href="./appendices#CD012368-sec-0262">Appendix 17</a>.<br/> <sup>b1</sup>Downgraded by one level because of inconsistency (non‐consistent direction of effect) and by one level because of imprecision (CI consistent with both benefit and harm) ‐ see <a href="./appendices#CD012368-sec-0263">Appendix 18</a>.<br/> <sup>c1</sup>Downgraded by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials) ‐ see <a href="./appendices#CD012368-sec-0265">Appendix 20</a>.<br/> <sup>d1</sup>Downgraded by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials) ‐ see <a href="./appendices#CD012368-sec-0266">Appendix 21</a>.<br/> <sup>e1</sup>Downgraded by one level because of inconsistency (point estimates varied widely) and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials, low event rate) ‐ see <a href="./appendices#CD012368-sec-0267">Appendix 22</a>. </p> <p><b>Cardiovascular mortality</b><br/> <sup>a2</sup>Downgraded by two levels because of serious imprecision (small number of trials, CI consistent with both benefit and harm) ‐ see <a href="./appendices#CD012368-sec-0262">Appendix 17</a>.<br/> <sup>b2</sup>Downgraded by one level because of because of inconsistency (non‐consistent direction of effect) and by one level because of imprecision (CI consistent with both benefit and harm) ‐ see <a href="./appendices#CD012368-sec-0263">Appendix 18</a>.<br/> <sup>c2</sup>Downgraded by two levels because of serious imprecision (small number of trials, CI consistent with both benefit and harm) ‐ see <a href="./appendices#CD012368-sec-0265">Appendix 20</a>.<br/> <sup>d2</sup>Downgraded by two levels because of serious imprecision (small number of trials, unknown event rate) ‐ see <a href="./appendices#CD012368-sec-0265">Appendix 20</a>.<br/> <sup>e2</sup>Downgraded by one level because of inconsistency (point estimates varied widely) and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials, low event rate) ‐ see <a href="./appendices#CD012368-sec-0267">Appendix 22</a>. </p> <p><b>Serious adverse events</b><br/> <sup>a3</sup>Downgraded by one level because of attrition bias and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials) ‐ see <a href="./appendices#CD012368-sec-0262">Appendix 17</a>.<br/> <sup>b3</sup>Downgraded by one level because of attrition bias, by one level because of inconsistency (non‐consistent direction of effect) and by one level because of imprecision (CI consistent with both benefit and harm) ‐ see <a href="./appendices#CD012368-sec-0263">Appendix 18</a>.<br/> <sup>c3</sup>Downgraded by one level because of attrition bias, by one level because of inconsistency (non‐consistent direction of effect) and by one level because of serious imprecision (CI consistent with both benefit and harm, small number of trials) ‐ see <a href="./appendices#CD012368-sec-0265">Appendix 20</a>.<br/> <sup>d3</sup>Downgraded by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials) ‐ see <a href="./appendices#CD012368-sec-0266">Appendix 21</a>.<br/> <sup>e3</sup>Downgraded by one level because of attrition bias and inconsistency (point estimates varied widely) and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials) ‐ see <a href="./appendices#CD012368-sec-0267">Appendix 22</a>. </p> <p><b>Non‐fatal stroke</b><br/> <sup>a4</sup>No adequate data for analysis.<br/> <sup>b4</sup>Downgraded by one level because of attrition bias and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials, low event rate) ‐ see <a href="./appendices#CD012368-sec-0263">Appendix 18</a>.<br/> <sup>c4</sup>Downgraded by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials) ‐ see <a href="./appendices#CD012368-sec-0265">Appendix 20</a>.<br/> <sup>d4</sup>Downgraded by two levels of evidence because of serious imprecision (low number of trials, unknown event rate) ‐ see <a href="./appendices#CD012368-sec-0266">Appendix 21</a>.<br/> <sup>e4</sup>Downgraded by one level because of attrition bias and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials, low event rate) ‐ see <a href="./appendices#CD012368-sec-0267">Appendix 22</a>. </p> <p><b>Non‐fatal myocardial infarction</b><br/> <sup>a5</sup>Downgraded by one level because of attrition bias and by two levels because of serious imprecision (small number of trials, CI consistent with both benefit and harm) ‐ see <a href="./appendices#CD012368-sec-0262">Appendix 17</a>.<br/> <sup>b5</sup>Downgraded by one level because of attrition bias and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials, low event rate) ‐ see <a href="./appendices#CD012368-sec-0263">Appendix 18</a>.<br/> <sup>c5</sup>Downgraded by one level because of attrition bias and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials) ‐ see <a href="./appendices#CD012368-sec-0265">Appendix 20</a>.<br/> <sup>d5</sup>Downgraded by two levels because of serious imprecision (low number of trials, low event rate) ‐ see <a href="./appendices#CD012368-sec-0266">Appendix 21</a>.<br/> <sup>e15</sup>Downgraded by one level because of attrition bias and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials, low event rate) ‐ see <a href="./appendices#CD012368-sec-0267">Appendix 22</a>. </p> <p><b>Microvascular complications</b><br/> <sup>a6</sup>No adequate data for analysis.<br/> <sup>b6</sup>Downgraded by three levels because of very serious imprecision (small number of participants, one trial only, unknown event rate) ‐ see <a href="./appendices#CD012368-sec-0263">Appendix 18</a>.<br/> <sup>c6</sup>Downgraded by one level because of attrition bias and reporting bias and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials, unknown event rate) ‐ see <a href="./appendices#CD012368-sec-0265">Appendix 20</a>.<br/> <sup>d6</sup>Downgraded by two levels because of serious imprecision (low number of trials, unknown event rate) ‐ see <a href="./appendices#CD012368-sec-0266">Appendix 21</a>.<br/> <sup>e6</sup>Downgraded by one level because of attrition bias and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials, low event rate) ‐ see <a href="./appendices#CD012368-sec-0267">Appendix 22</a>. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012368-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012368-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012368-sec-0280">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD012368-sec-0030"></div> <p>A number of medical organisations have developed guidelines or recommendations for treatment of type 2 diabetes mellitus (T2DM). Most people with T2DM are initially recommended to reduce calorie intake and increase physical activity in order to improve glycaemic control (<a href="./references#CD012368-bbs2-0108" title="American Diabetes Association. 7. Approaches to glycemic treatment. Diabetes Care2016;39(Suppl 1):S52‐9. [PUBMED: 26696682] ">ADA 2016</a>). However, in order to achieve and maintain specific glycaemic targets, the majority of people with T2DM will require pharmacological glucose‐lowering interventions. Metformin is currently the first‐line glucose‐lowering drug for people with T2DM because of its postulated benefits, including absence of weight gain, or even weight loss, and lack of hypoglycaemia (<a href="./references#CD012368-bbs2-0157" title="InzucchiSE , BergenstalRM , BuseJB , DiamantM , FerranniniE , NauckM , et al. Management of hyperglycemia in type 2 diabetes: a patient‐centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care2012;35(6):1364‐79. [PUBMED: 22517736] ">Inzucchi 2012</a>; <a href="./references#CD012368-bbs2-0181" title="NathanDM , BuseJB , DavidsonMB , FerranniniE , HolmanRR , SherwinR , et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia2009;52(1):17‐30. [PUBMED: 18941734] ">Nathan 2009</a>). If behavioural interventions like diet and exercise and maximum tolerated doses of one oral glucose‐lowering drug fail to achieve the glycaemic target, other glucose‐lowering drugs are often added (<a href="./references#CD012368-bbs2-0108" title="American Diabetes Association. 7. Approaches to glycemic treatment. Diabetes Care2016;39(Suppl 1):S52‐9. [PUBMED: 26696682] ">ADA 2016</a>). As T2DM is a progressive condition, a substantial proportion of people with T2DM will, with time, require insulin. Some guidelines recommend continuing metformin in this situation (<a href="./references#CD012368-bbs2-0108" title="American Diabetes Association. 7. Approaches to glycemic treatment. Diabetes Care2016;39(Suppl 1):S52‐9. [PUBMED: 26696682] ">ADA 2016</a>). </p> <p>As described below, people with T2DM have an elevated risk of developing macrovascular as well as microvascular complications (<a href="./references#CD012368-bbs2-0112" title="AlmdalT , ScharlingH , JensenJS , VestergaardH . The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population‐based study of 13,000 men and women with 20 years of follow‐up. Archives of Internal Medicine2004;164(13):1422‐6. [PUBMED: 15249351] ">Almdal 2004</a>). In the treatment of people with T2DM, researchers have considered which glycaemic target is appropriate in order to lower the risk of these complications. One hypothesis so far has been that lower glycosylated haemoglobin A1c (HbA1c) values are associated with reduced macrovascular and microvascular complications. However, this paradigm has been challenged by a Cochrane Review investigating intensive glycaemic control compared to conventional glycaemic control in people with T2DM (<a href="./references#CD012368-bbs2-0144" title="HemmingsenB , LundSS , GluudC , VaagA , AlmdalT , HemmingsenC , et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta‐analysis and trial sequential analysis of randomised clinical trials. BMJ (Clinical Research Ed.)2011;343:d6898. [PUBMED: 22115901] ">Hemmingsen 2011</a>). In this review, authors found insufficient information to confirm or exclude a risk reduction in macrovascular as well as microvascular complications with intensive compared to conventional glycaemic control. </p> <section id="CD012368-sec-0031"> <h3 class="title" id="CD012368-sec-0031">Description of the condition</h3> <p>Worldwide, the number of people with diabetes was estimated to be 177 million in 2000 and is foreseen to rise to 366 million in 2030 (<a href="./references#CD012368-bbs2-0215" title="WildS , RoglicG , GreenA , SicreeR , KingH . Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care2004;27(5):1047‐53. [PUBMED: 15111519] ">Wild 2004</a>). T2DM comprises 90% of people with diabetes and is associated with excess bodyweight and physical inactivity (<a href="./references#CD012368-bbs2-0214" title="World Health Organization. Diabetes. www.who.int/mediacentre/factsheets/fs312/en/ (accessed 29 February 2016). ">WHO 2015</a>). T2DM is characterised by hyperglycaemia, insulin resistance and impaired insulin secretion (<a href="./references#CD012368-bbs2-0167" title="LeRoithD . Beta‐cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. American Journal of Medicine2002;113 Suppl 6A:3S‐11S. [PUBMED: 12431757] ">LeRoith 2002</a>). Although the definition of T2DM relies on elevated blood glucose, T2DM occurs not in isolation, but as part of a complex metabolic‐cardiovascular syndrome that includes dyslipidaemia, hypertension, obesity, clotting abnormalities, microalbuminuria and accelerated atherosclerosis, although not every one of these disorders occurs in every person with T2DM (<a href="./references#CD012368-bbs2-0131" title="DeFronzoRA . Pharmacologic therapy for type 2 diabetes mellitus. Annals of Internal Medicine1999;131(4):281‐303. [PUBMED: 10454950] ">DeFronzo 1999</a>). People with T2DM have an elevated risk of developing macrovascular disease (such as cardiovascular death, myocardial infarction, stroke and peripheral ischaemia) as well as microvascular complications (such as retinopathy, nephropathy and neuropathy) (<a href="./references#CD012368-bbs2-0112" title="AlmdalT , ScharlingH , JensenJS , VestergaardH . The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population‐based study of 13,000 men and women with 20 years of follow‐up. Archives of Internal Medicine2004;164(13):1422‐6. [PUBMED: 15249351] ">Almdal 2004</a>). </p> </section> <section id="CD012368-sec-0032"> <h3 class="title" id="CD012368-sec-0032">Description of the intervention</h3> <p>Since the introduction of the sulphonylureas in the 1950s these glucose‐lowering drugs have been the mainstay in the treatment of T2DM. The first to be introduced on the market were the first‐generation sulphonylureas (acetohexamide, carbutamide, chlorpropamide, tolazamide and tolbutamide). Later, the second and third generations of sulphonylureas were introduced, and have now almost completely replaced the first‐generation sulphonylureas (<a href="./references#CD012368-bbs2-0141" title="HarrowerAD . Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Safety2000;22(4):313‐20. [PUBMED: 10789825] ">Harrower 2000</a>). The second‐generation sulphonylureas (e.g. glibenclamide (in the USA: glyburide), glipizide and gliclazide) and the third‐generation sulphonylureas (gliclazide modified release (MR), glipizide gastrointestinal therapeutic system (GITS) and glimepiride) are thought to have a better safety profile (<a href="./references#CD012368-bbs2-0141" title="HarrowerAD . Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Safety2000;22(4):313‐20. [PUBMED: 10789825] ">Harrower 2000</a>). In the late 1950s the biguanide metformin was introduced as another glucose‐lowering drug (<a href="./references#CD012368-bbs2-0118" title="BaileyCJ , TurnerRC . Metformin. New England Journal of Medicine1996;334(9):574‐9. [PUBMED: 8569826] ">Bailey 1996</a>). </p> <p>Metformin is usually the first choice of a glucose‐lowering drug if diet and exercise are insufficient in controlling T2DM. However, in case of metformin intolerance or contraindications, sulphonylureas might be prescribed as monotherapy. Sulphonylureas are mostly prescribed as a part of combination therapy with other glucose‐lowering drugs, especially metformin (<a href="./references#CD012368-bbs2-0108" title="American Diabetes Association. 7. Approaches to glycemic treatment. Diabetes Care2016;39(Suppl 1):S52‐9. [PUBMED: 26696682] ">ADA 2016</a>). All sulphonylureas are administered orally. The daily dose recommended in people with T2DM depends on the specific sulphonylurea compound. The sulphonylureas have different pharmacokinetic profiles due to different bindings to the sulphonylurea receptor in the pancreatic β‐cells. Chlorpropamide has a half‐life of 36 hours, whereas glimepiride has a half‐life of around 5 hours (<a href="./references#CD012368-bbs2-0174" title="McCallAL . Clinical review of glimepiride. Expert Opinion on Pharmacotherapy2001;2(4):699‐713. [PUBMED: 11336617] ">McCall 2001</a>). Metformin has an estimated plasma half‐life of 1.5 to 4.9 hours (<a href="./references#CD012368-bbs2-0118" title="BaileyCJ , TurnerRC . Metformin. New England Journal of Medicine1996;334(9):574‐9. [PUBMED: 8569826] ">Bailey 1996</a>). Because of variations in the half‐life of the different sulphonylureas, some have to be taken once daily and others two or three times daily. For glimepiride, the recommended dose is up to 6 mg per day (<a href="./references#CD012368-bbs2-0166" title="LangtryHD , BalfourJA . Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs1998;55(4):563‐84. [PUBMED: 9561345] ">Langtry 1998</a>). For gliclazide the daily dose is 30 mg to 120 mg (<a href="./references#CD012368-bbs2-0128" title="DeaconCF , LebovitzHE . A comparative review of DPP‐4 inhibitors and sulphonylureas. Diabetes, Obesity &amp; Metabolism2015;18(4):333‐47. [PUBMED: 26597596] ">Deacon 2015</a>; <a href="./references#CD012368-bbs2-0142" title="HarrowerA . Gliclazide modified release: from once‐daily administration to 24‐hour blood glucose control. Metabolism: Clinical and Experimental2000;49(10 Suppl 2):7‐11. [PUBMED: 11078469] ">Harrower 2000a</a>). Metformin is likewise administered orally. Titration of metformin begins with a low dose (500 mg) taken once or twice per day with meals. The maximum recommended dose is up to 1000 mg twice daily (<a href="./references#CD012368-bbs2-0181" title="NathanDM , BuseJB , DavidsonMB , FerranniniE , HolmanRR , SherwinR , et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia2009;52(1):17‐30. [PUBMED: 18941734] ">Nathan 2009</a>). </p> <section id="CD012368-sec-0033"> <h4 class="title">Adverse effects of the intervention</h4> <p>All sulphonylureas have the potential to cause hypoglycaemia. The risk of hypoglycaemia differs between the different types of sulphonylureas and some agents like glibenclamide are prone to cause prolonged hypoglycaemia. The risk of hypoglycaemia is more pronounced for the first‐generation sulphonylureas than the newer generations of sulphonylureas (<a href="./references#CD012368-bbs2-0141" title="HarrowerAD . Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Safety2000;22(4):313‐20. [PUBMED: 10789825] ">Harrower 2000</a>). In people with T2DM receiving metformin, gastrointestinal adverse effects, including abdominal discomfort and diarrhoea, are the most common adverse events, occurring in 20% to 30% of patients. Because metformin does not increase insulin secretion, hypoglycaemia is uncommon in people with T2DM taking metformin monotherapy (<a href="./references#CD012368-bbs2-0131" title="DeFronzoRA . Pharmacologic therapy for type 2 diabetes mellitus. Annals of Internal Medicine1999;131(4):281‐303. [PUBMED: 10454950] ">DeFronzo 1999</a>). Previously, metformin was considered to be contraindicated in many chronic conditions, due to an increased risk of lactic acidosis. However, a Cochrane Review has concluded that there is no evidence that metformin is associated with an increased risk of lactic acidosis and the list of contraindications for metformin use should be reassessed (<a href="./references#CD012368-bbs2-0194" title="SalpeterSR , GreyberE , PasternakGA , SalpeterEE . Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD002967.pub4] ">Salpeter 2010</a>). </p> <p>The University Group Diabetes Program (UGDP) trial suggested that tolbutamide was associated with adverse cardiovascular effects compared with placebo and insulin in people with T2DM (<a href="./references#CD012368-bbs2-0205" title="University Group Diabetes Program. A study of the effects of hypoglycemia agents on vascular complications in patients with adult‐onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes1976;25(12):1129‐53. [PUBMED: 992232] ">UGDP 1976</a>). Later, other randomised clinical trials did not demonstrate clear evidence of an increased risk of cardiovascular events with sulphonylurea use compared with other glucose‐lowering drugs in people with T2DM (<a href="./references#CD012368-bbs2-0110" title="KahnSE , HaffnerSM , HeiseMA , HermanWH , HolmanRR , JonesNP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine2006;355(23):2427‐43. [PUBMED: 17145742] ">ADOPT 2006</a>; <a href="./references#CD012368-bbs2-0206" title="UK Prospective Diabetes Study (UKPDS) Group. Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352(9131):837‐53. [PUBMED: 9742976] ">UKPDS‐33 1998</a>). Several observational studies have indicated increased mortality and risk of cardiovascular disease with sulphonylurea monotherapy compared with metformin monotherapy in people with T2DM (<a href="./references#CD012368-bbs2-0180" title="MorganCL , MukherjeeJ , Jenkins‐JonesS , HoldenSE , CurrieCJ . Association between first‐line monotherapy with sulphonylurea versus metformin and risk of all‐cause mortality and cardiovascular events: a retrospective, observational study. Diabetes, Obesity &amp; Metabolism2014;16(10):957‐62. [PUBMED: 24720708] ">Morgan 2014</a>; <a href="./references#CD012368-bbs2-0193" title="RoumieCL , HungAM , GreevyRA , GrijalvaCG , LiuX , MurffHJ , et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Annals of Internal Medicine2012;157(9):601‐10. [PUBMED: 23128859] ">Roumie 2012</a>; <a href="./references#CD012368-bbs2-0197" title="SchrammTK , GislasonGH , VaagA , RasmussenJN , FolkeF , HansenML , et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. European Heart Journal2011;32(15):1900‐8. [PUBMED: 21471135] ">Schramm 2011</a>). However, the risk seems to depend on the type of sulphonylurea (<a href="./references#CD012368-bbs2-0184" title="PantaloneKM , KattanMW , YuC , WellsBJ , ArrigainS , JainA , et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes, Obesity &amp; Metabolism2012;14(9):803‐9. [PUBMED: 22486923] ">Pantalone 2012</a>; <a href="./references#CD012368-bbs2-0197" title="SchrammTK , GislasonGH , VaagA , RasmussenJN , FolkeF , HansenML , et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. European Heart Journal2011;32(15):1900‐8. [PUBMED: 21471135] ">Schramm 2011</a>). Moreover, because of uncontrolled, or undetected, or both confounding factors in observational studies, the results of these studies have to be verified by randomised controlled trials (RCTs; <a href="./references#CD012368-bbs2-0129" title="DeeksJJ , DinnesJ , D'AmicoR , SowdenAJ , SakarovitchC , SongF , et al. Evaluating non‐randomised intervention studies. Health Technology Assessment (Winchester, England)2003;7(27):iii‐x, 1‐173. [PUBMED: 14499048] ">Deeks 2003</a>). </p> <p>A UKPDS substudy showed that the early addition of metformin in sulphonylurea‐treated participants was associated with an increased risk of mortality compared with continuation of sulphonylurea alone (<a href="./references#CD012368-bbs2-0207" title="UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood‐glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet1998;352(9131):854‐65. [PUBMED: 9742977] ">UKPDS‐34 1998</a>). Several observational studies have investigated the association between the combination of metformin and sulphonylureas and the risk of cardiovascular disease and mortality. Overall, these studies show conflicting results (<a href="./references#CD012368-bbs2-0132" title="EvansJM , OgstonSA , Emslie‐SmithA , MorrisAD . Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia2006;49(5):930‐6. [PUBMED: 16525843] ">Evans 2006</a>; <a href="./references#CD012368-bbs2-0139" title="GullifordM , LatinovicR . Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes/metabolism Research and Reviews2004;20(3):239‐45. [PUBMED: 15133756] ">Gulliford 2004</a>; <a href="./references#CD012368-bbs2-0158" title="JohnsonJA , MajumdarSR , SimpsonSH , TothEL . Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care2002;25(12):2244‐8. [PUBMED: 12453968] ">Johnson 2002</a>; <a href="./references#CD012368-bbs2-0160" title="KahlerKH , RajanM , RhoadsGG , SaffordMM , DemissieK , LuSE , et al. Impact of oral antihyperglycemic therapy on all‐cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care2007;30(7):1689‐93. [PUBMED: 17440170] ">Kahler 2007</a>). </p> </section> </section> <section id="CD012368-sec-0034"> <h3 class="title" id="CD012368-sec-0034">How the intervention might work</h3> <p>The primary mechanism of action for the sulphonylureas is to stimulate insulin release from the pancreatic β‐cells. Sulphonylureas increase pancreatic insulin release by closing of potassium‐sensitive adenosine triphosphate (P‐ATP) channels in the β‐cells (<a href="./references#CD012368-bbs2-0141" title="HarrowerAD . Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Safety2000;22(4):313‐20. [PUBMED: 10789825] ">Harrower 2000</a>; <a href="./references#CD012368-bbs2-0200" title="ScottLJ . Repaglinide: a review of its use in type 2 diabetes mellitus. Drugs2012;72(2):249‐72. [PUBMED: 22268393] ">Scott 2012</a>). Metformin is thought to increase insulin sensitivity, which may lead to a variety of metabolic effects. Inhibition of hepatic glucose production (through increased hepatic sensitivity to insulin) is regarded as the principal mechanism through which metformin lowers blood glucose (<a href="./references#CD012368-bbs2-0163" title="KrentzAJ , BaileyCJ . Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs2005;65(3):385‐411. [PUBMED: 15669880] ">Krentz 2005</a>). The enzyme adenosine 5'‐monophosphate‐activated protein kinase (AMPK) has been identified as a target of the drug. Through phosphorylation of key proteins affecting energy production, AMPK regulates and co‐ordinates cellular glucose and lipid metabolism (<a href="./references#CD012368-bbs2-0163" title="KrentzAJ , BaileyCJ . Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs2005;65(3):385‐411. [PUBMED: 15669880] ">Krentz 2005</a>). </p> </section> <section id="CD012368-sec-0035"> <h3 class="title" id="CD012368-sec-0035">Why it is important to do this review</h3> <p>Several studies have investigated the combination therapy of metformin and sulphonylureas and the risk of cardiovascular disease and mortality (<a href="./references#CD012368-bbs2-0132" title="EvansJM , OgstonSA , Emslie‐SmithA , MorrisAD . Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia2006;49(5):930‐6. [PUBMED: 16525843] ">Evans 2006</a>; <a href="./references#CD012368-bbs2-0139" title="GullifordM , LatinovicR . Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes/metabolism Research and Reviews2004;20(3):239‐45. [PUBMED: 15133756] ">Gulliford 2004</a>; <a href="./references#CD012368-bbs2-0158" title="JohnsonJA , MajumdarSR , SimpsonSH , TothEL . Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care2002;25(12):2244‐8. [PUBMED: 12453968] ">Johnson 2002</a>; <a href="./references#CD012368-bbs2-0160" title="KahlerKH , RajanM , RhoadsGG , SaffordMM , DemissieK , LuSE , et al. Impact of oral antihyperglycemic therapy on all‐cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care2007;30(7):1689‐93. [PUBMED: 17440170] ">Kahler 2007</a>; <a href="./references#CD012368-bbs2-0207" title="UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood‐glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet1998;352(9131):854‐65. [PUBMED: 9742977] ">UKPDS‐34 1998</a>). However, the data are primarily based on observational studies and show conflicting results. Therefore, it is still unclear whether metformin and sulphonylurea in combination increase the risk of cardiovascular disease and mortality. Guidelines suggest flexibility in choosing the next drug after metformin monotherapy failure (<a href="./references#CD012368-bbs2-0108" title="American Diabetes Association. 7. Approaches to glycemic treatment. Diabetes Care2016;39(Suppl 1):S52‐9. [PUBMED: 26696682] ">ADA 2016</a>). It therefore remains to be clarified which drug class is the most suitable second line, since most people with T2DM will need a combination therapy over time in order to achieve glycaemic targets. This systematic review aims to evaluate whether sulphonylureas are the best choice of combination therapy with metformin. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012368-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012368-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012368-sec-0286">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012368-sec-0036"></div> <p>To assess the effects of metformin and sulphonylurea (second‐ or third‐generation) combination therapy for adults with type 2 diabetes mellitus. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012368-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012368-sec-0037">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012368-sec-0287">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012368-sec-0037"></div> <section id="CD012368-sec-0038"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012368-sec-0039"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs).</p> </section> <section id="CD012368-sec-0040"> <h4 class="title">Types of participants</h4> <p>Adults aged 18 years or older with type 2 diabetes mellitus (T2DM).</p> <section id="CD012368-sec-0041"> <h5 class="title">Diagnostic criteria for diabetes mellitus</h5> <p>In order to be consistent with changes in the classification of and diagnostic criteria for diabetes mellitus over the years, the diagnosis should be established using the standard criteria valid at the time the trial commenced (e.g. <a href="./references#CD012368-bbs2-0106" title="Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care2003;26(Suppl 1):S5‐20. ">ADA 2003</a>; <a href="./references#CD012368-bbs2-0107" title="American Diabetes Association. Standards of medical care in diabetes ‐ 2008. Diabetes Care2008;31(Suppl 1):S12‐54. [PUBMED: 18165335] ">ADA 2008</a>; <a href="./references#CD012368-bbs2-0213" title="AlbertiKM , ZimmetPZ . Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine1998;15(7):539‐53. ">WHO 1998</a>). Ideally, the diagnostic criteria should have been described. We used the trial authors' definition of diabetes mellitus if necessary. We planned to subject diagnostic criteria to a sensitivity analysis. </p> </section> </section> <section id="CD012368-sec-0042"> <h4 class="title">Types of interventions</h4> <p>We planned to investigate the following comparisons of intervention versus control/comparator.</p> <section id="CD012368-sec-0043"> <h5 class="title">Intervention</h5> <p> <ul id="CD012368-list-0001"> <li> <p>Metformin plus second‐ or third‐generation sulphonylurea (M+S) combination therapy</p> </li> </ul> </p> </section> <section id="CD012368-sec-0044"> <h5 class="title">Comparator</h5> <p> <ul id="CD012368-list-0002"> <li> <p>Metformin plus another glucose‐lowering intervention as a combination therapy (e.g. metformin plus dipeptidylpeptidase‐4 inhibitor, metformin plus insulin) </p> </li> <li> <p>Metformin plus placebo</p> </li> <li> <p>Metformin monotherapy</p> </li> </ul> </p> <p>Concomitant interventions would have to be the same in both the intervention and comparator groups to establish fair comparisons. </p> <p>If a trial included multiple arms, we included any arm that met the review's inclusion criteria. </p> </section> <section id="CD012368-sec-0045"> <h5 class="title">Minimum duration of intervention</h5> <p>We included trials with a minimum duration of intervention of 52 weeks. Because we primarily intended to investigate patient‐important outcomes, we focused on longer‐term trials, since macrovascular and microvascular complications develop over time. </p> </section> <section id="CD012368-sec-0046"> <h5 class="title">Minimum duration of follow‐up</h5> <p>We included trials with a duration of the intervention of 52 weeks or more. Extended follow‐up periods (also called open‐label extension studies) defined as a follow‐up of participants once the original trial was terminated, as specified in the power calculation for this trial, are frequently of an observational nature, and we have only evaluated them for adverse events (<a href="./references#CD012368-bbs2-0123" title="BuchMH , AletahaD , EmeryP , SmolenJS . Reporting of long‐term extension studies: lack of consistency calls for consensus. Annals of the Rheumatic Diseases2011;70(6):886‐90. ">Buch 2011</a>; <a href="./references#CD012368-bbs2-0177" title="MeganB , PickeringRM , WeatherallM . Design, objectives, execution and reporting of published open‐label extension studies. Journal of Evaluation in Clinical Practice2012;18(2):209‐15. ">Megan 2012</a>). </p> </section> <section id="CD012368-sec-0047"> <h5 class="title">Summary of specific exclusion criteria</h5> <p> <ul id="CD012368-list-0003"> <li> <p>We excluded combinations of more than two glucose‐lowering agents.</p> </li> <li> <p>We excluded studies investigated women diagnosed with gestational diabetes.</p> </li> </ul> </p> </section> </section> <section id="CD012368-sec-0048"> <h4 class="title">Types of outcome measures</h4> <p>We did not exclude a trial only on the basis that one or several of our primary or secondary outcome measures were not reported in the publication. In case none of our primary or secondary outcomes were reported we did not include this trial but provided some basic information in an additional table. </p> <section id="CD012368-sec-0049"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012368-list-0004"> <li> <p>All‐cause mortality</p> </li> <li> <p>Health‐related quality of life</p> </li> <li> <p>Serious adverse events</p> </li> </ul> </p> </section> <section id="CD012368-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012368-list-0005"> <li> <p>Cardiovascular mortality</p> </li> <li> <p>Non‐fatal myocardial infarction</p> </li> <li> <p>Heart failure</p> </li> <li> <p>Non‐fatal stroke</p> </li> <li> <p>Amputation of lower extremity</p> </li> <li> <p>Blindness or severe vision loss</p> </li> <li> <p>End‐stage renal disease</p> </li> <li> <p>Non‐serious adverse events</p> </li> <li> <p>Hypoglycaemia</p> </li> <li> <p>Socio‐economic effects</p> </li> </ul> </p> <section id="CD012368-sec-0051"> <h6 class="title">Additional explorative outcomes</h6> <p> <ul id="CD012368-list-0006"> <li> <p>Weight</p> </li> <li> <p>HbA1c (glycosylated haemoglobin A1c)</p> </li> </ul> </p> </section> <section id="CD012368-sec-0052"> <h6 class="title">Method of outcome measurement</h6> <p> <ul id="CD012368-list-0007"> <li> <p>All‐cause mortality: defined as death from any cause</p> </li> <li> <p>Health‐related quality of life: defined as mental and physical health‐related quality of life, separate and combined, evaluated by a validated instrument such as Short‐Form 36 </p> </li> <li> <p>Serious adverse events: defined according to the International Conference on Harmonization Guidelines as any event that leads to death, that is life‐threatening, required in‐patient hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability, and any important medical event that may have jeopardised the participant or required intervention to prevent it (<a href="./references#CD012368-bbs2-0156" title="International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice //1997 CFR &amp; ICH Guidelines. PA 19063‐2043. USA: Barnett International/PAREXEL, 1997. ">ICH 1997</a>), or as reported in trials. </p> </li> <li> <p>Cardiovascular mortality: defined as death from myocardial infarction, heart failure or stroke </p> </li> <li> <p>Non‐fatal myocardial infarction, heart failure, non‐fatal stroke, amputation of lower extremity, blindness or severe vision loss, hypoglycaemia (mild/moderate, serious): defined as reported in trials. Measured at the end of the intervention and at the end of follow‐up. </p> </li> <li> <p>End‐stage renal disease: defined as dialysis, renal transplantation or death due to renal disease </p> </li> <li> <p>Non‐serious adverse events: defined as number of participants with any untoward medical occurrence not necessarily having a causal relationship with the intervention. </p> </li> <li> <p>Weight and HbA1c: measured in kg and %</p> </li> <li> <p>Socio‐economic effects: for example costs of the intervention, absence from work, medication consumption </p> </li> </ul> </p> </section> <section id="CD012368-sec-0053"> <h6 class="title">Timing of outcome measurement</h6> <p> <ul id="CD012368-list-0008"> <li> <p>For all‐cause mortality, serious adverse events and non‐serious adverse events: any time after participants were randomised to intervention/comparator groups </p> </li> <li> <p>For all other outcomes measures: at the end of the intervention and at the end of follow‐up. </p> </li> </ul> </p> </section> <section id="CD012368-sec-0054"> <h6 class="title">Specification of key prognostic variables</h6> <p> <ul id="CD012368-list-0009"> <li> <p>Ethnicity</p> </li> <li> <p>Obesity</p> </li> <li> <p>Hypertension</p> </li> <li> <p>Previous gestational diabetes</p> </li> <li> <p>Age</p> </li> <li> <p>Existing cardiovascular disease</p> </li> <li> <p>Kidney disease</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD012368-sec-0055"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012368-sec-0056"> <h4 class="title">Electronic searches</h4> <p>In 2016 the Agency for Healthcare Research and Quality (AHRQ) published an updated systematic review with meta‐analyses on the effectiveness and safety of glucose‐lowering interventions for people with T2DM, including metformin‐based combination therapies (<a href="./references#CD012368-bbs2-0172" title="MaruthurNM , TsengE , HutflessS , WilsonLM , Suarez‐CuervoC , BergerZ , et al. Diabetes medications as monotherapy or metformin‐based combination therapy for type 2 diabetes: a systematic review and meta‐analysis. Annals of Internal Medicine2016;164(11):740‐51. [DOI: 10.7326/M15‐2650] ">Maruthur 2016</a>). This report included search results from several databases up to April 2015 and a further update of MEDLINE up to December 2015. </p> <p>We based our search on the results of this systematic AHRQ report and added new references identified by a revised search strategy from 2015 onwards, in the following literature databases. </p> <p> <ul id="CD012368-list-0010"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 3) via the Cochrane Register of Studies Online (CRSO) </p> </li> <li> <p>MEDLINE Ovid (Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R); from 1946 to 5 March 2018) </p> </li> <li> <p>Embase Ovid (from 1974 to 13 July 2016)</p> </li> </ul> </p> <p>Additionally we searched the following trials registers:</p> <p> <ul id="CD012368-list-0011"> <li> <p><a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> (5 March 2018) </p> </li> <li> <p><a href="http://www.who.int/trialsearch/" target="_blank">World Health Organization International Clinical Trials Registry Platform (ICTRP)</a> (5 March 2018) </p> </li> </ul> </p> <p>We continuously applied a MEDLINE (Ovid SP) email alert service to identify newly published trials using the same search strategy as described for MEDLINE (for details on search strategies, see <a href="./appendices#CD012368-sec-0246">Appendix 1</a>). </p> </section> <section id="CD012368-sec-0057"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of included trials, systematic reviews, meta‐analyses and health technology assessment reports for other potentially eligible trials or ancillary publications. In addition, we contacted authors of included trials to identify any additional information about the retrieved trials and to determine whether further trials existed that we had missed. </p> <p>We also searched manufacturers' websites and the databases of regulatory agencies (European Medicines Agency (EMA), US Food and Drugs Administration (FDA); <a href="./references#CD012368-bbs2-0143" title="HartB , LundhA , BeroL . Effect of reporting bias on meta‐analyses of drug trials: reanalysis of meta‐analyses. BMJ2012;344:d7202. [DOI: 10.1136/bmj.d7202] ">Hart 2012</a>; <a href="./references#CD012368-bbs2-0198" title="SchrollJB , BeroL . Regulatory agencies hold the key to improving Cochrane Reviews of drugs [editorial]. Cochrane Database of Systematic Reviews2015; Vol. 4:10.1002/14651858.ED000098. ">Schroll 2015</a>). </p> <p>We did not use abstracts or conference proceedings for data extraction because this information source does not fulfil the CONSORT requirements which is "an evidence‐based, minimum set of recommendations for reporting randomized trials" (<a href="./references#CD012368-bbs2-0125" title="The CONSORT statement. www.consort‐statement.org (accessed 19 may 2016). ">CONSORT</a>; <a href="./references#CD012368-bbs2-0196" title="SchererRW , LangenbergP , vonElmE . Full publication of results initially presented in abstracts. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.MR000005.pub3] ">Scherer 2007</a>). </p> </section> </section> <section id="CD012368-sec-0058"> <h3 class="title" id="CD012368-sec-0058">Data collection and analysis</h3> <section id="CD012368-sec-0059"> <h4 class="title">Selection of studies</h4> <p>Two review authors (KM and PK, LK or FG) independently scanned the abstract, title, or both, of every record we retrieved in the literature searches, to determine which trials we should assess further. We obtained the full text of all potentially‐relevant records. We resolved any disagreements through consensus or by recourse to an additional review author (BH). If we could not resolve a disagreement, we categorised the trial as a 'study awaiting classification' and contacted the trial authors for clarification. We prepared a flow diagram of the number of trials identified and excluded at each stage in accordance with the PRISMA flow diagram of trial selection (<a href="./references#CD012368-bbs2-0168" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJPA , et al. The PRISMA statement for reporting systematic and meta‐analyses of studies that evaluate interventions: explanation and elaboration. PLoS Medicine2009;6(7):1‐28. [DOI: 10.1371/journal.pmed.1000100] ">Liberati 2009</a>). </p> </section> <section id="CD012368-sec-0060"> <h4 class="title">Data extraction and management</h4> <p>For trials that fulfilled our inclusion criteria, two review authors (KM and PK, LK or FG) independently extracted key participant and intervention characteristics. We reported data on efficacy outcomes and adverse events using standard data extraction sheets from the Cochrane Metabolic and Endocrine Disorders (CMED) Group. We resolved any disagreements by discussion or, if required, by consultation with an additional review author (BH) (for details see <a href="./references#CD012368-sec-0276" title="">Characteristics of included studies</a>; <a href="#CD012368-tbl-0002">Table 1</a>; <a href="#CD012368-tbl-0003">Table 2</a>; <a href="./appendices#CD012368-sec-0247">Appendix 2</a>; <a href="./appendices#CD012368-sec-0248">Appendix 3</a>; <a href="./appendices#CD012368-sec-0249">Appendix 4</a>; <a href="./appendices#CD012368-sec-0250">Appendix 5</a>; <a href="./appendices#CD012368-sec-0251">Appendix 6</a>; <a href="./appendices#CD012368-sec-0252">Appendix 7</a>; <a href="./appendices#CD012368-sec-0253">Appendix 8</a>; <a href="./appendices#CD012368-sec-0254">Appendix 9</a>; <a href="./appendices#CD012368-sec-0255">Appendix 10</a>; <a href="./appendices#CD012368-sec-0256">Appendix 11</a>; <a href="./appendices#CD012368-sec-0257">Appendix 12</a>; <a href="./appendices#CD012368-sec-0258">Appendix 13</a>; <a href="./appendices#CD012368-sec-0259">Appendix 14</a>). We tried to retrieve the protocol for each included trial. </p> <div class="table" id="CD012368-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial ID</b> </p> <p><b>(design)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description of power and sample size calculation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Screened/eligible<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysed<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Finishing trial<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised finishing trial<br/> (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up<br/> (extended follow‐up)<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg/day + glimepiride 1‐6 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "A sample size of ˜340 patients randomized to each treatment group was calculated to have 91% power to declare non‐inferiority for a margin of <i>δ=</i>0.35% at an overall two sided 5% alpha‐level, assuming that the true mean difference in HbA1c between omarigliptin and glimepiride is 0.0%" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>54 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin ≥ 1500 mg/day + omarigliptin 25 mg/week + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.1</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>751</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>750</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>574</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>76.4</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg/day + glimepiride 1‐8 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Quote from publication:</b> "With a non‐inferiority margin of 3.3 mmol/mol (0.3%), and assuming a true mean difference in HbA1c of 0 mmol/mol, randomisation of approximately 1230 patients (410 patients per group, to yield a sample size of 337 per group at week 52) was estimated to provide 97% power to demonstrate non‐inferiority of a given ertugliflozin dose to glimepiride in HbA1c reduction at week 52" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>52 weeks (104 weeks)<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: metformin ≥ 1500 mg/day + ertugliflozin 5 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: metformin ≥ 1500 mg/day + ertugliflozin 15 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1326</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1037</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1045</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>78.8</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a> </p> <p>(parallel RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 2000 mg/day + sulphonylurea (glibenclamide 5‐15 mg/day, gliclazide 30‐120 mg/day or glimepiride 2‐6 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "The study was designed to be event driven. The initial sample size calculation was based on an estimated primary endpoint rate of 3.5% per year, with the study intended to have 80% power to detect a reduction of 20% in the primary outcome in either group versus the other, based on the results of the PROACTIVE trial. On the basis of these assumptions, 652 events were needed for the primary efficacy analysis. Therefore, 4396 patients had to be enrolled and followed up for at least 4 years; assuming a trial discontinuation rate of 15%, 5172 patients needed to be recruited and randomly assigned (2586 in each treatment group). However, because of the lower than expected rate of recruitment and because the number of participants discontinuing the study was lower than initially foreseen, an approved protocol amendment (January, 2012) subsequently reduced the sample size requirement. Accordingly, 3371 patients should have been enrolled to expect the 498 endpoint events needed to detect a 20% reduction in the incidence of events with a statistical power of 80% (hazard ratio [HR] 0.80, p=0.05 [one‐sided log‐rank test]), assuming an estimated occurrence rate of the primary endpoint of 3.5% per year and a 5% loss to follow‐up. Nonetheless, nearly 9 years after the beginning of the study, the number of events needed was still not reached, and a futility analysis was done as recommended by the data and safety monitoring board" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4956</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Median follow‐up 57.3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 2000 mg/day + pioglitazone 15‐45 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.6</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3041</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3028</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2358</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>77.5</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg/day + glibenclamide 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "Sample size was calculated to achieve 80% power to reject the null hypothesis of equal mean changes in the primary endpoint when the population mean difference is 0.15 with a standard deviation of 0.2 in both groups and with a significance level (∝) of 0.05 using a two‐sided two sample equal‐variance T test (difference between the two treatments at 12 months) (software PASS‐ NCSS, USA). In addition, 40 subjects were sufficient to guarantee a delta value between 0 and 12 months in the treatment group of ˜10% (SD of pair differences 20%) with a alpha value of 5% and β = 80%" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin ≥ 1500 mg/day + vildagliptin 100 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>64</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>64</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>59</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>92.2</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg/day + glimepiride 1‐8 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Quote from publication:</b> "Sample size was calculated on the basis of the per‐protocol analysis; an estimated 277 patients per group would be needed to provide approximately 90% power to show non‐inferiority of canagliflozin to glimepiride for HbA1c lowering, with an assumed difference of 0.0% between canagliflozin and glimepiride and an assumed common SD of 1.0%. We assumed that 35% of patients would discontinue the study before week 52; therefore, about 427 patients were planned for inclusion in each group. For the body composition substudy, 46 or more patients per group would provide 90% power for the comparisons between groups in percentage of total fat and visceral adipose tissue; to assure collection of imaging at both baseline and week 52, approximately 70 patients per group were planned for inclusion" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>52 weeks (+ 52 weeks)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: metformin ≥ 1500 mg/day + canagliflozin 100 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: metformin ≥ 1500 mg/day + canagliflozin 300 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.6</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1452</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1500‐2500 mg/day + glipizide 5‐20 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "To demonstrate non‐inferiority of dapagliflozin in comparison with glipizide as add‐on therapy to metformin for changes from baseline to week 52 in HbA1c with a non‐inferiority margin of 0.35%, assuming a standard deviation (SD) of 1.25%, and at a one‐sided significance level of 0.025, 280 evaluable patients were needed in each treatment group to provide approximately 90% power (given a true difference of zero between the 2 treatment groups). Assuming a 5% exclusion rate from the full analysis set, 295 patients per treatment group are needed for the full analysis set. Additionally, to have 90% power for the per‐protocol population and assuming a 25% exclusion rate from the per‐protocol population, 373 patients per treatment group (746 patients in total) were planned for randomization" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks (+156 weeks)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1500‐2500 mg/day + dapagliflozin 2.5‐10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.7</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>814<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>801</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>302</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>37.0</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin at any dose + glimepiride 1‐6 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "A sample size of 698 patients (349/treatment arm) was calculated for detecting superiority of saxagliptin in the primary endpoint, with a two‐sided significance level of 0.05 and 80% power. This assumed a 10% dropout rate and an odds ratio (OR) of 1.55 for achieving target HbA1c without hypoglycaemia with saxagliptin compared with glimepiride" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>957</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin at any dose + saxagliptin 5 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>720</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>718</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>574</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>79.7</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a><sup>e</sup> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg once daily or maximum tolerated dose + glipizide 5‐20 mg once daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Quote from publication:</b> "The planned randomization sample size for the study was between 815 and 897 patients per treatment arm. This ensured at least 95% power to declare non‐inferiority between either alogliptin dose (12.5 or 25 mg) and glipizide at week 104, assuming a non‐inferiority margin of 0.3%, no difference between either alogliptin dose and glipizide, a standard deviation of change from baseline of 1.2%, an evaluability rate of 60%, and a one‐sided 0.0125 significance level. The 0.0125 significance level was chosen so that, combined with similar analyses conducted at week 52, the overall one‐sided type 1 error rate for the trial was maintained at the 0.025 level" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>5789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>104 weeks (+ 2 weeks)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: metformin ≥ 1500 mg once daily or maximum tolerated dose + alogliptin 12.5 mg once daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: metformin ≥ 1500 mg once daily or maximum tolerated dose + alogliptin 25 mg once daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>885</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.7</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2639</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1089</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1392</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>52.7</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg daily + glimepiride 2‐4 mg once daily + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Quote from publication:</b> "The planned sample size provided &gt;90% power to demonstrate superiority versus placebo and noninferiority versus sitagliptin and glimepiride (noninferiority margin = 0.3%). Superiority of albiglutide versus sitagliptin and glimepiride was tested if noninferiority was established" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>104 weeks (+ 52 weeks)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: metformin ≥ 1500 mg daily + albiglutide 30‐50 mg once weekly + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: metformin ≥ 1500 mg daily + sitagliptin 100 mg once daily + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C3: metformin ≥ 1500 mg daily + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.9</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1049</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>321</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>628</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>59.9</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin immediate release ≥ 1500 mg/day plus glimepiride 1‐4 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "698 patients per group were needed to provide a power of at least 95% to show non‐inferiority, based on a margin of 0.3%, for the primary endpoint at weeks 52 and 104 if the true treatment effect is 0.05% (in favour of glimepiride) and SD is 1.2%" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2637</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>648 ( 2 years)</p> <p>589 (4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.1 (2 years)</p> <p>75.5 (4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>208 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin immediate release ≥ 1500 mg/day plus empagliflozin 25 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>652 (2 years)</p> <p>610 (4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.8 (2 years)</p> <p>79.3 (4 years)</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1549</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1545</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1300 (2 years)</b> </p> <p><b>1199 (4 years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>83.9 (2 years)</b> </p> <p><b>77.4 (4 years)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg daily + glipizide 5‐20 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "With 419 patients per treatment group, there was a 95% power to establish the non‐inferiority comparison on change from baseline to week 52 HbA1c at the 5% level, assuming that the standard deviation of change from baseline HbA1c was 1.1%, with a non‐inferiority limit set at 0.35% and a zero true difference between the two randomised treatments. The sample size assumed that 35% of randomised patients would be excluded from the PP analysis set" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks (+ 52 weeks)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin ≥ 1500 mg daily + saxagliptin 5 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.6</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>858</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>852</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>312</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>36.4</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 2550 mg/day plus glibenclamide 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "Considering a difference of at least 10% as clinically significant compared with the baseline and an α error of 0.05, the actual sample size was adequate to obtain a power higher than 0.80 to detect a significant between‐group difference in variables related to ultrasonography parameters" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 2550 mg/day plus pioglitazone 30 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>170</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>160</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>160</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>94.1</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1500‐2000 mg/day + glimepiride 1‐4 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><b>Quote from publication:</b> "Sample size calculations were based on showing A1C and body weight differences of 0.5 and 3%, respectively, after 6 months of treatment. The assumed standard deviation for A1C and the coefficient of variance for weight were 1.2 and 3%, respectively. The combined power (calculated as the product of the marginal powers for A1C and weight) was at least 85%" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>1662</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>26 weeks (+ 18 months)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: metformin 1500‐2000 mg/day + liraglutide 0.6 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: metformin 1500‐2000 mg/day + liraglutide 1.2 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C3: metformin 1500‐2000 mg/day + liraglutide 1.8 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C4: metformin 1500‐2000 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.4</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1091</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1059</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>529</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>48.5</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin median dose 2000 mg/day + glimepiride mean dose 2.01 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "We calculated sample size on the basis of the non‐inferiority test of exenatide versus glimepiride, an expected mean baseline HbA1c concentration of 8.2%, a 1 year patient accrual, maximum follow‐up of 3 years, dropout rate of 15% per year (for reasons other than treatment failure), and a 58% event rate in each group after 1 year. With these assumptions, 527 patients per study group would provide about a 90% power to conclude non‐inferiority of exenatide" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Max. follow‐up 3 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin median dose 2000 mg/day + exenatide mean dose 17.35 μg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>488</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.2</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1029</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>973</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>727</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>71.1</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg/day + glimepiride 1‐4 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "On the assumption of an SD of change in HbA1c from baseline of 1.3%, a sample size of 707 participants per treatment group was needed for 90% power to show non‐inferiority through a 97.5% CI for treatment difference in the adjusted mean change from baseline to endpoint of &lt; 0.35% HbA1c at the level of α=0.0125 (one‐sided)" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>104 weeks (+ 1 week)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin ≥ 1500 mg/day + linagliptin 5 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>587</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1552</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1519</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1191</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>77</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1000‐2000 mg/day + glimepiride 6 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "Considering as clinically significant a difference of at least the 10% compared to the baseline and an alpha error of 0.05, the actual sample size was adequate to obtain a power higher than 0.80 for all measured variable" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1000‐2000 mg/day + exenatide 20 μg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.2</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>111</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>101</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>101</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>91.0</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1700 ± 850 mg/day + glibenclamide 5‐15 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "Considering as clinically significant a difference of at least the 10% compared to the baseline and an alpha error of 0.05, the actual sample size was adequate to obtain a power higher than 0.80 for all measured variables" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1700 ± 850 mg/day + pioglitazone 15‐45 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.1</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>201</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>194</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>194</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>96.5</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1700 mg/day plus glimepiride 4 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>1 year</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1700 mg/day plus pioglitazone 30 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.2</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>78</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>68</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>68</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>87.2</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1500 ± 500 mg/day + glibenclamide 15 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1500 ± 500 mg/day + exenatide 20 μg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.7</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>128</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>116</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>116</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>90.6</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg twice a day + glimepiride 2‐6 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "With 3120 patients randomized (i.e. 1560 patients per treatment arm) and an overall 20% discontinuation rate, the study had 96% power to show non‐inferiority of vildagliptin compared with glimepiride (one‐sided α level of 0.0125, assuming a non‐inferiority margin of 0.3% HbA1c and a standard deviation of 1.25%)" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>approx. 6000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>953</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin ≥ 1500 mg twice a day + vildagliptin 50 mg twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.6</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3118</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2994</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1947</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>62.4</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1500 mg/day plus gliclazide 80‐320 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "Eight hundred patients (400 per group) were required to demonstrate non‐inferiority of vildagliptin to gliclazide in HbA1c reduction, with a one‐sided α level of 0.025 at the end of the study with 92% power (assuming a true difference of 0.1% in favour of gliclazide, standard deviation of HbA1c reduction at week 52 of 1.25 units and discontinuation rate of 20% over the 52‐week period)" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1500 mg/day plus vildagliptin 100 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>407</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1007</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>779</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>819</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>81.3</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg/day plus glipizide 5‐20 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin ≥ 1500 mg/day plus sitagliptin 100 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.4</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1172</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1135</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>519</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>44.3</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin up to 2550 mg/day + glibenclamide (or equivalent for different preparations) up to 15 mg/day or gliclazide up to 240 mg/day or glimepiride up to 4 mg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "For the non‐inferiority hypothesis, 4000 participants followed for a median time of 6 years were needed to give 99% power, provided that the active control group had an 11% event rate per year, allowing 2% annual loss to follow‐up. Blinded overall event tracking showed the event rate during the study was well below this rate. Therefore, endpoint sweeps were implemented to identify any missed events. An in‐depth review of a sample of individual records showed very few missed events" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Mean follow‐up: 5.5 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin up to 2550 mg/day + rosiglitazone up to 8 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>939</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.1</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2228</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2222</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1845</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>83.0</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 850 mg/day + glimepiride 2‐6 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Quote from publication:</b> "Considering as clinically significant a difference of at least 10% compared with the baseline and an α error of 0.05, the actual sample size is adequate to obtain a power higher than 0.80 for all variables related to glucose metabolism..." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>15 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: metformin 850‐2550 mg/day + pioglitazone 15‐45 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: metformin 1000‐3000 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>202</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>180</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>89.1</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1500‐3000 mg/day + glibenclamide 7.5‐15 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>1 year</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1500‐3000 mg/day + nateglinide 180‐360 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>248</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>233</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>233</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>94.0</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1700 mg/day + glimepiride 4 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>1 year</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1700 mg/day plus rosiglitazone 4 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>44</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>77.3</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 2000 mg/day + gliclazide 80‐320 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>36 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 2000 mg/day + rosiglitazone 4‐8 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.1</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>89</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>62</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>62</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69.7</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 2000 mg/day + glibenclamide 5‐15 mg/day or gliclazide 80‐320 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "The non‐inferiority margin was set at 0.4%. A sample size of 190 per treatment group was required to give a 90% probability that the upper limit of a two‐sided 95% CI for the difference in treatment means would be below 0.4% (significance level of 0.025 in a one‐sided test), assuming an SD of 1.2%. Assuming an attrition rate of 30%, 544 subjects were to be recruited" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 2000 mg/day + rosiglitazone 4‐8 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>596</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>573</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>463</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>77.7</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin &gt; 1000 mg/day + gliclazide 80‐240 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "A planned sample size of 120 patients per treatment was considered sufficient to detect an HbA1c difference of 0.5% with 90% power, assuming a dropout rate of 15% and an SD of 1.1 (calculated for 24 weeks treatment)" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks (+6 months)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin &gt; 1000 mg/day + nateglinide 180‐540 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.2</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>262</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>213</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>206</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>78.6</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin at pre‐study dose + gliclazide 80‐320 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "Sample size was based on demonstrating a between‐group difference of 0.35% in the change in HbA1c from baseline to week 52 (the primary efficacy variable) using a two‐sided t‐test. A total of 225 patients/group completing at least 24 weeks of the study was required, on the basis of a level of 95% power at 5% significance" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>104 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin at pre‐study dose + pioglitazone 15‐45 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.5</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>630</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>471</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>74.8</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1500 mg/day plus glimepiride 2 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "The study power was a priori calculated by using the World Wide Web‐available power calculator of the university of California, Los Angeles, Department of statistics (Los Angeles, CA)" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1500 mg/day plus rosiglitazone 4 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>99</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>96.0</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 500‐2000 mg/day + glyburide 1.25‐15 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>104 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 500‐2000 mg/day + nateglinide 180‐540 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.4</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>428</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>406</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>263</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>61.4</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><i>Grand total</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All interventions</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>12,863</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="3" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All c</i> <i>omparators</i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>15,883</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All interventions and c</i> <i>omparators</i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>28,746</i> </b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>‐ denotes not reported</p> <p><sup>a</sup>Follow‐up under randomised conditions until end of trial (= duration of intervention + follow‐up post‐intervention or identical to duration of intervention); extended follow‐up refers to follow‐up of participants once the original trial was terminated as specified in the power calculation.<br/> <sup>b</sup>The trial was conducted over 104 weeks in two 52‐week phases; the primary and secondary hypotheses were pre‐specified for testing at week 52 (phase A); treatment was continued for another 52 weeks (phase B) to evaluate longer‐term safety and efficacy.<br/> <sup>c</sup>The median duration of therapy was 12 (IQR 11–13) months, 12 (11–12) months for vildagliptin and 12 (7–13) months for glibenclamide.<br/> <sup>d</sup>Two participants did not take the drug.<br/> <sup>e</sup>The primary efficacy endpoint was the change in HbA1c from baseline to week 52 and to week 104. </p> <p><b>C</b> : comparator; <b>CI</b> : confidence interval; <b>FPG</b> : fasting plasma glucose; <b>HbA1c</b> : glycosylated haemoglobin A1c; <b>I</b> : intervention; <b>IQR</b> : interquartile range; <b>PP</b> : per protocol; <b>RCT</b> : randomised controlled trial; <b>SD</b>: standard deviation </p> </div> </div> <div class="table" id="CD012368-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Overview of trials (trial arms), comparators, intervention and number of randomised participants</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Drug class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trials (trial arms) (N)<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metformin + comparator: randomised participants (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Metformin + sulphonylurea: randomised participants (N)<sup>b</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thiazolidinediones</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p><b>Total</b> :<b>11 (11)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pioglitazone 15‐45 mg: 1541</p> <p>Pioglitazone 15‐45 mg: 102</p> <p>Pioglitazone 15‐45 mg: 69</p> <p>Pioglitazone: 15‐45 mg: 317</p> <p>Pioglitazone 30 mg: 86</p> <p>Pioglitazone 30 mg: 39</p> <p>Rosiglitazone 4 mg: 22</p> <p>Rosiglitazone 4 mg: 50</p> <p>Rosiglitazone 4‐8 mg: 45</p> <p>Rosiglitazone 4‐8 mg: 294</p> <p>Rosiglitazone up to 8 mg: 1120</p> <p><b>Total</b> :<b>3685</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glimepiride/glibenclamide/gliclazide: 1500</p> <p>Glibenclamide: 99</p> <p>Glimepiride: 66</p> <p>Gliclazide: 313</p> <p>Glibenclamide: 84</p> <p>Glimepiride: 39</p> <p>Glimepiride: 22</p> <p>Glimepiride: 49</p> <p>Gliclazide: 44</p> <p>Glibenclamide/gliclazide: 302</p> <p>Glibenclamide/gliclazide/glimepiride: 1108</p> <p><b>Total</b> :<b>3626</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DPP‐4 inhibitors</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p><b>Total</b> : <b>10 (11)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alogliptin 12.5 mg: 880</p> <p>Alogliptin 25 mg: 885</p> <p>Linagliptin 5 mg: 777</p> <p>Omarigliptin 25 mg: 376</p> <p>Saxagliptin 5 mg: 360</p> <p>Saxagliptin 5 mg: 428</p> <p>Sitagliptin 100 mg: 313</p> <p>Sitagliptin 100 mg: 588</p> <p>Vildagliptin 50 mg: 1562</p> <p>Vildagliptin 100 mg: 40</p> <p>Vildagliptin 100 mg: 513</p> <p><b>Total</b> : <b>6722</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glipizide: 874<br/> (Glipizide: 874) </p> <p>Glimepiride: 775</p> <p>Glimepiride: 375</p> <p>Glimepiride: 360</p> <p>Glipizide: 430</p> <p>Glimepiride: 317</p> <p>Glipizide: 584</p> <p>Glimepiride: 1556</p> <p>Glibenclamide: 24</p> <p>Gliclazide: 494</p> <p><b>Total</b> : <b>5789</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GLP‐1 agonists</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p><b>Total</b> : <b>5 (7)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albiglutide 30‐50 mg: 315</p> <p>Exenatide 17.35 µg: 515</p> <p>Exenatide 20 µg: 57</p> <p>Exenatide 20 µg: 63</p> <p>Liraglutide 0.6 mg: 242</p> <p>Liraglutide 1.2 mg: 241</p> <p>Liraglutide 1.8 mg: 242</p> <p><b>Total</b> : <b>1675</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glimepiride: 317</p> <p>Glimepiride: 514</p> <p>Glimepiride: 54</p> <p>Glibenclamide: 65</p> <p>Glimepiride: 244</p> <p>(Glimepiride: 244)</p> <p>(Glimepiride: 244)</p> <p><b>Total</b> : <b>1194</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SGLT‐2 inhibitors</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p><b>Total</b> : <b>4 (6)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canagliflozin 100 mg: 483</p> <p>Canagliflozin 300 mg: 485</p> <p>Dapagliflozin 2.5‐10 mg: 406</p> <p>Empagliflozin 25 mg: 769</p> <p>Ertugliflozin 5 mg: 448</p> <p>Ertugliflozin 15 mg: 441</p> <p><b>Total</b> : <b>3032</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glimepiride: 484</p> <p>(Glimepiride: 484)</p> <p>Glipizide: 408</p> <p>Glimepiride: 780</p> <p>Glimepiride: 437</p> <p>(Glimepiride: 437)</p> <p><b>Total</b> : <b>2109</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Glinides</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> <p>1</p> <p>1</p> <p><b>Total</b> : <b>3 (3)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nateglinide 180‐360 mg: 124</p> <p>Nateglinide 180‐540 mg: 133</p> <p>Nateglinide 180‐540 mg: 219</p> <p><b>Total</b> : <b>476</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glibenclamide: 124</p> <p>Gliclazide: 129</p> <p>Glyburide: 209</p> <p><b>Total</b> : <b>462</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metformin monotherapy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> <p>1</p> <p>1</p> <p><b>Total</b> :<b>3 (3)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metformin ≥1500 mg: 104</p> <p>Metformin 1500‐2000 mg: 122</p> <p>Metformin 1000‐3000 mg: 67</p> <p><b>Total</b> : <b>293</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(Glimepiride: 317)</p> <p>(Glimepiride: 244)</p> <p>(Glimepiride: 66)</p> <p>(Total: 627)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Total number of unique included trials was 32 with 41 trial arms.<br/> <sup>b</sup>Numbers of randomised participants for metformin combination therapy do not add up correctly because several trials had one intervention with several comparator groups, the intervention group may therefore appear in several drug classes and is characterised by parentheses; combination therapy data for metformin monotherapy are shown for illustrative purposes. </p> <p><b>DPP4‐I</b> : dipeptidyl‐peptidase 4; <b>GLP‐1</b> : glucagon‐like peptide‐1 agonist; <b>SGLT‐2</b>: sodium‐glucose transport 2 </p> </div> </div> <p>We provided information about potentially relevant ongoing trials in the <a href="./references#CD012368-sec-0279" title="">Characteristics of ongoing studies</a> table and in <a href="./appendices#CD012368-sec-0252">Appendix 7</a> 'Matrix of trial outcome (publications and trial endpoints)'. </p> <p>We emailed all authors of included trials to enquire whether they were willing to answer questions regarding their trials. We presented the results of this survey in <a href="./appendices#CD012368-sec-0260">Appendix 15</a> 'Survey of trial investigators providing information on studies'. We sought relevant missing information on the trial from the primary author(s) of the article, if possible. </p> <section id="CD012368-sec-0061"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents or multiple reports of a primary trial, we maximised the information yield by collating all available data and used the most complete dataset aggregated across all known publications. We listed duplicate publications, companion documents, multiple reports of a primary trial and trial documents of included trials (such as trial registry information) as secondary references under the study identifier (ID) of the included trial. Furthermore, we also listed duplicate publications, companion documents, multiple reports of a trial and trial documents of excluded trials (such as trial registry information) as secondary references under the study ID of the excluded trial. </p> </section> <section id="CD012368-sec-0062"> <h5 class="title">Data from clinical trial registers</h5> <p>In case data of included trials were available as study results in clinical trials registers such as <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>, we made full use of this information and extracted the data. If there was also a full publication of the trial, we collated and critically appraised all available data. If a trial fulfilled the inclusion criteria and was marked as a completed study in the clinical trials register but no additional information was available, we added this trial to the table of '<a href="./references#CD012368-bbs1-0003" title="">Studies awaiting classification</a>'. </p> </section> </section> <section id="CD012368-sec-0063"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (KM and PK, LK or FG) independently assessed the risk of bias of each included trial. We resolved disagreements by consensus, or by consultation with an additional review author (BH). In cases of disagreement, we consulted the remainder of the review author team and made a judgement based on consensus. If adequate information was not available from the publications, trial protocols, or other sources, we contacted the trial authors for more detail to request missing data on 'Risk of bias' items. </p> <p>We used the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD012368-bbs2-0150" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. ">Higgins 2011a</a>; <a href="./references#CD012368-bbs2-0152" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>) assigning assessments of low, high, or unclear risk of bias (for details, see <a href="./appendices#CD012368-sec-0247">Appendix 2</a>; <a href="./appendices#CD012368-sec-0248">Appendix 3</a>). We evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, according to the criteria and associated categorisations contained therein (<a href="./references#CD012368-bbs2-0152" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). </p> <section id="CD012368-sec-0064"> <h5 class="title">Summary assessment of risk of bias</h5> <p>We presented a 'Risk of bias' graph and a 'Risk of bias' summary figure.</p> <p>We distinguished between self‐reported, investigator‐assessed and adjudicated outcome measures. </p> <p>We considered the following outcomes as self‐reported.</p> <p> <ul id="CD012368-list-0012"> <li> <p>Health‐related quality of life</p> </li> <li> <p>Non‐serious adverse events</p> </li> <li> <p>Hypoglycaemia</p> </li> <li> <p>Weight</p> </li> </ul> </p> <p>We considered the following outcomes as investigator‐assessed.</p> <p> <ul id="CD012368-list-0013"> <li> <p>All‐cause mortality</p> </li> <li> <p>Serious adverse events</p> </li> <li> <p>Cardiovascular mortality</p> </li> <li> <p>Non‐fatal myocardial infarction</p> </li> <li> <p>Heart failure</p> </li> <li> <p>Non‐fatal stroke</p> </li> <li> <p>Amputation of lower extremity</p> </li> <li> <p>Blindness or severe vision loss</p> </li> <li> <p>End‐stage renal disease</p> </li> <li> <p>Hypoglycaemia</p> </li> <li> <p>Socio‐economic effects</p> </li> <li> <p>Weight</p> </li> <li> <p>HbA1c</p> </li> </ul> </p> <p><b>Risk of bias for a trial across outcomes</b><br/> Some risk of bias domains, such as selection bias (sequence generation and allocation sequence concealment), affected the risk of bias across all outcome measures in a trial. In case of high risk of selection bias, we marked all outcomes investigated in the associated trial as high risk. Otherwise, we did not perform a summary assessment of the risk of bias across all outcomes for a trial. </p> <p><b>Risk of bias for an outcome within a trial and across domains</b><br/> We assessed the risk of bias for an outcome measure by including all entries relevant to that outcome (i.e. both trial‐level entries and outcome‐specific entries). We considered low risk of bias to denote a low risk of bias for all key domains, unclear risk to denote an unclear risk of bias for one or more key domains and high risk to denote a high risk of bias for one or more key domains. </p> <p><b>Risk of bias for an outcome across trials and across domains</b><br/> These were our main summary assessments that we incorporated into our judgements about the certainty of the evidence in <a href="./full#CD012368-tbl-0001">summary of findings Table for the main comparison</a>. We defined outcomes as at low risk of bias when most information came from trials at low risk of bias, unclear risk when most information came from trials at low or unclear risk of bias, and high risk when a sufficient proportion of information came from trials at high risk of bias. </p> </section> </section> <section id="CD012368-sec-0065"> <h4 class="title">Measures of treatment effect</h4> <p>When at least two trials were available for a comparison of a given outcome, we expressed dichotomous data as risk ratio (RR) or an odds ratio (OR) with 95% confidence interval (CI). For continuous outcomes measured on the same scale (e.g. weight loss in kg) we estimated the intervention effect using the mean difference (MD) with 95% CI. For continuous outcomes measuring the same underlying concept (e.g. health‐related quality of life) but applying different measurement scales, we calculated the standardised mean difference (SMD). We planned to calculate time‐to‐event data as hazard ratio (HR) with 95% CI with the generic inverse variance method. </p> <p>The scales measuring health‐related quality of life could go in different directions. Some scales increase in values with improved health‐related quality of life, whereas other scales decrease in values with improved health‐related quality of life. To adjust for the different directions of the scales, we planned to multiply the scales that reported better health‐related quality of life with decreasing values by ‐1. </p> </section> <section id="CD012368-sec-0066"> <h4 class="title">Unit of analysis issues</h4> <p>We took into account the level at which randomisation occurred, for example in cross‐over trials, cluster‐randomised trials and multiple observations for the same outcome. If more than one comparison from the same trial was eligible for inclusion in the same meta‐analysis, we either combined groups to create a single pair‐wise comparison or we appropriately reduced the sample size so that the same participants did not contribute multiply (splitting the 'shared' group into two or more groups). Although the latter approach offers some solution for adjusting the precision of the comparison, it does not account for correlation arising from inclusion of the same set of participants in multiple comparisons (<a href="./references#CD012368-bbs2-0151" title="HigginsJP , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.cochrane.org. ">Higgins 2011b</a>). </p> <p>We planned to re‐analyse cluster‐RCTs that did not appropriately adjust for potential clustering of participants within clusters in their analyses. Variance of the intervention effects was planned to be inflated by a design effect (DEFF). Calculation of a DEFF involves estimation of an intra‐cluster correlation (ICC). We planned to obtain estimates of ICCs by contacting trial authors, or by imputing ICC values using either estimates from other included trials that reported ICCs or external estimates from empirical research (e.g. <a href="./references#CD012368-bbs2-0119" title="BellML , McKenzieJE . Designing psycho‐oncology randomised trials and cluster randomised trials: variance components and intra‐cluster correlation of commonly used psychosocial measures. Psycho‐oncology2013;22:1738‐47. ">Bell 2013</a>). We planned to examine the impact of clustering by performing sensitivity analyses. </p> </section> <section id="CD012368-sec-0067"> <h4 class="title">Dealing with missing data</h4> <p>We tried to obtain missing data from trial authors and carefully evaluate important numerical data such as screened, randomly‐assigned participants as well as intention‐to‐treat (ITT), and as‐treated and per‐protocol populations. We investigated attrition rates (e.g. dropouts, losses to follow‐up, withdrawals), and we critically appraised issues concerning missing data and imputation methods (e.g. last observation carried forward (LOCF)). </p> <p>In trials where the standard deviation of the outcome was not available at follow‐up or could not be recreated, we standardised by the average of the pooled baseline standard deviation (SD) from those trials in which this information was reported. </p> <p>When included trials did not report means and SDs for outcomes and we did not receive the necessary information from trial authors, we imputed these values by estimating the mean and variance from the median, range, and the size of the sample (<a href="./references#CD012368-bbs2-0154" title="HozoSP , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology2005;5:13. [DOI: 10.1186/1471‐2288‐5‐13] ">Hozo 2005</a>). </p> <p>We planned to investigate the impact of imputation on meta‐analyses by performing sensitivity analyses. </p> </section> <section id="CD012368-sec-0068"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of substantial clinical or methodological heterogeneity, we planned not to report trial results as the pooled effect estimate in a meta‐analysis. </p> <p>We identified heterogeneity (inconsistency) by visually inspecting the forest plots and by using a standard Chi² test with a significance level of α = 0.1 (<a href="./references#CD012368-bbs2-0130" title="DeeksJJ , HigginsJP , Altman DG (editors): on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). In view of the low power of this test, we also considered the I² statistic, which quantifies inconsistency across trials to assess the impact of heterogeneity on the meta‐analysis (<a href="./references#CD012368-bbs2-0146" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21:1539‐58. ">Higgins 2002</a>; <a href="./references#CD012368-bbs2-0147" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analysis. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>); an I² statistic of 75% or more indicates a considerable level of heterogeneity (<a href="./references#CD012368-bbs2-0151" title="HigginsJP , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.cochrane.org. ">Higgins 2011b</a>). </p> <p>When heterogeneity was present, we attempted to determine possible reasons for it by examining individual trial and subgroup characteristics. </p> </section> <section id="CD012368-sec-0069"> <h4 class="title">Assessment of reporting biases</h4> <p>If we included 10 or more trials investigating a particular outcome, we planned to use funnel plots to assess small‐trial effects. Several explanations may account for funnel plot asymmetry, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials) and publication bias (<a href="./references#CD012368-bbs2-0204" title="SterneJA , EggerM , MoherD , BoutronI (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Sterne 2017</a>). Therefore, we planned to interpret the results carefully (<a href="./references#CD012368-bbs2-0203" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ2011;343:d4002. ">Sterne 2011</a>). </p> </section> <section id="CD012368-sec-0070"> <h4 class="title">Data synthesis</h4> <p>We undertook meta‐analysis only if we judged participants, interventions, comparisons and outcomes to be sufficiently similar to ensure an answer that was clinically meaningful. Unless good evidence showed homogeneous effects across trials, we primarily summarised data at low risk of bias using a random‐effects model (<a href="./references#CD012368-bbs2-0218" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. ">Wood 2008</a>). We interpreted random‐effects meta‐analyses with consideration to the whole distribution of effects, ideally by presenting a prediction interval (<a href="./references#CD012368-bbs2-0148" title="HigginsJP , ThompsonSG , SpiegelhalterDJ . A re‐evaluation of random‐effects meta‐analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society)2009;172(1):137‐59. ">Higgins 2009</a>). A prediction interval specifies a predicted range for the true treatment effect in an individual trial (<a href="./references#CD012368-bbs2-0190" title="RileyRD , HigginsJP , DeeksJJ . Interpretation of random effects meta‐analyses. BMJ2011;342:d549. ">Riley 2011</a>). In addition, we performed statistical analyses according to the statistical guidelines presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012368-bbs2-0130" title="DeeksJJ , HigginsJP , Altman DG (editors): on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> <section id="CD012368-sec-0071"> <h5 class="title">Trial sequential analyses</h5> <p>In a single trial, sparse data and interim analyses increase the risk of type I and type II errors. To avoid type I errors, group sequential monitoring boundaries are applied to decide whether a trial could be terminated early because of a sufficiently small P value, that is the cumulative Z‐curve crosses the monitoring boundaries (<a href="./references#CD012368-bbs2-0165" title="LanKK , DeMetsDL . Discrete sequential boundaries for clinical trials. Biometrika1983;70:659‐63. ">Lan 1983</a>). Likewise, before reaching the planned sample size of a trial, the trial may be stopped due to futility if the cumulative Z‐score crosses the futility monitoring boundaries (<a href="./references#CD012368-bbs2-0151" title="HigginsJP , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.cochrane.org. ">Higgins 2011b</a>). Sequential monitoring boundaries for benefit, harm, or futility can be applied to meta‐analyses as well, called trial sequential monitoring boundaries (<a href="./references#CD012368-bbs2-0149" title="HigginsJP , WhiteheadA , SimmondsM . Sequential methods for random‐effects meta‐analysis. Statistics in Medicine2011;30(9):903‐21. [PUBMED: 21472757] ">Higgins 2011</a>; <a href="./references#CD012368-bbs2-0211" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). In a trial sequential analysis (TSA), the addition of each trial in a cumulative meta‐analysis is regarded as an interim meta‐analysis and helps to clarify if significance is reached or futility is reached or whether additional trials are needed (<a href="./references#CD012368-bbs2-0211" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). </p> <p>TSA combines a calculation of the diversity‐adjusted required information size (cumulated meta‐analysis sample size to detect or reject a specific relative intervention effect) for meta‐analysis with the threshold of data associated with statistics (<a href="./references#CD012368-bbs2-0187" title="PogueJM , YusufS . Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta‐analysis. Controlled Clinical Trials1997;18(6):580‐93; discussion 661‐6. [PUBMED: 9408720] ">Pogue 1997</a>; <a href="./references#CD012368-bbs2-0211" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). </p> <p>The idea in TSA is that if the cumulative Z‐curve crosses the boundary for benefit or harm before a diversity‐adjusted required information size is reached, a sufficient level of evidence for the anticipated intervention effect has been reached with the assumed type I error and no further trials may be needed. If the cumulative Z‐curve crosses the boundary for futility before a diversity‐adjusted required information size is reached, the assumed intervention effect can be rejected with the assumed type II error and no further trials may be needed. If the Z‐curve does not cross any boundary, then there is insufficient evidence to reach a conclusion. To construct the trial sequential monitoring boundaries, the required information size is needed and is calculated as the least number of participants needed in a well‐powered single trial and subsequently adjusted for diversity among the included trials in the meta‐analysis (<a href="./references#CD012368-bbs2-0211" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). We applied TSA as it decreases the risk of type I and II errors due to sparse data and multiple updating in a cumulative meta‐analysis, and it provides us with important information in order to estimate the risks of imprecision when the required information size is not reached. Additionally, TSA provides important information regarding the need for additional trials and the required information size of such trials (<a href="./references#CD012368-bbs2-0211" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). </p> <p>We applied trial sequential monitoring boundaries according to an estimated clinical important effect. We based the required information size on an a priori effect corresponding to a 10% relative risk reduction (RRR). </p> <p>We performed TSA for continuous outcomes with mean differences, by using the trials applying the same scale to calculate the required sample size. For the continuous outcomes we tested the evidence for the achieved differences in the cumulative meta‐analyses. </p> <p>For the heterogeneity adjustment of the required information size we used the diversity (D²) estimated in the meta‐analyses of included trials. </p> <p>We performed TSA on primary and secondary outcomes.</p> </section> </section> <section id="CD012368-sec-0072"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to introduce clinical heterogeneity and carried out the following subgroup analyses (on our primary and secondary outcomes) including investigation of interactions (<a href="./references#CD012368-bbs2-0113" title="AltmanDG , BlandJM . Interaction revisited: the difference between two estimates. BMJ2003;326(7382):219. [PUBMED: 12543843] ">Altman 2003</a>). </p> <p> <ul id="CD012368-list-0014"> <li> <p>Trials with a long duration (≥ 2 years) versus trials with a short duration (&lt; 2 years).</p> </li> <li> <p>Trials including obese participants versus trials including non‐obese participants.</p> </li> </ul> </p> </section> <section id="CD012368-sec-0073"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses on our primary and secondary outcomes to explore the influence of the following factors (when applicable) on effect sizes, by restricting the analysis to the following. </p> <p> <ul id="CD012368-list-0015"> <li> <p>Published trials</p> </li> <li> <p>Effect of risk of bias, as specified in the <a href="#CD012368-sec-0063">Assessment of risk of bias in included studies</a> section </p> </li> <li> <p>Very long or large trials, to establish the extent to which they dominate the results</p> </li> <li> <p>Use of the following filters: diagnostic criteria, imputation, language of publication, source of funding (industry versus other), or country </p> </li> </ul> </p> <p>We also tested the robustness of results by repeating analyses using different measures of effect size (i.e. RR, OR, etc.) and different statistical models (fixed‐effect and random‐effects models). </p> <section id="CD012368-sec-0074"> <h5 class="title">Certainty of the evidence</h5> <p>We presented the overall certainty of the evidence for each outcome specified below, according to the GRADE approach, which takes into account issues relating not only to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity, such as directness of results<i>.</i> Two review authors (KM and PK, LK or FG) independently rated the certainty of the evidence for each outcome. </p> <p>We included an appendix titled 'Checklist to aid consistency and reproducibility of GRADE assessments' to help with the standardisation of the 'Summary of findings' tables (<a href="./references#CD012368-bbs2-0175" title="MeaderN , KingK , LlewellynA , NormanG , BrownJ , RodgersM , et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews2014;3:82. ">Meader 2014</a>). Alternatively, we would have used the GRADEpro Guideline Development Tool (GDT) software and presented evidence profile tables as an appendix (<a href="./references#CD012368-bbs2-0137" title="McMaster University (developed by Evidence Prime). GRADEproGDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015 (accessed 28 February 2018). ">GRADEproGDT 2015</a>). We presented results for outcomes as described in the <a href="#CD012368-sec-0048">Types of outcome measures</a> section. If meta‐analysis was not possible, we presented the results in a narrative format in the 'Summary of findings' table. We justified all decisions to downgrade the certainty of the evidence using footnotes, and we made comments to aid the reader's understanding of the Cochrane Review when necessary. </p> <section id="CD012368-sec-0075"> <h6 class="title">'Summary of findings' table</h6> <p>We presented a summary of the evidence in <a href="./full#CD012368-tbl-0001">summary of findings Table for the main comparison</a>. This provides key information about the best estimate of the magnitude of effect, in relative terms and as absolute differences for each relevant comparison of alternative management strategies, numbers of participants and trials addressing each important outcome, and rates the overall confidence in effect estimates for each outcome. We created the 'Summary of findings' table using the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012368-bbs2-0199" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , et al. on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2017</a>), along with Review Manager 5 (RevMan 5) table editor (<a href="./references#CD012368-bbs2-0189" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We reported the following outcomes, listed according to priority. </p> <p> <ul id="CD012368-list-0016"> <li> <p>All‐cause mortality</p> </li> <li> <p>Cardiovascular mortality</p> </li> <li> <p>Serious adverse events</p> </li> <li> <p>Non‐fatal stroke</p> </li> <li> <p>Non‐fatal myocardial infarction</p> </li> <li> <p>Microvascular complications (end‐stage renal disease, blindness or severe vision loss, amputation of lower extremity) </p> </li> <li> <p>Health‐related quality of life</p> </li> </ul> </p> </section> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012368-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012368-sec-0076"></div> <section id="CD012368-sec-0077"> <h3 class="title">Description of studies</h3> <p>For a detailed description of trials, see <a href="#CD012368-tbl-0002">Table 1</a>, <a href="#CD012368-tbl-0003">Table 2</a>, '<a href="./references#CD012368-sec-0276" title="">Characteristics of included studies</a>', '<a href="./references#CD012368-sec-0277" title="">Characteristics of excluded studies,</a> and '<a href="./references#CD012368-sec-0279" title="">Characteristics of ongoing studies</a>'. </p> <section id="CD012368-sec-0078"> <h4 class="title">Results of the search</h4> <p>Our databases search identified 2754 records to be screened. We excluded most of the records on the basis of their titles and abstracts because they clearly did not meet the inclusion criteria. We assessed a total of 296 full‐text articles/records for eligibility. After screening, 32 trials with 41 trial arms, published in 164 publications/records finally met our inclusion criteria. </p> <p>Handsearching of systematic reviews and reference lists identified two trials described in seven publications (<a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>). Handsearching of manufacturers' websites identified eight records. </p> <p>We excluded a total of 118 full‐text articles/records, 80 of these publications/records described 62 trials and 38 of these publications/records did not describe trials. We identified nine ongoing trials described in 11 publications/records (see '<a href="./references#CD012368-bbs1-0004" title="">Ongoing studies</a>'). We identified two trials awaiting assessment (see '<a href="./references#CD012368-sec-0278" title="">Characteristics of studies awaiting classification</a>'). For an overview of trial selection, please see <a href="#CD012368-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD012368-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Trial flow diagram  AHRQ: Agency for Healthcare Research and Quality; DPP4‐I: dipeptidyl‐peptidase 4 inhibitor; GLP1‐A: glucagon‐like peptide 1 analogue; M+S: metformin + sulphonylurea; SGLT2‐I: sodium‐glucose co‐transporter 2 inhibitor" data-id="CD012368-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial flow diagram<br/> <b>AHRQ</b> : Agency for Healthcare Research and Quality; <b>DPP4‐I</b> : dipeptidyl‐peptidase 4 inhibitor; <b>GLP1‐A</b> : glucagon‐like peptide 1 analogue; <b>M+S</b> : metformin + sulphonylurea; <b>SGLT2‐I</b>: sodium‐glucose co‐transporter 2 inhibitor </p> </div> </div> </div> </section> <section id="CD012368-sec-0079"> <h4 class="title">Included studies</h4> <p>A detailed description of the characteristics of included trials is presented elsewhere (see <a href="./references#CD012368-sec-0276" title="">Characteristics of included studies</a> and <a href="./appendices#CD012368-sec-0249">Appendix 4</a>; <a href="./appendices#CD012368-sec-0250">Appendix 5</a>; <a href="./appendices#CD012368-sec-0251">Appendix 6</a>; <a href="./appendices#CD012368-sec-0252">Appendix 7</a>; <a href="./appendices#CD012368-sec-0253">Appendix 8</a>; <a href="./appendices#CD012368-sec-0254">Appendix 9</a>; <a href="./appendices#CD012368-sec-0255">Appendix 10</a>; <a href="./appendices#CD012368-sec-0256">Appendix 11</a>; <a href="./appendices#CD012368-sec-0257">Appendix 12</a>; <a href="./appendices#CD012368-sec-0258">Appendix 13</a>; <a href="./appendices#CD012368-sec-0259">Appendix 14</a>). The following is a succinct overview. </p> <section id="CD012368-sec-0080"> <h5 class="title">Source of data</h5> <p>Twenty‐six trials reported data with relevance for this review, published in medical journals (<a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). </p> <p>Fourteen trials reported data in trials registers (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>). </p> <p>Six trials reported data on the manufacturer's website (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>). </p> <p>We contacted all trial authors or investigators by email (see <a href="./appendices#CD012368-sec-0260">Appendix 15</a>). When important information was lacking on ongoing studies and excluded trials, we contacted investigators for clarification (see <a href="./appendices#CD012368-sec-0260">Appendix 15</a>). We only received additional data on four included trials through correspondence with authors (<a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). </p> </section> <section id="CD012368-sec-0081"> <h5 class="title">Comparisons</h5> <p>One trial compared M+S with metformin monotherapy (<a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>). Two trials compared M+S with metformin plus placebo (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). Five trials compared M+S with metformin plus a GLP‐1 analogue (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). Nine trials compared M+S with metformin plus a DPP‐4 inhibitor (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>). One trial compared M+S with metformin plus long‐acting DPP‐4 inhibitor (<a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>). Eleven trials compared M+S with metformin plus a thiazolidinedione (<a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a>; <a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). Three trials compared M+S with metformin plus a glinide (<a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>). Four trials compared M+S with metformin plus a SGLT‐2 inhibitor (<a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>). </p> <p>Several trials implemented more than two comparison groups within their trial designs. For an overview of trials, trial arms, comparators, interventions and number of randomised participants see <a href="#CD012368-tbl-0003">Table 2</a>. </p> </section> <section id="CD012368-sec-0082"> <h5 class="title">Overview of trial populations</h5> <p>All, but seven trials provided information on sample size calculations (<a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>). All, but 10 trials reported the total number of participants screened (<a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>). A total of 12,863 participants were randomised to M+S and 15,833 participants were randomised to a comparator. The percentage of participants finishing the trial was approximately 69% in the M+S group and 69% in the comparator groups. Number of randomised participants ranged from 22 to 1556 in the M+S groups and from 22 to 1765 in the comparator groups (<a href="#CD012368-tbl-0002">Table 1</a>). </p> </section> <section id="CD012368-sec-0083"> <h5 class="title">Trial design</h5> <p>All of the 32 trials were randomised controlled trials with a parallel design. In 15 trials the primary trial structure had a non‐inferiority design (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>). </p> <p>Two trials had both a placebo group and an active comparator group (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>), the rest of the included trials had an active comparator group. Two trials were single‐centre trials (<a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>). Two trials did not report number of centres (<a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>). The remaining trials were multicentre trials, defined as two or more centres. Seven trials were open‐labelled for participants and personnel (<a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). Two trials were single‐blind for investigators but not for the participants (<a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>). The remaining trials were double‐blinded for investigators and participants. Three trials did not report blinding of outcome assessors for any outcome (<a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>). The remaining trials reported blinding of outcome assessors for one or more outcomes. Trials were performed between the years 2001 to 2017. The duration of the intervention ranged from 52 weeks to 208 weeks. Twenty trials had a run‐in period (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>). The remaining trials did not report any run‐in period. Two trials were terminated early (<a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a> had a higher than expected discontinuation rate and fewer participants than expected reached the primary endpoint. <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a> had a lower than expected rate of primary endpoint events during follow‐up. </p> <p>Eleven trials had an extended follow‐up period (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a>; <a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>). With the exception of <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a> all had high attrition rates between the original time of follow‐up and the extended follow‐up. Four trials reported that they were able to keep the double‐blinding conditions (<a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>). </p> </section> <section id="CD012368-sec-0084"> <h5 class="title">Settings</h5> <p>All trials were conducted in outpatient clinics.</p> </section> <section id="CD012368-sec-0085"> <h5 class="title">Participants</h5> <p>All the trials included people with T2DM and with HbA1c ranging from 7% to 9% (<a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>); 7% to 9.5% (<a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>); 6.5% to 10% (<a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>); 7% to 10% (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>); 7% to 11% (<a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>); 6.8% to 9% (<a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>); 7.5% to 11% (<a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>); 6.5% to 8.5% (<a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>); 6.5% to 9% (<a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>); more than 6.5% (<a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>); more than 7% (<a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>) and more than 8% (<a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>). </p> <p>One trial did not report the duration of T2DM at baseline (<a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>). For the rest of the trials the mean duration of T2DM ranged from newly diagnosed to more than 10 years. </p> <p>All trials included both genders. The percentage of women ranged from 29% to 65%.</p> <p>The mean age of the participants ranged from 52 years to 73 years. One trial only included participants aged 65 years and more (<a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>). </p> <p>Mean HbA1c at baseline ranged from 7.3% to 9.3%.</p> <p>Ten trials did not report any comorbidities, cointerventions or comedications (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>). </p> <p>Major exclusion criteria were type 1 diabetes mellitus or secondary forms of diabetes, diabetic complications (nephropathy, retinopathy, neuropathy), history of ketoacidosis, organ failure (renal, hepatic, heart), history of pancreatitis, new cardiovascular event or pregnancy. </p> </section> <section id="CD012368-sec-0086"> <h5 class="title">Diagnosis</h5> <p>Five trials applied the diagnostic criteria of T2DM as defined by the European Association for the Study of Diabetes (EASD) 2007 guideline (<a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>), four trials used the definition of the World Health Organization (WHO) 1999/2006 criteria (<a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>), two trials used the American Diabetes Association (ADA) 2001 criteria (<a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>), one trial applied the ADA 1997 criteria (<a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>), and one trial applied the ADA 2017 criteria (<a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>). The remaining trials did not report diagnostic criteria for T2DM. </p> </section> <section id="CD012368-sec-0087"> <h5 class="title">Interventions</h5> <p>Metformin was administered in all intervention and comparator arms and was mostly given in doses of 500 mg/day to 3000 mg/day (<a href="./appendices#CD012368-sec-0249">Appendix 4</a>). </p> <p>Second‐generation sulphonylurea was administered either as glibenclamide, in doses of 5 mg/day to 15 mg/day (<a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>); gliclazide, in doses of 30 to 320 mg/day (<a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>); or glipizide, in doses of 5 to 20 mg/day (<a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>). Third‐generation sulphonylurea was administered as glimepiride, in doses of 1 mg/day to 8 mg/day (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>). Two trials administered more than one kind of sulphonylurea, that is, glibenclamide or gliclazide (<a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>), or glibenclamide, gliclazide or glimepiride (<a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). </p> <p>GLP‐1 analogues were administered as albiglutide, in doses of 30 mg to 50 mg once weekly (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>); exenatide, in doses of 10 μg/day to 20 μg/day (<a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>); or liraglutide, in doses of 0.6 mg/day to 1.8 mg/day (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). </p> <p>DPP‐4 inhibitors were administered as either sitagliptin, in doses of 100 mg/day (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>); vildagliptin (in doses of 100 mg/day (<a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>); alogliptin, in doses of 12.5 mg/day to 25 mg/day (<a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>); linagliptin (in doses of 5 mg/day (<a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>); or saxagliptin, in doses of 5 mg/day (<a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>). </p> <p>Thiazolidinediones were administered as either rosiglitazone, in doses of 4 mg/day to 8 mg/day (<a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>); or pioglitazone, in doses of 15 mg/day to 45 mg/day (<a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). </p> <p>Glinides were administered as nateglinide, in doses of 180 mg/day to 540 mg/day (<a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>). </p> <p>SGLT‐2 inhibitors were administered as either dapagliflozin, in doses of 2.5 mg/day to 10 mg/day (<a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>); canagliflozin, in doses of 100 mg/day to 300 mg/day (<a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>); empagliflozin, in doses of 25 mg/day (<a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>); or ertugliflozin, in doses of 5 mg/day to 15 mg/day (<a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>). </p> <p>Long‐acting DPP‐4 inhibitors were administered as omarigliptin, in doses of 25 mg/week (<a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>). </p> <p>Two trials compared M+S with metformin plus placebo (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). </p> <p>Twelve trials reported counselling for diet and exercise (<a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>). One trial counselled on diet only (<a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a>). The remaining trials did not provide information about counselling. </p> </section> <section id="CD012368-sec-0088"> <h5 class="title">Outcomes</h5> <p>Six trials did not define a primary outcome (<a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>). None of these trials was registered in ClinicalTrials.gov or had a design paper published. </p> <p>Twenty trials were registered at ClinicalTrials.gov (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). </p> <p>Most trials used HbA1c as the primary outcome measure.</p> <p>We included 32 trials. All the included trials but eight reported one or more of the primary outcomes of relevance for this review (<a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>). All the included trials but nine reported on all‐cause mortality (<a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>). All the included trials but nine reported on serious adverse events and non‐serious adverse events (<a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>), see <a href="./appendices#CD012368-sec-0256">Appendix 11</a>. Three trials only reported adverse events leading to discontinuation (<a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>). In three trials, the authors provided safety‐data without the number of participants included in the safety‐analysis (<a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>). One trial reported on adverse events for up to six months and 6 to 12 months separately (<a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>). </p> <p>One trial reported on health‐related quality of life (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). This trial measured the outcome 'impact of weight on quality of life' (IWQOL). Authors did not report results per intervention groups. </p> <p>Four trials reported on 'amputation of lower extremity' (<a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). Three trials reported on 'end‐stage renal disease' (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>). Two trials reported on 'blindness or severe vision loss' (<a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>). </p> <p>Three trials reported cost effectiveness data (<a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>). </p> <p>For definitions of outcomes see <a href="./appendices#CD012368-sec-0254">Appendix 9</a> and <a href="./appendices#CD012368-sec-0255">Appendix 10</a>. </p> </section> </section> <section id="CD012368-sec-0089"> <h4 class="title">Excluded studies</h4> <p>We excluded 118 publications/records after full‐text evaluation (see <a href="./references#CD012368-sec-0277" title="">Characteristics of excluded studies</a>) mainly for the following reasons. The trial did not compare interventions of interest (N = 45). Two of these trials investigated an investigational drug (<a href="./references#CD012368-bbs2-0044" title="Eudract:2004‐002549‐11 . An open, multi‐centre and long‐term extension study to evaluate the safety and tolerability of oral tesaglitazar therapy in patients with type 2 diabetes ‐ GALLEX 1. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2004‐002549‐11 (accessed 3 March 2018). ">EUCTR2004‐002549‐11‐FI</a> (tesaglitazar); <a href="./references#CD012368-bbs2-0079" title="NCT01481116 . Efficacy and safety of TAK‐875 compared to glimepiride when used with metformin in participants with type 2 diabetes. clinicaltrials.gov/ct2/show/results/NCT01481116 (accessed 26 June 2017). ">NCT01481116</a> (fasiglifam)) and one trial investigated a drug no longer approved for use (<a href="./references#CD012368-bbs2-0089" title="NCT00095030 . Study comparing muraglitazar with glimepiride in type 2 diabetics who are not controlled with metformin alone. clinicaltrials.gov/ct2/show/NCT00095030 (accessed 26 June 2017). RubinCJ , LedeineJM , FiedorekFT . Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active‐control trial with glimepiride. Diabetes &amp; Vascular Disease Research2008;5(3):168‐76. ">Rubin 2008</a> (muraglitazar)). Other reasons for exclusion included: duration of intervention less than 52 weeks (N = 15), not an RCT (N = 7), trial cancelled or withdrawn (N = 7) and different duration of the intervention between the intervention groups (N = 4). One trial compared interventions of interest (metformin compared with M+S), but the trial only reported on metformin compared with usual care (<a href="./references#CD012368-bbs2-0041" title="CryerDR , NicholasSP , HenryDH , MillsDJ , StadelBV . Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care2005;28(3):539‐43. ">Cryer 2005</a>). We contacted the trial authors to request data, but did not receive a reply. One trial ended prematurely and had no study results (<a href="./references#CD012368-bbs2-0046" title="Eudract:2009‐014727‐23 . Multi‐center, randomized, open‐label, two‐parallel arm, intervention trial comparing DPP‐IV inhibitor vildagliptin with glibenclamide (glyburide) in achieving and maintaining good blood glucose control in type 2 diabetic patients in treatment failure with metformin alone ‐ Long‐term clinical effectiveness of DPP‐IV inhibitors. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐014727‐23 (accessed 3 March 2018). ">EUCTR2009‐014727‐23‐IT</a>). Six publications were expert reviews (<a href="./references#CD012368-bbs2-0111" title="AlbarranOG , Ampudia‐BlascoFJ . Dapagliflozin, the first SGLT‐2 inhibitor in the treatment of type 2 diabetes. Medicina Clinica2013;141 Suppl 2:36‐43. ">Albarran 2013</a>; <a href="./references#CD012368-bbs2-0133" title="FlemingJW , FlemingLW , DavisCS . Fixed‐dose combinations in type 2 diabetes ‐ role of the canagliflozin metformin combination. Diabetes, Metabolic Syndrome and Obesity2015;8:287‐94. ">Fleming 2015</a>; <a href="./references#CD012368-bbs2-0182" title="NishioS , AbeM , ItoH . Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability. Diabetes, Metabolic Syndrome and Obesity: targets and therapy2015;8:163‐71. ">Nishio 2015</a>; <a href="./references#CD012368-bbs2-0183" title="OdawaraM , SagaraR . Effects of vildagliptin as add‐on treatment in patients with type 2 diabetes mellitus: insights from long‐term clinical studies in Japan. Journal of Diabetes and Metabolic Disorders2015;15:21. ">Odawara 2015</a>; <a href="./references#CD012368-bbs2-0195" title="ScheenAJ . Dulaglutide (Trulicity(R)), a new once‐weekly agonist of glucagon‐like peptide‐1 receptors for type 2 diabetes. Revue Medicale de Liege2016;71(3):154‐60. ">Scheen 2016</a>; <a href="./references#CD012368-bbs2-0201" title="SeufertJ . Oral add‐on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and glimepiride. Deutsche Medizinische Wochenschrift (1946)2014;139 Suppl 2:S65‐9. ">Seufert 2014</a>), one was a correspondence (<a href="./references#CD012368-bbs2-0161" title="KannanS , MahadevanS , RamakrishnanA . Fixed dose combinations for type 2 diabetes. Lancet Diabetes &amp; Endocrinology2015;3(6):408. ">Kannan 2015</a>), one was a commentary on a systematic review (<a href="./references#CD012368-bbs2-0120" title="BellaryS . For type 2 diabetes poorly controlled by metformin monotherapy, the addition of any non‐insulin antidiabetic drug reduces HbA1c to a similar extent, but with differing effects on weight and hypoglycaemic risk. Evidence‐based Medicine2011;16(2):39‐40. ">Bellary 2011</a>) and two were analysing pooled data from multiple RCTs (<a href="./references#CD012368-bbs2-0188" title="Reid2016 . How much is too much? Outcomes in patients using high‐dose insulin glargine. International Journal of Clinical Practice2016;70(1):56‐65. ">Reid 2016</a>; <a href="./references#CD012368-bbs2-0192" title="RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Rosenstock 2015</a>). We identified 26 systematic reviews (<a href="./references#CD012368-bbs2-0115" title="AmateJM , Lopez‐CuadradoT , AlmendroN , BouzaC , Saz‐ParkinsonZ , Rivas‐RuizR , et al. Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta‐analysis. International Journal of Clinical Practice2015;69(3):292‐304. ">Amate 2015</a>; <a href="./references#CD012368-bbs2-0117" title="AylsworthA , DeanZ , VanNormanC , Nkemdirim OkereA . Dapagliflozin for the treatment of type 2 diabetes mellitus. Annals of Pharmacotherapy2014;48(9):1202‐8. ">Aylsworth 2014</a>; <a href="./references#CD012368-bbs2-0121" title="BelseyJ , KrishnarajahG . Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta‐analysis. Diabetes, Obesity &amp; Metabolism2008;10 Suppl 1:1‐7. ">Belsey 2008</a>; <a href="./references#CD012368-bbs2-0124" title="ChanSP , ColagiuriS . Systematic review and meta‐analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Research and Clinical Practice2015;110(1):75‐81. ">Chan 2015</a>; <a href="./references#CD012368-bbs2-0127" title="DaiX , WangH , JingZ , FuP . The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta‐analysis. Current Medical Research and Opinion2014;30(9):1777‐86. ">Dai 2014</a>; <a href="./references#CD012368-bbs2-0134" title="ForoutanN , MuratovS , LevineM . Safety and efficacy of dipeptidyl peptidase‐4 inhibitors vs sulfonylurea in metformin‐based combination therapy for type 2 diabetes mellitus: systematic review and meta‐analysis. Clinical and Investigative Medicine, Medecine Clinique et Experimentale2016;39(2):E48‐62. ">Foroutan 2016</a>; <a href="./references#CD012368-bbs2-0135" title="GengJ , YuH , MaoY , ZhangP , ChenY . Cost effectiveness of dipeptidyl peptidase‐4 inhibitors for type 2 diabetes. Pharmaco Economics2015;33(6):581‐97. ">Geng 2015</a>; <a href="./references#CD012368-bbs2-0136" title="GoringS , HawkinsN , WygantG , RoudautM , TownsendR , WoodI , et al. Dapagliflozin compared with other oral anti‐diabetes treatments when added to metformin monotherapy: a systematic review and network meta‐analysis. Diabetes, Obesity &amp; Metabolism2014;16(5):433‐42. ">Goring 2014</a>; <a href="./references#CD012368-bbs2-0138" title="GuS , DengJ , ShiL , MuY , DongH . Cost‐effectiveness of saxagliptin vs glimepiride as a second‐line therapy added to metformin in type 2 diabetes in China. Journal of Medical Economics2015;18(10):808‐20. ">Gu 2015</a>; <a href="./references#CD012368-bbs2-0140" title="GuthrieRM . Clinical use of dipeptidyl peptidase‐4 and sodium‐glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Postgraduate Medicine2015;127(5):463‐79. ">Guthrie 2015</a>; <a href="./references#CD012368-bbs2-0145" title="HershonKS . Options for empagliflozin in combination therapy in type 2 diabetes mellitus. International Journal of General Medicine2016;9:155‐72. ">Hershon 2016</a>; <a href="./references#CD012368-bbs2-0153" title="HouL , ZhaoT , LiuY , ZhangY . Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: a meta‐analysis. Experimental and Therapeutic Medicine2015;9(4):1528‐36. ">Hou 2015</a>; <a href="./references#CD012368-bbs2-0164" title="KueckerCM , VivianEM . Patient considerations in type 2 diabetes ‐ role of combination dapagliflozin‐metformin XR. Diabetes, Metabolic Syndrome and Obesity: targets and therapy2016;9:25‐35. ">Kuecker 2016</a>; <a href="./references#CD012368-bbs2-0169" title="Lim2015 . What's next after metformin? Focus on sulphonylurea: add‐on or combination therapy. Pharmacy Practice2015;13(3):606. ">Lim 2015</a>; <a href="./references#CD012368-bbs2-0170" title="LiuX , XiaoQ , ZhangL , YangQ , LiuX , XuL , et al. The long‐term efficacy and safety of DPP‐IV inhibitors monotherapy and in combination with metformin in 18,980 patients with type‐2 diabetes mellitus‐‐a meta‐analysis. Pharmacoepidemiology and Drug Safety2014;23(7):687‐98. ">Liu 2014</a>; <a href="./references#CD012368-bbs2-0172" title="MaruthurNM , TsengE , HutflessS , WilsonLM , Suarez‐CuervoC , BergerZ , et al. Diabetes medications as monotherapy or metformin‐based combination therapy for type 2 diabetes: a systematic review and meta‐analysis. Annals of Internal Medicine2016;164(11):740‐51. [DOI: 10.7326/M15‐2650] ">Maruthur 2016</a>; <a href="./references#CD012368-bbs2-0176" title="MearnsES , SobierajDM , WhiteCM , SaulsberryWJ , KohnCG , DolehY , et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta‐analysis. PloS one2015;10(4):e0125879. ">Mearns 2015</a>; <a href="./references#CD012368-bbs2-0178" title="MishrikyBM , CummingsDM , TanenbergRJ . The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add‐on therapy to metformin in patients with type 2 diabetes: a systematic review and meta‐analysis. Diabetes Research and Clinical Practice2015;109(2):378‐88. ">Mishriky 2015</a>; <a href="./references#CD012368-bbs2-0179" title="MonamiM , LamannaC , MarchionniN , MannucciE . Comparison of different drugs as add‐on treatments to metformin in type 2 diabetes: a meta‐analysis. Diabetes Research and Clinical Practice2008;79(2):196‐203. ">Monami 2008</a>; <a href="./references#CD012368-bbs2-0185" title="PhungOJ , ScholleJM , TalwarM , ColemanCI . Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA2010;303(14):1410‐8. ">Phung 2010</a>; <a href="./references#CD012368-bbs2-0186" title="PhungOJ , SobierajDM , EngelSS , RajpathakSN . Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta‐analysis. Diabetes, Obesity &amp; Metabolism2014;16(5):410‐7. ">Phung 2014</a>; <a href="./references#CD012368-bbs2-0191" title="RosenstockJ , MarxN , KahnSE , ZinmanB , KasteleinJJ , LachinJM , et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active‐comparator CAROLINA trial. Diabetes &amp; Vascular Disease Research2013;10(4):289‐301. ">Rosenstock 2013</a>; <a href="./references#CD012368-bbs2-0208" title="Varvaki RadosD , Catani PintoL , Reck RemontiL , Bauermann LeitaoC , GrossJL . The association between sulfonylurea use and all‐cause and cardiovascular mortality: a meta‐analysis with trial sequential analysis of randomized clinical trials. PLoS Medicine2016;13(4):e1001992. ">Varvaki 2016</a>; <a href="./references#CD012368-bbs2-0212" title="WhalenK , MillerS , OngeES . The role of sodium‐glucose co‐transporter 2 inhibitors in the treatment of type 2 diabetes. Clinical Therapeutics2015;37(6):1150‐66. ">Whalen 2015</a>; <a href="./references#CD012368-bbs2-0219" title="Zhou2015 . The benefits and risks of DPP4‐inhibitors vs sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial. International Journal of Clinical Practice2016;70(2):132‐41. ">Zhou 2015</a>; <a href="./references#CD012368-bbs2-0220" title="ZintzarasE , MiligkosM , ZiakasP , BalkEM , MademtzoglouD , DoxaniC , et al. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta‐analysis. Clinical Therapeutics2014;36(10):1443‐53. ">Zintzaras 2014</a>), and one conference abstract (<a href="./references#CD012368-bbs2-0114" title="AlvaresJ , AraujoVE , IzidoroJB , DinizLM , NascimentoRC , SilvaMR , et al. Efficacy and safety of antidiabetic drugs available on Brazilian public health system (Sus) ‐ regular insulin, NPH insulin, metformin, glibenclamide and gliclazide ‐ In treatment of type 2 diabetes (T2DM) ‐ systematic review and meta‐analysis. Value in Health2015;18(7):A862. ">Alvares 2015</a>). This publication is listed in <a href="./references#CD012368-bbs1-0005" title="">Additional references</a>. </p> </section> </section> <section id="CD012368-sec-0090"> <h3 class="title">Risk of bias in included studies</h3> <p>For details on the risk of bias of the included trials see <a href="./references#CD012368-sec-0276" title="">Characteristics of included studies</a>. For an overview of review authors' judgements about each risk of bias item for individual trials and across all trials see <a href="#CD012368-fig-0002">Figure 2</a> and <a href="#CD012368-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD012368-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials)." data-id="CD012368-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> </div> <div class="figure" id="CD012368-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial ((blank cells indicate that the particular outcome was not measured in some trials)" data-id="CD012368-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial ((blank cells indicate that the particular outcome was not measured in some trials) </p> </div> </div> </div> <section id="CD012368-sec-0091"> <h4 class="title">Allocation</h4> <p>We judged 24 trials at low risk of selection bias regarding the method of randomisation and allocation concealment (<a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a>; <a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). The remaining trials only reported that the participants were randomised but did not provide any further description (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>). Therefore, we judged these trials at unclear risk of bias regarding randomisation and allocation concealment. </p> <p>We evaluated trial baseline data for our predefined prognostic baseline variables. None of the included trials reported data on all our key prognostic variables. However, all trials reported some variables of interest. None of the trials reporting prognostic variables showed important differences between the intervention groups. </p> </section> <section id="CD012368-sec-0092"> <h4 class="title">Blinding</h4> <p>Blinding of participants and investigators for all outcomes was adequate in 21 trials (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>). Trials ensured blinding of participants and investigators by using identical placebo tablets or injections. Seven trials were open‐label (<a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). Two trials were single‐blinded (<a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>). </p> <p>In one trial the participants and investigators were blinded in the first 26 weeks of the intervention period followed by a 78‐week open‐label extension phase (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). </p> <p>Eight trials described a blinded outcome committee evaluating cardiovascular and cerebrovascular events (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). </p> <p>Where measured, all primary outcomes of this review were investigator‐assessed and we judged these at low risk of performance and detection bias. The trials reporting blood glucose measurements were all performed by the investigators and we judged these outcomes measures at low risk of performance and detection bias. Overall, the risk of performance bias and detection bias was low or unclear for our secondary outcomes. </p> </section> <section id="CD012368-sec-0093"> <h4 class="title">Incomplete outcome data</h4> <p>All trials reported the complete number of participants randomised and finishing the trial. Two trials adequately addressed incomplete data for all outcomes (<a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>). We judged the following outcomes to be at unclear or high risk of attrition bias in one or more trials: amputation of lower extremity, blindness or severe vision loss, end‐stage renal disease (<a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>); hypoglycaemia (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>); non‐fatal myocardial infarction, heart failure, non‐fatal stroke (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>); non‐serious adverse events (<a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>); serious adverse events (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>); weight (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>) and HbA1c (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). </p> <p>The reasons for a high risk of attrition bias for dichotomous outcomes were: high dropout rate; dropout rate not balanced between intervention groups; reason for dropout not balanced between intervention groups; no information on imputation method; missing data imputed with 'last observation carried forward' technique; proportion of missing outcomes compared with the observed event risk was substantial enough to result in potentially clinically relevant bias for the intervention effect estimate. </p> <p>The reasons for an unclear or high risk of attrition bias for continuous outcomes were: high dropout rate; dropout rate not balanced between intervention groups; reason for dropout not balanced between intervention groups; no information on imputation method; missing data imputed with 'last observation carried forward' technique; only participants with a value at baseline and at a specified visit were analysed; only participants who completed the study (excluding participants receiving rescue therapy) were included in the analysis; analyses based on per protocol population; and substantial amount of missing outcomes to potentially result in clinically relevant bias for the observed effect size. </p> </section> <section id="CD012368-sec-0094"> <h4 class="title">Selective reporting</h4> <p>Twenty‐two of the included trials had a published protocol (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). </p> <p>We judged 11 of the included trials at high risk of reporting bias for one or more of our outcomes (<a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>). For more details, see <a href="./appendices#CD012368-sec-0253">Appendix 8</a>. </p> <p>We judged nine trials as at high risk of selective outcome reporting regarding one or more of the primary outcomes with relevance to this review (<a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>); we judged 10 trials as high risk of selective outcome reporting regarding one or more of the secondary outcomes with relevance to this review (<a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>). </p> <p>We judged two trials as high risk of selective outcome reporting regarding one or more of the additional explorative outcomes of relevance to this review (<a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>). </p> </section> <section id="CD012368-sec-0095"> <h4 class="title">Other potential sources of bias</h4> <p>Twenty‐two trials received support or funding from a pharmaceutical company (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a>; <a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>). For some comparisons, the same author had performed similar trials (<a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>). </p> </section> </section> <section id="CD012368-sec-0096"> <h3 class="title" id="CD012368-sec-0096">Effects of interventions</h3> <p>See: <a href="./full#CD012368-tbl-0001"><b>Summary of findings for the main comparison</b> Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy compared with metformin plus another antidiabetic drug for adults with type 2 diabetes mellitus</a> </p> <p>See <a href="./full#CD012368-tbl-0001">summary of findings Table for the main comparison</a> for details on the most important comparisons of this review (M+S compared with metformin plus GLP‐1 analogue, metformin plus DPP‐4 inhibitor, metformin plus thiazolidinedione, metformin plus glinide and metformin plus SGLt‐2 inhibitor). </p> <section id="CD012368-sec-0097"> <h4 class="title">Baseline characteristics</h4> <p>For details on baseline characteristics, see <a href="./appendices#CD012368-sec-0250">Appendix 5</a> and <a href="./appendices#CD012368-sec-0251">Appendix 6</a>. </p> </section> <section id="CD012368-sec-0098"> <h4 class="title">Metformin‐sulfonylurea combination therapy versus metformin plus insulin</h4> <p>We identified no trials comparing M+S with metformin plus insulin.</p> </section> <section id="CD012368-sec-0099"> <h4 class="title">Metformin‐sulfonylurea combination therapy versus metformin monotherapy</h4> <p>One trial compared M+S combination therapy with metformin monotherapy (<a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>). The intervention group received metformin in doses of 850 mg/day and glimepiride in doses of 2 mg/day to 6 mg/day. The comparator group received metformin in doses of 1000 mg/day to 3000 mg/day. </p> <section id="CD012368-sec-0100"> <h5 class="title">Primary outcomes</h5> <p>The included trial did not report on all‐cause mortality, health‐related quality of life or serious adverse events. </p> </section> <section id="CD012368-sec-0101"> <h5 class="title">Secondary outcomes</h5> <p>The included trial did not report on cardiovascular mortality, non‐fatal myocardial infarction, heart failure, non‐fatal stroke, amputation of lower extremity, blindness or severe vision loss, end‐stage renal disease, non‐serious adverse events, hypoglycaemia or socioeconomic effects. </p> </section> <section id="CD012368-sec-0102"> <h5 class="title">Additional explorative outcomes</h5> <section id="CD012368-sec-0103"> <h6 class="title">Weight</h6> <p>The included trial did not report on weight.</p> </section> <section id="CD012368-sec-0104"> <h6 class="title">HbA1c</h6> <p>The included trial reported final HbA1c measurements of 7.8% (SD 0.4) and 7.9% (SD 0.5) in the M+S group compared with the metformin monotherapy, respectively. They did not report the number of participants included in the analysis. </p> </section> </section> </section> <section id="CD012368-sec-0105"> <h4 class="title">Metformin‐sulfonylurea combination therapy versus metformin plus placebo</h4> <p>Two trials compared M+S combination therapy with metformin plus placebo (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). Both trials administered glimepiride, given in doses of 1 mg/day to 4 mg/day; and metformin in doses of ≥ 1500 mg/day. Both trials had multiple intervention arms with glimepiride, GLP‐1 analogue, DPP‐4 inhibitor or placebo in combination with metformin (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>), as well as glimepiride, GLP‐1 analogue or placebo in combination with metformin (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). For details of the certainty of the evidence see <a href="./appendices#CD012368-sec-0261">Appendix 16</a>. </p> <section id="CD012368-sec-0106"> <h5 class="title">Primary outcomes</h5> <section id="CD012368-sec-0107"> <h6 class="title">All‐cause mortality</h6> <p>Both included trials reported data on all‐cause mortality (low‐certainty evidence because of serious imprecision; <a href="./references#CD012368-fig-0004" title="">Analysis 1.1</a>). One trial reported 6 deaths out of 307 participants (2%) and 1 death out of 101 participants (1%) in the M+S combination group compared with the metformin plus placebo group, respectively (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>). However, the number of deaths was unclear due to varied reporting. We contacted the trial authors for clarification but did not receive a reply. To be sure to account for all deaths, we extracted data from the publication that reported the highest number. One trial reported data after an 18‐month, open‐label extension: there were no deaths in 242 participants and no deaths in 121 participants in the M+S combination group compared with the metformin plus placebo group, respectively (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). </p> </section> <section id="CD012368-sec-0108"> <h6 class="title">Health‐related quality of life</h6> <p>None of the included trials reported on this outcome.</p> </section> <section id="CD012368-sec-0109"> <h6 class="title">Serious adverse effects</h6> <p>Both included trials reported that a total of 84 participants experienced a serious adverse event; in the M+S group 60/549 (10.9%) participants had a serious adverse event compared with 24/222 (10.8%) participants in the metformin plus placebo group (RR 0.97, 95% CI 0.59 to 1.61; P = 0.91; 2 trials; 771 participants; very low‐certainty evidence because of attrition bias and serious imprecision; <a href="./references#CD012368-fig-0005" title="">Analysis 1.2</a>). One trial reported data after an 18‐month, open‐label extension phase (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). </p> <p>TSA showed that 2.45% of the diversity‐adjusted required information size to detect or reject a 10% relative risk reduction (RRR) had been accrued. Diversity was 21%. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> </section> <section id="CD012368-sec-0110"> <h5 class="title">Secondary outcomes</h5> <section id="CD012368-sec-0111"> <h6 class="title">Cardiovascular mortality</h6> <p>Both included trials reported data on cardiovascular mortality (low‐certainty evidence because of serious imprecision; <a href="./references#CD012368-fig-0006" title="">Analysis 1.3</a>). One trial reported 1 cardiovascular death in 307 (0.3%) participants in the M+S group compared with 1 cardiovascular death in 101 (1%) participants in the metformin plus placebo group (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>). One trial reported that no participants died in either intervention group after an 18‐month, open‐label extension phase (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). </p> </section> <section id="CD012368-sec-0112"> <h6 class="title">Non‐fatal myocardial infarction</h6> <p>Both included trials reported that a total of three participants experienced a non‐fatal myocardial infarction; in the M+S group 2/549 (0.4%) participants had a myocardial infarction compared with 1/222 (0.5%) participants in the metformin plus placebo group (RR 0.63, 95% CI 0.08 to 5.10; P = 0.67; 2 trials; 771 participants; very low‐certainty evidence because of attrition bias and serious imprecision; <a href="./references#CD012368-fig-0007" title="">Analysis 1.4</a>). One trial reported data after an 18‐month, open‐label extension phase (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). </p> <p>TSA showed that 0.13% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was zero. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> <section id="CD012368-sec-0113"> <h6 class="title">Heart failure</h6> <p>Both included trials reported data on heart failure (<a href="./references#CD012368-fig-0008" title="">Analysis 1.5</a>). One trial reported one heart failure in 307 participants (0.3%) and no heart failure in 101 participants in the M+S group compared with the metformin plus placebo group, respectively (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>). One trial reported that no participants experienced a heart failure in either intervention group after an 18‐month, open‐label extension phase (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). </p> </section> <section id="CD012368-sec-0114"> <h6 class="title">Non‐fatal stroke, amputation of lower extremity, blindness or severe vision loss</h6> <p>None of the included trials reported on this outcome.</p> </section> <section id="CD012368-sec-0115"> <h6 class="title">End‐stage renal disease</h6> <p>One trial reported that no participants had end‐stage renal disease in either intervention group after an 18‐month, open‐label extension phase (very low‐certainty evidence because of attrition bias and serious imprecision; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). </p> </section> <section id="CD012368-sec-0116"> <h6 class="title">Non‐serious adverse events</h6> <p>Both included trials reported that a total of 505 participants experienced a non‐serious adverse event: in the M+S group 386/549 (70.3%) participants had a non‐serious adverse event compared with 119/222 (53.6%) participants in the metformin plus placebo group (random RR 1.25, 95% CI 0.96 to 1.64; P = 0.10; fixed RR 1.24, 95% CI 1.10 to 1.41; P &lt; 0.001; 2 trials; 771 participants; <a href="./references#CD012368-fig-0009" title="">Analysis 1.6</a>). None of the trials provided a detailed definition of the outcome. One trial reported data after an 18‐month, open‐label extension phase (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). </p> <p>TSA showed that 5.8% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 78%. The TSA‐adjusted 95% CI was 0.47 to 3.32. </p> </section> <section id="CD012368-sec-0117"> <h6 class="title">Hypoglycaemia</h6> <p>Both included trials reported that a total of 181 participants experienced a mild or moderate hypoglycaemic episode; in the M+S group there were 160/549 (29.1%) participants with hypoglycaemic episodes compared with 21/222 (9.5%) participants in the metformin plus placebo group (random RR 3.93, 95% CI 0.71 to 21.88; P = 0.12; fixed RR 2.87, 95% CI 1.90 to 4.34; P &lt; 0.001; 2 trials; 771 participants; <a href="./references#CD012368-fig-0010" title="">Analysis 1.7</a> in favour of metformin plus placebo). <a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a> defined mild or moderate hypoglycaemia by blood glucose levels 3.9 mmol/L or lower and <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a> used blood glucose values 3.1 mmol/L or lower. One trial reported data after an 18‐month, open‐label extension phase (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). </p> <p>TSA showed that 0.18% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 93%. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> <p>Both included trials reported data on serious hypoglycaemia (<a href="./references#CD012368-fig-0011" title="">Analysis 1.8</a>). One trial reported one participant with serious hypoglycaemia out of 307 participants (0.3%) and no participants with serious hypoglycaemia out of 101 participants in the M+S group compared with the metformin plus placebo group, respectively (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>). One trial reported that no participants had serious hypoglycaemia in either intervention group after an 18‐month, open‐label extension phase (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). </p> </section> <section id="CD012368-sec-0118"> <h6 class="title">Socioeconomic effects</h6> <p>None of the included trials reported on this outcome.</p> </section> </section> <section id="CD012368-sec-0119"> <h5 class="title">Additional explorative outcomes</h5> <section id="CD012368-sec-0120"> <h6 class="title">Weight</h6> <p>Both included trials reported weight change in favour of metformin plus placebo (mean difference (MD) 3.4 kg, 95% CI 1.4 to 5.4; P = 0.001; 2 trials; 476 participants; <a href="./references#CD012368-fig-0012" title="">Analysis 1.9</a>). <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a> reported data after an 18‐month, open‐label extension phase. </p> </section> <section id="CD012368-sec-0121"> <h6 class="title">HbA1c</h6> <p>Both included trials reported change in HbA1c in favour of M+S (random MD −0.5%, 95% CI −1.1 to 0.1; P = 0.13; fixed MD −0.6%, 95% CI −0.8 to −0.4; P &lt; 0.001; 2 trials; 472 participants; <a href="./references#CD012368-fig-0013" title="">Analysis 1.10</a>). One trial reported data after an 18‐month, open‐label extension phase (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). </p> </section> </section> </section> <section id="CD012368-sec-0122"> <h4 class="title">Metformin‐sulfonylurea combination therapy versus metformin plus GLP‐1 analogue</h4> <p>Five trials compared M+S with metformin plus a GLP‐1 analogue (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). Four trials administered glimepiride in doses of 2 mg/day to 6 mg/day (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>), and one trial administered glibenclamide in doses of 15 mg/day (<a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>). Three trials administered exenatide in doses of 10 μg/day to 20 μg/day (<a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>), one trial administered albiglutide in doses of 30 mg/week to 50 mg/week (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>), and one trial administered liraglutide in doses of 0.6 mg/day to 1.8 mg/day (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). Metformin was given in doses of 1000 mg/day to 1500 mg/day or more. </p> <section id="CD012368-sec-0123"> <h5 class="title">Primary outcomes</h5> <section id="CD012368-sec-0124"> <h6 class="title">All‐cause mortality</h6> <p>Three trials reported that a total of 22 participants died: in the M+S group 11/1057 participants (1.0%) died compared with 11/1537 participants (0.7%) in the metformin plus GLP‐1 analogue group (RR 1.15, 95% CI 0.49 to 2.67; P = 0.75; 3 trials; 2594 participants; low‐certainty evidence; <a href="./references#CD012368-fig-0014" title="">Analysis 2.1</a>). Calculation of the 95% prediction interval did not provide a meaningful estimate. One trial reported data after an 18‐month, open‐label extension phase (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). </p> <p><a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a> reported that no participants died but did not provide the number of participants included in the analysis. </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. Sensitivity analysis restricted to trials with low risk of selection bias did not change the direction of the effect estimate (RR 0.93, 95% CI 0.30 to 2.93; P = 0.91; 2 trials; 1985 participants). We could not perform sensitivity analysis excluding large trials because none of the included trials for this comparison had more than 1000 participants randomised to each intervention group. We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company since all trials received funding from a pharmaceutical company. </p> <p>TSA showed that 0.61% of the diversity‐adjusted information size had been accrued to detect or reject a 10% RRR. Diversity was zero. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> <section id="CD012368-sec-0125"> <h6 class="title">Health‐related quality of life</h6> <p>We did not identify trials with data on health‐related quality of life for this comparison. One trial reported on 'impact of weight on quality of life' (IWQOL; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). They reported the result separately for each intervention group. </p> </section> <section id="CD012368-sec-0126"> <h6 class="title">Serious adverse effects</h6> <p>Three trials reported that a total of 322 participants experienced a serious adverse event: in the M+S group 128/1057 participants (12.1%) had a serious adverse event compared with 194/1537 participants (12.6%) in the metformin plus GLP‐1 analogue group (RR 0.90, 95% CI 0.73 to 1.11; P = 0.32; 3 trials; 2594 participants; very low‐certainty evidence; <a href="./references#CD012368-fig-0015" title="">Analysis 2.2</a>). The 95% prediction interval ranged between 0.23 and 3.51. One of the trials reported data after an 18‐month, open‐label extension (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a> reported that no participants experienced serious adverse events but did not provide the number of participants included in the analysis. </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. Sensitivity analysis according to trials with low risk of selection bias and duration of intervention (excluding trials with duration of intervention longer than 104 weeks) contained the same two trials (<a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). The effect estimate did not change substantially (RR 0.94, 95% CI 0.73 to 1.20; P = 0.60; 2 trials; 1985 participants). We could not perform sensitivity analysis excluding large trials because no trials had more than 1000 participants randomised to each intervention group. We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> <p>TSA showed that 12.4% of the diversity‐adjusted information size had been accrued to detect or reject a 10% RRR. Diversity was zero. The TSA‐adjusted 95% CI was 0.38 to 2.15. </p> </section> </section> <section id="CD012368-sec-0127"> <h5 class="title">Secondary outcomes</h5> <section id="CD012368-sec-0128"> <h6 class="title">Cardiovascular mortality</h6> <p>Three trials reported on cardiovascular disease (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a> reported that no participants died due to cardiovascular disease but did not provide the number of participants included in the analysis. <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a> reported that no participants died due to cardiovascular disease in any of the intervention groups referring to the 18‐month, open‐label extension phase. </p> <p><a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a> reported that in the M+S group 1/307 (0.3%) participants died of cardiovascular disease compared with 1/302 (0.3%) participants in the metformin plus GLP‐1 analogue group (<a href="./references#CD012368-fig-0016" title="">Analysis 2.3</a>; low‐certainty evidence). </p> </section> <section id="CD012368-sec-0129"> <h6 class="title">Non‐fatal myocardial infarction</h6> <p>Two trials reported that a total of eight participants experienced a non‐fatal myocardial infarction: in the M+S group 2/549 (0.4%) participants had a non‐fatal myocardial infarction compared with 6/1026 (0.6%) participants in the metformin plus GLP‐1 analogue group (RR 0.57, 95% CI 0.12 to 2.82; P = 0.49; 2 trials; 1575 participants; very low‐certainty evidence; <a href="./references#CD012368-fig-0017" title="">Analysis 2.4</a>). </p> <p><a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a> reported data after an 18‐month, open‐label extension phase. <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a> reported that no participants experienced a non‐fatal myocardial infarction but did not provide the number of participants included in the analysis. </p> <p>We could not perform sensitivity analyses due to lack of data.</p> <p>TSA showed that 0.4% of the diversity‐adjusted information size had been accrued to detect or reject a 10% RRR. Diversity was zero. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> <section id="CD012368-sec-0130"> <h6 class="title">Heart failure</h6> <p>Four trials reported that a total of five participants developed heart failure: in the M+S group 1/1057 (0.1%) participants developed heart failure compared with 4/1537 (0.3%) participants in the metformin plus GLP‐1 analogue group (RR 0.54, 95% CI 0.10 to 2.77; P = 0.46; 3 trials; 2594 participants; <a href="./references#CD012368-fig-0018" title="">Analysis 2.5</a>). Calculation of the 95% prediction interval did not provide a meaningful estimate. </p> <p><a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a> reported data after an 18‐month, open‐label extension phase. <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a> reported that no participants developed heart failure but did not provide the number of participants included in the analysis. </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. Sensitivity analysis restricted to trials with low risk of selection bias and duration of intervention (excluding trials with duration of intervention more than 104 weeks) contained the same two trials (<a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). The effect estimate did not change substantially (RR 0.58, 95% CI 0.06 to 5.54; P = 0.63; 2 trials; 1985 participants). We could not perform sensitivity analysis excluding large trials because no trials had more than 1000 participants randomised to each intervention group. We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> <p>TSA showed that 0.26% of the diversity‐adjusted information size had been accrued to detect or reject a 10% RRR. Diversity was zero. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> <section id="CD012368-sec-0131"> <h6 class="title">Non‐fatal stroke</h6> <p><a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a> reported that no participants experienced a stroke during the intervention period but did not provide the number of participants included in the analysis. </p> </section> <section id="CD012368-sec-0132"> <h6 class="title">Amputation of lower extremity</h6> <p><a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a> reported that no participants had amputation of lower extremity during the intervention period but did not provide the number of participants included in the analysis. </p> </section> <section id="CD012368-sec-0133"> <h6 class="title">Blindness or severe vision loss</h6> <p><a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a> reported that no participants had blindness or severe vision loss during the intervention period but did not provide the number of participants included in the analysis. </p> </section> <section id="CD012368-sec-0134"> <h6 class="title">End‐stage renal disease</h6> <p>One trial provided data on end‐stage renal disease, however only after the 18‐month, open‐label extension phase (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). In the M+S group no participants out of 242 participants had end‐stage renal disease compared with 1 participant out of 724 (0.1%) participants in the metformin plus GLP‐1 analogue group (<a href="./references#CD012368-fig-0019" title="">Analysis 2.6</a>). </p> <p><a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a> reported that no participants had end‐stage renal disease during the intervention period but did not provide the number of participants included in the analysis. </p> </section> <section id="CD012368-sec-0135"> <h6 class="title">Non‐serious adverse events</h6> <p>Three trials reported that a total of 1621 participants experienced a non‐serious adverse event: in the M+S group 634/1057 (60.0%) participants had a non‐serious adverse event compared with 987/1537 (64.2%) participants in the metformin plus GLP‐1 analogue group (<a href="./references#CD012368-fig-0020" title="">Analysis 2.7</a>). Due to substantial heterogeneity, aggregating the trials in a meta‐analysis was not appropriate. With regard to the M+S groups, the trial with most of the non‐serious adverse events had two placebo interventions (GLP‐1 analogue as subcutaneous injection and placebo DPP‐4 inhibitor as tablet) in addition to M+S (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>). </p> <p>One trial was open‐label and did not apply placebo (<a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>), and one trial (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>), reported data after an 18‐month, open‐label extension. With regard to the metformin plus GLP‐1 analogue treatment arms, each trial used a different GLP‐1 analogue: one administered albiglutide (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>), and one administered exenatide (<a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>), or liraglutide (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). </p> <p><a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a> reported that no participants experienced non‐serious adverse events but did not provide the number of participants included in the analysis. </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. Sensitivity analyses restricted to trials with low risk of selection bias and duration of intervention (excluding trials with duration of intervention longer than 104 weeks) contained the same two trials (<a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). The effect estimate was in favour of M+S combination therapy (RR 0.84, 95% CI 0.76 to 0.92; P = 0.0001; 2 trials; 1985 participants). We could not perform sensitivity analysis excluding large trials because no trials had more than 1000 participants randomised to each intervention group. We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> </section> <section id="CD012368-sec-0136"> <h6 class="title">Hypoglycaemia</h6> <p>Three trials reported that a total of 569 participants experienced a mild or moderate hypoglycaemic episode: in the M+S group 400/1057 (37.8%) participants had a hypoglycaemic episode compared with 169/1537 (11.0%) participants in the metformin plus GLP‐1 analogue group (RR 3.24, 95% CI 2.05 to 5.13; P &lt; 0.001; 3 trials; 2594 participants; <a href="./references#CD012368-fig-0021" title="">Analysis 2.8</a>; in favour of metformin plus GLP‐1 analogue). Calculation of the 95% prediction interval did not provide a meaningful estimate. The trial with mostly mild or moderate hypoglycaemic events defined hypoglycaemia as any sign or symptom of hypoglycaemia or blood glucose 3.9 mmol/L or less (<a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>), whereas the other trials defined hypoglycaemia as symptoms of hypoglycaemia plus blood glucose values 3.9 mmol/L or less, or blood glucose values 3.9 mmol/L or less without symptoms (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>), or symptoms of hypoglycaemia or blood glucose values 3.1 mmol/L or less (<a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a> reported data after an 18‐month, open‐label extension phase. </p> <p><a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a> reported two events of mild or moderate hypoglycaemia in the glimepiride group and one in the exenatide group but did not provide the number of participants included in the analysis. </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. Sensitivity analyses restricted to trials with low risk of selection bias and duration of intervention (excluding trials with duration of intervention longer than 104 weeks) contained the same two trials (<a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). We could not perform sensitivity analysis excluding large trials because no trials had more than 1000 participants randomised to each intervention group. We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> <p>Only three participants reported serious hypoglycaemia: in the M+S group 1/1057 (0.1%) participants had a serious hypoglycaemic event compared with 2/1537 (0.1%) participants in the metformin plus GLP‐1 analogue group (RR 1.00, 95% CI 0.16 to 6.30; P = 1.00; 3 trials; 2594 participants; <a href="./references#CD012368-fig-0022" title="">Analysis 2.9</a>). </p> <p><a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a> reported data after an 18‐month, open‐label extension phase. <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a> reported that no event of serious hypoglycaemia was observed but did not provide the number of participants included in the analysis. </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. Sensitivity analyses restricted to trials with low risk of selection bias and duration of intervention (excluding trials with duration of intervention longer than 104 weeks) contained the same two trials (<a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>). The effect estimate did not change substantially (RR 0.58, 95% CI 0.06 to 5.54; P = 0.63; 2 trials; 1985 participants). We could not perform sensitivity analysis excluding large trials because no trial had more than 1000 participants randomised to each intervention group. We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> <p>TSA for severe hypoglycaemia showed that 0.09% of the diversity‐adjusted information size had been accrued to detect or reject a 10% RRR. Diversity was zero. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> <section id="CD012368-sec-0137"> <h6 class="title">Socioeconomic effects</h6> <p>We did not identify trials with data on socioeconomic effects for this comparison.</p> </section> </section> <section id="CD012368-sec-0138"> <h5 class="title">Additional explorative outcomes</h5> <section id="CD012368-sec-0139"> <h6 class="title">Weight</h6> <p>Five trials reported weight change in favour of metformin plus GLP‐1 analogue (MD 5.5 kg, 95% CI 3.6 to 7.5; P &lt; 0.001; 5 trials; 1777 participants; <a href="./references#CD012368-fig-0023" title="">Analysis 2.10</a>). Calculation of the 95% prediction interval did not provide a meaningful estimate. Heterogeneity in the findings could have been caused by the various durations of follow‐up, ranging from 52 weeks to 156 weeks, and various doses of glimepiride ranging from 1 mg/day to 6 mg/day. <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a> did not report the number of participants included in the analysis. </p> <p><a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a> reported data after an 18‐month, open‐label extension phase. </p> </section> <section id="CD012368-sec-0140"> <h6 class="title">HbA1c</h6> <p>Five trials reported change in HbA1c (MD 0.01%, 95% CI ‐0.2 to 0.2; P = 0.91; 5 trials; 2346 participants; <a href="./references#CD012368-fig-0024" title="">Analysis 2.11</a>). The 95% prediction interval ranged between 0% and 1.0%. </p> <p><a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a> reported data after an 18‐month, open‐label extension phase. Trials with 52 weeks of treatment reported at greater decrease in Hba1c with sulphonylurea treatment, whereas trials with 104 weeks of treatment or more reported a greater decrease in HbA1c with GLP‐1 analogue treatment. </p> <p>TSA showed that 0.61% of the diversity‐adjusted information size had been accrued to detect or reject a 10% RRR. Diversity was 91%. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> </section> </section> <section id="CD012368-sec-0141"> <h4 class="title">Metformin‐sulfonylurea combination therapy versus metformin plus DPP‐4 inhibitor</h4> <p>Nine trials compared M+S combination therapy with metformin plus a DPP‐4 inhibitor (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>). Four trials administered glimepiride in doses of 1 mg/day to 6 mg/day (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>), three trials administered glipizide in doses of 5 mg/day to 20 mg/day (<a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>), one trial administered glibenclamide in doses of 10 mg/day (<a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>), and one trial administered gliclazide in doses of 80 mg/day to 320 mg/day (<a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>). Three trials administered vildagliptin in doses of 100 mg/day (<a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>), two trials administered sitagliptin in doses of 100 mg/day (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>), two trials administered saxagliptin in doses of 5 mg/day ( <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>), one trial administered alogliptin (in doses of 12.5 mg/day to 25 mg/day (<a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>), and one trial administered linagliptin in doses of 5 mg/day (<a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>). One trial administered metformin at any dose (<a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>), the remaining trials administered metformin in doses of 1500 mg/day or more. </p> <section id="CD012368-sec-0142"> <h5 class="title">Primary outcomes</h5> <section id="CD012368-sec-0143"> <h6 class="title">All‐cause mortality</h6> <p>Nine trials reported that a total of 59 participants died: in the M+S group 33 participants died out of 5387 (0.6%) participants, compared with 26 deaths in 6307 (0.4%) participants in the metformin plus DPP‐4 inhibitor group (RR 1.32, 95% CI 0.76 to 2.28; P = 0.32; 9 trials; 11,694 participants; low‐certainty evidence; <a href="./references#CD012368-fig-0025" title="">Analysis 3.1</a>). The 95% prediction interval ranged between 0.68 and 2.55. </p> <p>A test for subgroup differences according to duration of follow‐up did not indicate interaction (P = 0.77). </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. Sensitivity analysis restricted to trials with low risk of selection bias did not substantially change the effect estimate (RR 1.29, 95% CI 0.41 to 4.10; P = 0.66; 5 trials; 4363 participants). Sensitivity analysis excluding large trials did not substantially change the effect estimate (RR 1.52, 95% CI 0.81 to 2.88; P = 0.19; 8 trials; 8595 participants). We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials had received funding from a pharmaceutical company. </p> <p>TSA showed that 2.4% of the diversity‐adjusted information size had been accrued to detect or reject a 10% RRR. Diversity was zero. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> <section id="CD012368-sec-0144"> <h6 class="title">Health‐related quality of life</h6> <p>We did not identify trials reporting data on health‐related quality of life for this comparison. </p> </section> <section id="CD012368-sec-0145"> <h6 class="title">Serious adverse effects</h6> <p>Nine trials reported that a total of 1514 participants experienced a serious adverse event: in the M+S group 735/5387 (13.6%) participants had a serious adverse event compared with 779/6307 (12.4%) participants in the metformin plus DPP‐4 inhibitor group (RR 1.07, 95% CI 0.97 to 1.18; P = 0.17; 9 trials; 11,694 participants; very low‐certainty evidence; <a href="./references#CD012368-fig-0026" title="">Analysis 3.2</a>). The 95% prediction interval ranged between 0.95 and 1.20. </p> <p>A test for subgroup differences according to duration of follow‐up did not indicate interaction (P = 0.82). </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. Sensitivity analysis restricted to only trials with low risk of selection bias did not substantially change the effect estimate (RR 1.09, 95% CI 0.93 to 1.28; P = 0.27; 5 trials; 4363 participants). Sensitivity analysis excluding large trials did not substantially change the effect estimate (RR 1.06, 95% CI 0.94 to 1.20; P = 0.33; 8 trials; 8595 participants). We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> <p>TSA showed that 61% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was zero. The TSA‐adjusted 95% CI was 0.93 to 1.23. </p> </section> </section> <section id="CD012368-sec-0146"> <h5 class="title">Secondary outcomes</h5> <section id="CD012368-sec-0147"> <h6 class="title">Cardiovascular mortality</h6> <p>Six trials reported that a total of 20 participants died due to cardiovascular disease: in the M+S group 11 participants died out of 2989 (0.4%) participants compared with 9 out of 3885 (0.2%) participants in the metformin plus DPP‐4 inhibitor group (RR 1.54, 95% CI 0.63 to 3.79; P = 0.34; 6 trials; 6874 participants; low‐certainty evidence; <a href="./references#CD012368-fig-0027" title="">Analysis 3.3</a>). The 95% prediction interval ranged between 0.43 and 5.52. Two trials reported a composite outcome of cardiovascular and cerebrovascular events (<a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>: M+S 12/493 (2.4%) participants, metformin plus DPP‐4 inhibitor 7/510 (1.4%) participants; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>: M+S 60/1546 (3.9%) participants, metformin plus DPP‐4 inhibitor 59/1553 (3.8%) participants). </p> <p>We could not perform a test for subgroup differences according to duration of follow‐up due to lack of data. </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. Sensitivity analysis restricted to only trials with low risk of selection bias did not substantially change the effect estimate (RR 1.72, 95% CI 0.44 to 6.69; P = 0.43; 4 trials; 3645 participants). </p> <p>We could not perform sensitivity analysis excluding large trials because no trials had more than 1000 participants randomised to each intervention group. We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> <p>TSA showed that 0.92% of the diversity‐adjusted information size had been accrued to detect or reject a 10% RRR. Diversity was zero. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> <section id="CD012368-sec-0148"> <h6 class="title">Non‐fatal myocardial infarction</h6> <p>Six trials reported that a total of 28 participants experienced a non‐fatal myocardial infarction: in the M+S group 15/2989 (0.5%) participants had a myocardial infarction compared with 13/3885 (0.3%) participants in the metformin plus DPP‐4 inhibitor group (RR 1.45, 95% CI 0.69 to 3.07; P = 0.33; 6 trials; 6874 participants; very low‐certainty evidence; <a href="./references#CD012368-fig-0028" title="">Analysis 3.4</a>). The 95% prediction interval ranged between 0.50 and 4.20. </p> <p>We could not perform a test for subgroup differences according to duration of follow‐up due to lack of data. </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. Sensitivity analysis restricted to trials with low risk of selection bias did not substantially change the effect estimate (RR 1.44, 95% CI 0.55 to 3.77; P = 0.45; 4 trials; 3645 participants). We could not perform sensitivity analysis excluding large trials because no trials had more than 1000 participants randomised to each intervention group. We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> <p>TSA showed that 0.95% of the diversity‐adjusted information size had been accrued to detect or reject a 10% RRR. Diversity was zero. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> <section id="CD012368-sec-0149"> <h6 class="title">Heart failure</h6> <p>Eight trials reported that a total of 29 participants developed heart failure: in the M+S group 15/4894 (0.3%) participants developed heart failure compared with 14/5797 (0.2%) participants in the metformin plus DPP‐4 inhibitor group (RR 1.05, 95% CI 0.47 to 2.34; P = 0.90; 8 trials; 10,691 participants; <a href="./references#CD012368-fig-0029" title="">Analysis 3.5</a>). The 95% prediction interval ranged between 0.39 and 2.86. </p> <p>A test for subgroup differences according to duration of follow‐up did not indicate interaction (P = 0.08). </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. Sensitivity analysis restricted to only trials with low risk of selection bias did not substantially change the direction of the effect estimate (RR 1.21, 95% CI 0.38 to 3.78; P = 0.75; 5 trials; 4363 participants). Sensitivity analysis excluding large trials did not substantially change the direction of the effect estimate (RR 1.07, 95% CI 0.42 to 2.69; P = 0.89; 7 trials; 7592 participants). We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> </section> <section id="CD012368-sec-0150"> <h6 class="title">Non‐fatal stroke</h6> <p>Four trials reported that a total of 22 participants experienced a non‐fatal stroke: in the M+S group 14/2098 (0.7%) participants had a non‐fatal stroke compared with 8/2995 (0.3%) participants in the metformin plus DPP‐4 inhibitor group (RR 2.21, 95% CI 0.74 to 6.58; P = 0.15; 4 trials; 5093 participants; very low‐certainty evidence; <a href="./references#CD012368-fig-0030" title="">Analysis 3.6</a>). The 95% prediction interval ranged between 0.12 and 40.89. </p> <p>We could not perform subgroup analysis due to lack of data.</p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. We could not perform sensitivity analysis restricted to trials with low risk of selection bias due to lack of data. We could not perform sensitivity analysis excluding long trials because all trials had a follow‐up of 104 weeks or less. We could not perform sensitivity analysis excluding large trials because no trials had more than 1000 participants randomised to each intervention group. We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> <p>TSA showed that 0.76% of the diversity‐adjusted information size had been accrued to detect or reject a 10% RRR. Diversity was 23%. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> <section id="CD012368-sec-0151"> <h6 class="title">Amputation of lower extremity</h6> <p><a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a> did not observe amputation of the lower extremity in either intervention group (64 participants; very low‐certainty evidence). </p> </section> <section id="CD012368-sec-0152"> <h6 class="title">Blindness or severe vision loss</h6> <p><a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a> did not observe blindness or severe vision loss in either intervention group (64 participants; very low‐certainty evidence). </p> </section> <section id="CD012368-sec-0153"> <h6 class="title">End‐stage renal disease</h6> <p><a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a> did not observe end‐stage renal disease in either intervention group (64 participants; very low‐certainty evidence). </p> </section> <section id="CD012368-sec-0154"> <h6 class="title">Non‐serious adverse events</h6> <p>Seven trials reported that a total of 4751 participants experienced a non‐serious adverse event: in the M+S group 2156/3348 (64.4%) participants had a non‐serious adverse event compared with 2595/4244 (61.1%) participants in the metformin plus DPP‐4 inhibitor group (RR 1.18, 95% CI 1.03 to 1.35; P = 0.02; 7 trials; 7592 participants; <a href="./references#CD012368-fig-0031" title="">Analysis 3.7</a> in favour of metformin plus DPP‐4 inhibitor). The 95% prediction interval ranged between 0.73 and 1.91. There was substantial heterogeneity, which could be caused by various definitions of the outcome (most trials did not adequately specify this outcome measure). </p> <p>A test for subgroup differences according to duration of follow‐up did not indicate interaction (P = 0.11). </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. Sensitivity analysis restricted to trials with low risk of selection bias did not substantially change the effect estimate (RR 1.27, 95% CI 1.06 to 1.52; P = 0.01; 5 trials; 4363 participants). We could not perform sensitivity analysis excluding large trials because no trials had more than 1000 participants randomised to each intervention group. We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> <p>TSA showed that 21.5% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 94%. The TSA‐adjusted 95% CI was 0.88 to 1.58. </p> </section> <section id="CD012368-sec-0155"> <h6 class="title">Hypoglycaemia</h6> <p>Seven trials reported that a total of 1544 participants experienced a mild or moderate hypoglycaemic event: in the M+S group 1359/4535 (30.0%) participants had a mild or moderate hypoglycaemic episode compared with 185/5438 (3.4%) participants in the metformin plus DPP‐4 inhibitor group (RR 7.42, 95% CI 4.77 to 11.53; P &lt; 0.001; 7 trials; 9973 participants; <a href="./references#CD012368-fig-0032" title="">Analysis 3.8</a> in favour of metformin plus DPP‐4 inhibitor). The 95% prediction interval ranged between 1.86 and 29.66. There was substantial heterogeneity, probably caused by various definitions of the outcome. All trials that stated a definition of outcome defined mild/moderate hypoglycaemia in different ways (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>). </p> <p>The test for subgroup differences analysing trials according to duration of intervention showed a statistically significant difference between subgroups (P = 0.04; <a href="./references#CD012368-fig-0032" title="">Analysis 3.8</a>). However, CIs overlap indicating that in fact there was no true interaction. </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. Sensitivity analysis restricted to trials with low risk of selection bias did not substantially change the effect estimate (RR 6.71, 95% CI 3.94 to 11.44; P &lt; 0.001; 4 trials; 3645 participants). Sensitivity analysis excluding large trials did not substantially change the effect estimate (RR 6.00, 95% CI 4.33 to 8.32; P &lt; 0.001; 6 trials; 6874 participants). We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> <p>TSA showed that 1.4% of the diversity‐adjusted information size had been accrued to detect or reject a 10% RRR. Diversity was 88%. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> <p>Eight trials reported that a total of 55 participants experienced a serious hypoglycaemic event: in the M+S group 51/4894 (1.0%) participants had a serious hypoglycaemic episode compared with 4/5797 (0.1%) participants in the metformin plus DPP‐4 inhibitor group (RR 8.04, 95% CI 3.31 to 19.53; P &lt; 0.01; 8 trials; 10,691 participants; <a href="./references#CD012368-fig-0033" title="">Analysis 3.9</a> in favour of metformin plus DPP‐4 inhibitor). The 95% prediction interval ranged between 2.66 and 24.35. </p> <p>A test for subgroup differences according to duration of follow‐up did not indicate interaction (P = 0.78). </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. Sensitivity analysis restricted to trials with low risk of selection bias did not substantially change the effect estimate (RR 8.62, 95% CI 2.81 to 26.43; P = 0.0002; 5 trials; 4363 participants). Sensitivity analysis excluding large trials did not substantially change the effect estimate (RR 6.93, 95% CI 2.72 to 17.65; P &lt; 0.001; 7 trials; 7592 participants). We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> <p>TSA showed that 0.62% of the diversity‐adjusted information size had been accrued to detect or reject a 10% RRR. Diversity was 0%. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> <section id="CD012368-sec-0156"> <h6 class="title">Socioeconomic effects</h6> <p>Two trials performed economic analyses of trial data (<a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>). </p> <p>One trial presented an economic analysis using the IMS Core Diabetes Model (<a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>). Treatment with alogliptin 12.5 mg or 25 mg compared with sulphonylurea was associated with an incremental cost‐effectiveness ratio of GBP 10,959 or GBP 7217 per quality adjusted life year, respectively. </p> <p>One trial presented an economic analysis using the Cardiff Stochastic Simulation Cost‐utility Model (<a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>). The overall mean cost per quality adjusted life year gained with saxagliptin plus metformin compared with M+S was GBP 7888. </p> </section> </section> <section id="CD012368-sec-0157"> <h5 class="title">Additional explorative outcomes</h5> <section id="CD012368-sec-0158"> <h6 class="title">Weight</h6> <p>Nine trials reported weight change. Metformin plus DPP‐4 inhibitor compared with M+S combination therapy resulted in a weight loss of 2.2 kg (95% CI 1.7 to 2.6; P &lt; 0.001; 9 trials; 10,228 participants; <a href="./references#CD012368-fig-0034" title="">Analysis 3.10</a>). The 95% prediction interval ranged between 0.8 kg and 3.5 kg. </p> </section> <section id="CD012368-sec-0159"> <h6 class="title">HbA1c</h6> <p>Nine trials reported HbA1c (random MD −0.1%, 95% CI −0.1 to 0.03; P = 0.25; 9 trials; 9320 participants; fixed MD −0.1%, 95% CI −0.1 to −0.04; P &lt; 0.001; <a href="./references#CD012368-fig-0035" title="">Analysis 3.11</a> in favour of M+S). The 95% prediction interval ranged between −0.3% and 0.2%. </p> </section> </section> </section> <section id="CD012368-sec-0160"> <h4 class="title">Metformin‐sulfonylurea combination therapy versus metformin plus a long‐acting DPP‐4 inhibitor </h4> <p>One trial compared M+S with metformin plus a long‐acting DPP‐4 inhibitor (<a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>). Glimepiride was given in doses of 1 mg/day to 6 mg/day, omarigliptin in doses of 25 mg/week and metformin in doses of 1500 mg/day or more. For details of the certainty of the evidence see <a href="./appendices#CD012368-sec-0264">Appendix 19</a>. </p> <section id="CD012368-sec-0161"> <h5 class="title">Primary outcomes</h5> <section id="CD012368-sec-0162"> <h6 class="title">All‐cause mortality</h6> <p>In the M+S group no participants died out of 375 participants, compared with 2 deaths in 375 (0.5%) participants in the metformin plus long‐acting DPP‐4 inhibitor group (RR 0.20, 95% CI 0.01 to 4.15; P = 0.30; very low‐certainty evidence because of indirectness and very serious imprecision; <a href="./references#CD012368-fig-0038" title="">Analysis 4.1</a>). </p> </section> <section id="CD012368-sec-0163"> <h6 class="title">Health‐related quality of life</h6> <p><a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a> did not report on this outcome. </p> </section> <section id="CD012368-sec-0164"> <h6 class="title">Serious adverse effects</h6> <p>In the M+S group 18/375 (4.8%) participants experienced a serious adverse event compared with 24/375 (6.4%) participants in the metformin plus long‐acting DPP‐4 inhibitor group (RR 0.75, 95% CI 0.41 to 1.36; P = 0.34; very low‐certainty evidence because of very serious imprecision, <a href="./references#CD012368-fig-0039" title="">Analysis 4.2</a>). </p> </section> </section> <section id="CD012368-sec-0165"> <h5 class="title">Secondary outcomes</h5> <section id="CD012368-sec-0166"> <h6 class="title">Cardiovascular mortality</h6> <p>In the M+S group no participants out of 375 died compared with 1 death in 375 (0.3%) participants in the metformin plus long‐acting DPP‐4 inhibitor (RR 0.33, 95% CI 0.01 to 8.16; P = 0.50; very low‐certainty evidence because of indirectness and very serious imprecision; <a href="./references#CD012368-fig-0040" title="">Analysis 4.3</a>). </p> </section> <section id="CD012368-sec-0167"> <h6 class="title">Non‐fatal myocardial infarction</h6> <p>In the M+S group 1/375 (0.3%) participants experienced a non‐fatal myocardial infarction compared with 0/375 participants in the metformin plus long‐acting DPP‐4 inhibitor (RR 3.00, 95% CI 0.12 to 73.41; P = 0.50; very low‐certainty evidence because of indirectness and very serious imprecision, <a href="./references#CD012368-fig-0041" title="">Analysis 4.4</a>). </p> </section> <section id="CD012368-sec-0168"> <h6 class="title">Heart failure, non‐fatal stroke, amputation of lower extremity, blindness or severe vision loss, end‐stage renal disease </h6> <p><a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a> did not report on these outcomes. </p> </section> <section id="CD012368-sec-0169"> <h6 class="title">Non‐serious adverse events</h6> <p>In the M+S group 125/375 (33.3%) participants experienced a non‐serious adverse event compared with 43/375 (11.5%) participants in the metformin plus long‐acting DPP‐4 inhibitor (RR 2.91, 95% CI 2.12 to 3.99; P &lt; 0.001; <a href="./references#CD012368-fig-0042" title="">Analysis 4.5</a>), favouring metformin plus long‐acting DPP‐4 inhibitor. </p> </section> <section id="CD012368-sec-0170"> <h6 class="title">Hypoglycaemia</h6> <p>In the M+S group 110/375 (29.3%) participants experienced a mild or moderate hypoglycaemic episode compared with 21/375 (5.6%) participants in the metformin plus long‐acting DPP‐4 inhibitor (RR 5.24, 95% CI 3.36 to 8.17; P &lt; 0.001; <a href="./references#CD012368-fig-0043" title="">Analysis 4.6</a> in favour of metformin plus long‐acting DPP‐4 inhibitor). </p> <p>In the M+S group 6/375 (1.6%) participants experienced a serious hypoglycaemic episode compared with 1/375 (0.3%) participant in the metformin plus long‐acting DPP‐4 inhibitor (RR 6.00, 95% CI 0.73 to 49.60; P = 0.10; <a href="./references#CD012368-fig-0044" title="">Analysis 4.7</a>). </p> </section> <section id="CD012368-sec-0171"> <h6 class="title">Socioeconomic effects</h6> <p><a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a> did not report on this outcome. </p> </section> </section> <section id="CD012368-sec-0172"> <h5 class="title">Additional explorative outcomes</h5> <section id="CD012368-sec-0173"> <h6 class="title">Weight</h6> <p>Change from baseline in body weight increased by 1.5 kg (SD 4.0) in 375 participants in the M+S group compared with a weight reduction of 0.4 kg in 375 participants in the metformin plus long‐acting DPP‐4 inhibitor group (MD 1.9 kg, 95% CI 1.3 to 2.5; P &lt; 0.001; <a href="./references#CD012368-fig-0045" title="">Analysis 4.8</a>). </p> </section> <section id="CD012368-sec-0174"> <h6 class="title">HbA1c</h6> <p>In the M+S group there was a MD in HbA1c change of −0.5% in 375 participants compared with −0.3% in 375 participants in the metformin plus long‐acting DPP‐4 inhibitor group (MD of −0.2%, 95% CI −0.3 to −0.1; P = 0.006; <a href="./references#CD012368-fig-0046" title="">Analysis 4.9</a>). </p> </section> </section> </section> <section id="CD012368-sec-0175"> <h4 class="title">Metformin‐sulfonylurea combination therapy versus metformin plus thiazolidinedione</h4> <p>Eleven trials compared M+S combination therapy with metformin plus a thiazolidinedione (<a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a>; <a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). Four trials administered glimepiride in doses of 2 mg/day to 4 mg/day (<a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>), two trials administered glibenclamide in doses of 5 mg/day to 15 mg/day (<a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>), and two trials administered gliclazide in doses of 80 mg/day to 320 mg/day (<a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>). Three trials treated participants with various sulphonylureas: glibenclamide and gliclazide in doses of 5 mg/day to 15 mg/day and 80 mg/day to 320 mg/day, respectively (<a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>); glibenclamide, gliclazide and glimepiride in doses up to 15 mg/day, 240 mg/day and 4 mg/day, respectively (<a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>); glibenclamide, gliclazide and glimepiride in doses of 5 mg/day to 15 mg/day, 30 mg/day to 120 mg/day and 2 mg/day to 6 mg/day, respectively (<a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). Five trials administered rosiglitazone in doses of 4 mg/day to 8 mg/day (<a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>), and six trials administered pioglitazone in doses of 15 mg/day to 45 mg/day (<a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a>; <a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). Metformin was given in doses of 850 mg/day to 2550 mg/day. </p> <section id="CD012368-sec-0176"> <h5 class="title">Primary outcomes</h5> <section id="CD012368-sec-0177"> <h6 class="title">All‐cause mortality</h6> <p>Six trials reported that a total of 237 participants died: in the M+S group 123/3300 (3.7%) participants died compared with 114/3354 (3.4%) participants in the metformin plus thiazolidinedione group (RR 1.09, 95% CI 0.85 to 1.40; P = 0.51; 6 trials; 6654 participants; low‐certainty evidence; <a href="./references#CD012368-fig-0047" title="">Analysis 5.1</a>). The 95% prediction interval ranged between 0.75 and 1.55. One of the trials provided data from a time‐to‐event analysis on all‐cause mortality: the HR for metformin plus pioglitazone versus M+S was 1.10 (95% CI 0.75 to 1.61, P = 0.63; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). </p> <p>In one trial, comparing M+S with metformin plus pioglitazone, the investigators reported that no participants died but did not provide the number of participants included in the analysis (<a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>). </p> <p>A test for subgroup differences comparing rosiglitazone with pioglitazone did not indicate interaction (P = 0.84; <a href="./references#CD012368-fig-0047" title="">Analysis 5.1</a>). A test for subgroup differences according to duration of follow‐up did not indicate interaction (P = 0.91; <a href="./references#CD012368-fig-0061" title="">Analysis 6.1</a>). </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. Sensitivity analysis according to trials with low risk of selection bias did not substantially change the effect estimate (RR 1.08, 95% CI 0.84 to 1.38; P = 0.57; 5 trials; 6570 participants). Sensitivity analysis excluding large trials did not substantially change the effect estimate (RR 2.08, 95% CI 0.49 to 8.80; P = 0.32; 4 trials; 1404 participants). We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company due to lack of data. </p> <p>TSA showed that 7.7% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 0%. The TSA‐adjusted 95% CI was 0.39 to 3.01. </p> </section> <section id="CD012368-sec-0178"> <h6 class="title">Health‐related quality of life</h6> <p>None of the included trials reported on this outcome.</p> </section> <section id="CD012368-sec-0179"> <h6 class="title">Serious adverse effects</h6> <p>Six trials reported that a total of 1337 participants experienced a serious adverse event: in the M+S group 666/3300 (20.2%) participants had a serious adverse event compared with 671/3354 (20.0%) participants in the metformin plus thiazolidinedione group (RR 1.01, 95% CI 0.93 to 1.11; P = 0.80; 6 trials; 6654 participants; very low‐certainty evidence; <a href="./references#CD012368-fig-0048" title="">Analysis 5.2</a>). The 95% prediction interval ranged between 0.88 and 1.16. </p> <p><a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a> compared M+S with metformin plus pioglitazone and reported that no participants experienced a serious adverse event but did not provide the number of participants included in the analysis. </p> <p>A test for subgroup differences comparing rosiglitazone with pioglitazone did not indicate interaction (P = 0.84; <a href="./references#CD012368-fig-0048" title="">Analysis 5.2</a>). A test for subgroup differences according to duration of follow‐up did not indicate interaction (P = 0.28; <a href="./references#CD012368-fig-0062" title="">Analysis 6.2</a>). </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. Sensitivity analysis according to trials with low risk of selection bias did not substantially change the effect estimate (RR 1.01, 95% CI 0.92 to 1.10; P = 0.90; 5 trials; 6570 participants). Sensitivity analysis excluding large trials did not substantially change the effect estimate (RR 1.13, 95% CI 0.69 to 1.86; P = 0.63; 4 trials; 1404 participants). We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company due to lack of data. </p> <p>TSA showed that 10.6% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 81%. The TSA‐adjusted 95% CI was 0.41 to 2.22. </p> </section> </section> <section id="CD012368-sec-0180"> <h5 class="title">Secondary outcomes</h5> <section id="CD012368-sec-0181"> <h6 class="title">Cardiovascular mortality</h6> <p>Four trials reported that a total of 78 participants died due to cardiovascular disease: in the M+S group 37/2946 (1.3%) participants died compared with 41/2994 (1.4%) participants in the metformin plus thiazolidinedione group (RR 0.78, 95% CI 0.36 to 1.67; P = 0.52; 4 trials; 5940 participants; low‐certainty evidence; <a href="./references#CD012368-fig-0049" title="">Analysis 5.3</a>). The 95% prediction interval ranged between 0.07 and 8.92. <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a> provided data from a time‐to‐event analysis on cardiovascular mortality: metformin plus pioglitazone versus M+S had a HR of 2.24 (95% CI 0.69 to 7.28, P = 0.18). <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>, compared M+S with metformin plus pioglitazone and reported that no participants died due to cardiovascular disease but did not provide the number of participants included in the analysis. </p> <p>A test for subgroup differences comparing rosiglitazone with pioglitazone did not indicate interaction (P = 0.40; <a href="./references#CD012368-fig-0049" title="">Analysis 5.3</a>). A test for subgroup differences according to duration of follow‐up did not indicate interaction (P = 0.36; <a href="./references#CD012368-fig-0063" title="">Analysis 6.3</a>). </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. We could not perform sensitivity analysis according to trials with low risk of selection bias since all trials were evaluated as low risk of selection bias. We could not perform sensitivity analyses excluding large trials and trials funded by a pharmaceutical company due to lack of data. </p> <p>TSA showed that 1.3% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 66%. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> <section id="CD012368-sec-0182"> <h6 class="title">Non‐fatal myocardial infarction</h6> <p>Three trials reported that a total of 46 participants experienced a non‐fatal myocardial infarction: in the M+S group 25/1841 (1.4%) participants had a non‐fatal myocardial infarction compared with 21/1877 (1.1%) participants in the metformin plus thiazolidinedione group (RR 1.21, 95% CI 0.68 to 2.14; P = 0.51; 3 trials; 3718 participants; very low‐certainty evidence; <a href="./references#CD012368-fig-0050" title="">Analysis 5.4</a>). The 95% prediction interval ranged between 0.03 and 48.76. </p> <p><a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a> provided data from a time‐to‐event analysis on non‐fatal myocardial infarction: M+S versus metformin plus pioglitazone had a HR of 0.87 (95% CI 0.48 to 1.55; P = 0.63). </p> <p><a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a> compared M+S with metformin plus pioglitazone and reported that no participants experienced a non‐fatal myocardial infarction but did not provide the number of participants included in the analysis. </p> <p>A test for subgroup differences comparing rosiglitazone with pioglitazone did not indicate interaction (P = 0.58; <a href="./references#CD012368-fig-0050" title="">Analysis 5.4</a>). A test for subgroup differences according to duration of follow‐up did not indicate interaction (P = 0.58; <a href="./references#CD012368-fig-0064" title="">Analysis 6.4</a>). </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. We could not perform sensitivity analysis according to trials with low risk of selection bias because all trials were evaluated as low risk of selection bias. Sensitivity analyses excluding large trials and trials funded by a pharmaceutical company could not be performed due to lack of data. </p> <p>TSA showed that 1.72% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 0%. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> <p><b>Heart failure</b> </p> <p>Five trials reported that a total of 83 participants developed heart failure: in the M+S group 33/3259 (1.0%) participants developed heart failure compared with 50/3311 (1.5%) participants in the metformin plus thiazolidinedione group (RR 0.67, 95% CI 0.43 to 1.04; P = 0.08; 5 trials; 6570 participants; <a href="./references#CD012368-fig-0051" title="">Analysis 5.5</a>). The 95% prediction interval ranged between 0.33 and 1.37. </p> <p><a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a> provided data from a time‐to‐event analysis on heart failure: the HR comparing participants in the sulphonylureas group with participants in the pioglitazone group was 1.57 (95% CI 0.76 to 3.24; P = 0.22). </p> <p><a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a> compared M+S with metformin plus pioglitazone and reported that no participants developed heart failure but did not report the number of participants included in the analysis. </p> <p>A test for subgroup differences comparing rosiglitazone with pioglitazone did not indicate interaction (P = 0.65; <a href="./references#CD012368-fig-0051" title="">Analysis 5.5</a>). A test for subgroup differences according to duration of follow‐up did not indicate interaction (P = 0.79; <a href="./references#CD012368-fig-0065" title="">Analysis 6.5</a>). </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. We could not perform sensitivity analysis according to trials with low risk of selection bias because all trials were evaluated as low risk of selection bias. Sensitivity analysis excluding large trials did not substantially change the effect estimate (RR 0.51, 95% CI 0.12 to 2.07; P = 0.35; 3 trials; 1320 participants). We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company due to lack of data. </p> <p>TSA showed that 3.3% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 0%. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> <section id="CD012368-sec-0183"> <h6 class="title">Non‐fatal stroke</h6> <p>Two trials compared M+S with metformin plus thiazolidinedione: in the M+S group 20/1540 (1.3%) participants had a non‐fatal stroke compared with 16/1583 (1%) participants in the metformin plus thiazolidinedione group (RR 1.29, 95% CI 0.67 to 2.47; P = 0.45; 2 trials; 3123 participants; very low‐certainty evidence; <a href="./references#CD012368-fig-0052" title="">Analysis 5.6</a>). <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a> administered pioglitazone combined with metformin and also provided data from a time‐to‐event analysis on non‐fatal stroke: M+S compared with metformin plus pioglitazone showed a HR of 0.79 (95% CI 0.41 to 1.53; P = 0.49; 3028 participants). Only <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>, in his trial of long duration, observed non‐fatal strokes (<a href="./references#CD012368-fig-0066" title="">Analysis 6.6</a>). </p> <p><a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a> administered pioglitazone combined with metformin and reported that no participants experienced a non‐fatal stroke but did not provide the number of participants included in the analysis. </p> </section> <section id="CD012368-sec-0184"> <h6 class="title">Amputation of lower extremity</h6> <p>Two trials with 3123 participants provided data on amputation of lower extremity (very low‐certainty evidence; <a href="./references#CD012368-fig-0053" title="">Analysis 5.7</a>). Neither of the trials reported any events. </p> </section> <section id="CD012368-sec-0185"> <h6 class="title">Blindness or severe vision loss</h6> <p>One trial with 95 participants provided data on blindness or severe vision loss (very low‐certainty evidence; <a href="./references#CD012368-fig-0054" title="">Analysis 5.8</a>). They did not report any events. </p> </section> <section id="CD012368-sec-0186"> <h6 class="title">End‐stage renal disease</h6> <p>One trial with 95 participants provided data on end‐stage renal disease (very low‐certainty evidence; <a href="./references#CD012368-fig-0055" title="">Analysis 5.9</a>). They did not report any events. </p> </section> <section id="CD012368-sec-0187"> <h6 class="title">Non‐serious adverse events</h6> <p>Five trials reported that a total of 3072 participants experienced a non‐serious adverse event: in the M+S group 1510/2987 (50.6%) participants had a non‐serious adverse event compared with 1562/3037 (51.4%) participants in the metformin plus thiazolidinedione group (RR 0.94, 95% CI 0.44 to 2.01; P = 0.87; 5 trials; 6024 participants; <a href="./references#CD012368-fig-0056" title="">Analysis 5.10</a>). The 95% prediction interval ranged between 0.05 and 16.49. </p> <p><a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a> compared M+S with metformin plus pioglitazone and reported that two and three participants experienced non‐serious adverse events, respectively. However, they did not provide the number of participants included in the analysis. </p> <p>A test for subgroup differences comparing rosiglitazone with pioglitazone did not indicate interaction (P = 0.36; <a href="./references#CD012368-fig-0056" title="">Analysis 5.10</a>). A test for subgroup differences according to duration of follow‐up did not indicate interaction (P = 0.94; <a href="./references#CD012368-fig-0067" title="">Analysis 6.7</a>). </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. Sensitivity analysis according to trials with low risk of selection bias did not substantially change the effect estimate (RR 0.92, 95% CI 0.36 to 2.35; P = 0.87; 4 trials; 5940 participants). Sensitivity analysis excluding large trials did not substantially change the effect estimate (RR 0.97, 95% CI 0.76 to 1.25; P = 0.83; 3 trials; 774 participants). Sensitivity analysis excluding trials funded by a pharmaceutical company did not substantially change the effect estimate (RR 0.93, 95% CI 0.82 to 1.05; P = 0.24; 2 trials; 3123 participants). </p> <p>TSA showed that the cumulative z‐curve crossed the futility boundaries suggesting that a 10% or greater RRR could be rejected at this point. Diversity was 0%. The TSA‐adjusted 95% CI was 0.74 to 1.19. </p> </section> <section id="CD012368-sec-0188"> <h6 class="title">Hypoglycaemia</h6> <p>Five trials reported that a total of 926 participants had a mild or moderate hypoglycaemic episode: in the M+S group 721/2999 (24.0%) participants had a mild or moderate hypoglycaemic episode compared with 205/3060 (6.7%) participants in the metformin plus thiazolidinedione group (RR 3.63, 95% CI 2.98 to 4.44; P &lt; 0.001; 5 trials; 6059 participants; <a href="./references#CD012368-fig-0057" title="">Analysis 5.11</a> in favour of metformin plus thiazolidinedione). The 95% prediction interval ranged between 2.30 and 5.73. <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a> compared M+S with metformin plus pioglitazone and reported two and one events of mild/moderate hypoglycaemia, respectively. However, they did not provide the number of participants included in the analysis. </p> <p>A test for subgroup differences comparing rosiglitazone with pioglitazone did not indicate interaction (P = 0.62; <a href="./references#CD012368-fig-0057" title="">Analysis 5.11</a>). A test for subgroup differences according to duration of follow‐up did not indicate interaction (P = 0.48; <a href="./references#CD012368-fig-0068" title="">Analysis 6.8</a>). </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. Sensitivity analysis according to trials with low risk of selection bias did not substantially change the effect estimate (RR 3.63, 95% CI 2.92 to 4.52; P &lt; 0.00001; 4 trials; 5975 participants). Sensitivity analysis excluding large trials did not substantially change the effect estimate (RR 5.99, 95% CI 2.43 to 14.76; P = 0.0001; 3 trials; 809 participants). Sensitivity analysis excluding trials funded by a pharmaceutical company did not substantially change the effect estimate (RR 3.37, 95% CI 2.84 to 3.99; P &lt; 0.00001; 2 trials; 3123 participants). </p> <p>TSA showed that 8.0% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 45%. The TSA‐adjusted 95% CI was 1.63 to 8.09. </p> <p>Five trials reported that 36 participants experienced serious hypoglycaemia: in the M+S group 30/3259 (0.9%) participants had a serious hypoglycaemic episode compared with 6/3311 (0.2%) participants in the metformin plus thiazolidinedione group (random RR 3.98, 95% CI 0.34 to 46.01; P = 0.27; fixed RR 4.77, 95% CI 2.05 to 11.09; P &lt; 0.001; 5 trials; 6570 participants; <a href="./references#CD012368-fig-0058" title="">Analysis 5.12</a>; in favour of metformin plus thiazolidinedione). However, there was substantial heterogeneity, probably caused by various definitions of serious hypoglycaemia. Only one trial provided a clear description of serious hypoglycaemia (<a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). </p> <p><a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a> compared M+S with metformin plus pioglitazone and reported no serious hypoglycaemic events. However, they did not provide the number of participants included in the analysis. </p> <p>A test for subgroup differences comparing rosiglitazone with pioglitazone showed a statistically significant difference between subgroups (P = 0.009; <a href="./references#CD012368-fig-0058" title="">Analysis 5.12</a>). However, CIs overlap slightly indicating that in fact there was no true interaction. A test for subgroup differences according to duration of follow‐up did not indicate interaction (P = 0.85; <a href="./references#CD012368-fig-0069" title="">Analysis 6.9</a>). </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. We could not perform sensitivity analysis according to trials with low risk of selection bias because all trials were evaluated as low risk of selection bias. We could not perform sensitivity analysis of large trials and trials funded by a pharmaceutical company due to lack of data. </p> <p>TSA showed that 0.08% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 79%. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> <section id="CD012368-sec-0189"> <h6 class="title">Socioeconomic effects</h6> <p>None of the included trials reported on this outcome.</p> </section> </section> <section id="CD012368-sec-0190"> <h5 class="title">Additional explorative outcomes</h5> <section id="CD012368-sec-0191"> <h6 class="title">Weight</h6> <p>Seven trials reported weight change (random MD −0.6 kg, 95% CI −2.8 to 1.6; P = 0.62; fixed MD −2.0 kg, 95% CI −2.4 to −1.6; P &lt; 0.001; 7 trials; 6877 participants; <a href="./references#CD012368-fig-0059" title="">Analysis 5.13</a>; in favour of M+S). The 95% prediction interval ranged between −8.3 kg and 7.2 kg.There was substantial heterogeneity probably caused by two of the rosiglitazone trials (<a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>), and by duration of follow‐up (ranging from one year to 5.5 years), various sulphonylureas (glimepiride, glibenclamide, gliclazide) and various doses of rosiglitazone ranging from 4 mg/day to 8 mg/day. </p> <p><b>HbA1c</b> </p> <p>Ten trials reported change in HbA1c (random MD 0.2%, 95% CI 0.04 to 0.3; P = 0.01; fixed MD 0.2%, 95% CI 0.1 to 0.2; P &lt; 0.001; 10 trials; 7020 participants; <a href="./references#CD012368-fig-0060" title="">Analysis 5.14</a>; in favour of metformin plus thiazolidinedione). The 95% prediction interval ranged between −0.2% and 0.5%. There was substantial heterogeneity probably caused by duration of follow‐up (ranging from 1 year to 5.5 years), various sulphonylureas (glimepiride, glibenclamide, gliclazide) and various doses of sulphonylureas and thiazolidinediones. </p> <p><a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a> reported HbA1c final values of 7.8% (SD 0.4) in the M+S group and 7.2% (SD 0.3) in the metformin plus pioglitazone group. However, they did not provide the number of participants included in the analysis. </p> </section> </section> </section> <section id="CD012368-sec-0192"> <h4 class="title">Metformin‐sulfonylurea combination therapy versus metformin plus glinide</h4> <p>Three trials compared M+S combination therapy with metformin plus a glinide (<a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>). Two trials administered glibenclamide in doses of 1.25 mg/day to 15 mg/day and one trial administered gliclazide in doses of 80 mg/day to 240 mg/day. All trials administered nateglinide in doses of 180 mg/day to 540 mg/day. The trials administered metformin in doses of 500 mg/day to 3000 mg/day. </p> <section id="CD012368-sec-0193"> <h5 class="title">Primary outcomes</h5> <section id="CD012368-sec-0194"> <h6 class="title">All‐cause mortality</h6> <p>Three trials with 874 participants reported data on all‐cause mortality and one person died in each intervention group (low‐certainty evidence; <a href="./references#CD012368-fig-0072" title="">Analysis 7.1</a>). </p> </section> <section id="CD012368-sec-0195"> <h6 class="title">Health‐related quality of life</h6> <p>None of the included trials reported on this outcome.</p> </section> <section id="CD012368-sec-0196"> <h6 class="title">Serious adverse effects</h6> <p>Three trials reported that a total of 61 participants experienced a serious adverse event: in the M+S group 34/424 (8%) participants had a serious adverse event compared with 27/450 (6%) participants in the metformin plus thiazolidinedione group (RR 1.68, 95% CI 0.54 to 5.21; P = 0.37; 3 trials; 874 participants; low‐certainty evidence; <a href="./references#CD012368-fig-0073" title="">Analysis 7.2</a>). </p> <p>In one trial serious adverse events were reported for up to six months and six to 12 months separately. For up to six months 5/126 (4.0%) participants in the M+S group had a serious adverse event compared with 7/130 (5.4%) participants in the metformin plus glinide group. For six to 12 months, 7/101 (6.9%) participants and 2/112 (1.8%) participants experienced a serious adverse event in the M+S group compared with the metformin plus glinide group, respectively (<a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>). </p> </section> </section> <section id="CD012368-sec-0197"> <h5 class="title">Secondary outcomes</h5> <section id="CD012368-sec-0198"> <h6 class="title">Cardiovascular mortality</h6> <p>Two trials with 446 participants provided data on cardiovascular mortality (<a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>). No cardiovascular death was observed in either trial (low‐certainty evidence; <a href="./references#CD012368-fig-0074" title="">Analysis 7.3</a>). </p> </section> <section id="CD012368-sec-0199"> <h6 class="title">Non‐fatal myocardial infarction</h6> <p>Two trials provided data on non‐fatal myocardial infarction in 446 participants. In total two non‐fatal myocardial infarctions were reported in 2/215 (0.9%) participants in the M+S group compared with 0/231 participants in the metformin plus thiazolidinedione group (2 trials; 446 participants; low‐certainty evidence). <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a> stated that no participants experienced a non‐fatal myocardial infarction. One trial reported non‐fatal myocardial infarction for up to six months and six to 12 months separately (<a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>). For up to six months no event occurred in either intervention group. For six to 12 months, 2/101 (2%) participants had non‐fatal myocardial infarction in the M+S group compared to 0/112 participant in the metformin plus glinide group (RR 5.54, 95% CI 0.27 to 114.02; P = 0.27). </p> </section> <section id="CD012368-sec-0200"> <h6 class="title">Heart failure</h6> <p>Two trials provided data on heart failure. <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a> stated that no heart failure occurred. One trial reported data on heart failure for up to six months and six to 12 months separately. For up to six months no event occurred in either intervention group. For six to 12 months, 0/101 participants and 1/112 (0.9%) participants developed heart failure in the M+S group compared to the metformin plus glinide group, respectively (<a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>). </p> </section> <section id="CD012368-sec-0201"> <h6 class="title">Non‐fatal stroke</h6> <p><a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a> stated that no non‐fatal stroke occurred (233 participants; very low‐certainty evidence). </p> </section> <section id="CD012368-sec-0202"> <h6 class="title">Amputation of lower extremity</h6> <p><a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a> stated that no amputation of lower extremity occurred (233 participants; low‐certainty evidence). </p> </section> <section id="CD012368-sec-0203"> <h6 class="title">Blindness or severe vision loss</h6> <p><a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a> stated that no blindness or severe vision loss occurred (233 participants; low‐certainty evidence). </p> </section> <section id="CD012368-sec-0204"> <h6 class="title">End‐stage renal disease</h6> <p><a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a> stated that no end‐stage renal disease occurred (233 participants; low‐certainty evidence). </p> </section> <section id="CD012368-sec-0205"> <h6 class="title">Non‐serious adverse events</h6> <p><a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a> stated that no non‐serious adverse events occurred. </p> </section> <section id="CD012368-sec-0206"> <h6 class="title">Hypoglycaemia</h6> <p>Two trials provided data on mild or moderate hypoglycaemia. <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a> reported data from a subgroup analysis of participants 65 years and older: in the M+S group 7/40 (17.5%) participants had mild or moderate hypoglycaemia compared with 1/35 (2.9%) participants in the metformin plus glinide group (<a href="./references#CD012368-fig-0075" title="">Analysis 7.4</a>). <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a> reported two mild or moderate hypoglycaemic episodes in the M+S group compared with three events in the metformin plus glinide group. </p> <p>Two trials provided data on serious hypoglycaemia. <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a> reported that 2/209 (1%) participants in the M+S group compared with 0/219 participants in the metformin plus glinide group experienced a serious hypoglycaemic episode (<a href="./references#CD012368-fig-0076" title="">Analysis 7.5</a>). <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a> stated that no serious hypoglycaemia occurred. </p> </section> <section id="CD012368-sec-0207"> <h6 class="title">Socioeconomic effects</h6> <p>Neither of the included trials reported on this outcome.</p> </section> </section> <section id="CD012368-sec-0208"> <h5 class="title">Additional explorative outcomes</h5> <section id="CD012368-sec-0209"> <h6 class="title">Weight</h6> <p>Two trials reported weight change (MD 1.1 kg, 95% CI −0.1 to 2.3; P = 0.06; 2 trials; 619 participants; <a href="./references#CD012368-fig-0077" title="">Analysis 7.6</a>). </p> </section> <section id="CD012368-sec-0210"> <h6 class="title">HbA1c</h6> <p>Three trials reported change in HbA1c (random MD 0.2%, 95% CI ‐0.6 to 1.0; P = 0.69; fixed MD 0.4%, 95% CI 0.3 to 0.5; P &lt; 0.00001; 3 trials; 852 participants; <a href="./references#CD012368-fig-0078" title="">Analysis 7.7</a>; in favour of metformin plus glinide). Calculation of the 95% prediction interval did not provide a meaningful estimate. There was substantial heterogeneity probably caused by various durations of follow‐up (ranging from 52 weeks to 104 weeks), various sulphonylureas (glibenclamide and gliclazide) and various doses of nateglinide (ranging from 180 mg/day to 540 mg/day). </p> </section> </section> </section> <section id="CD012368-sec-0211"> <h4 class="title">Metformin‐sulfonylurea combination therapy versus metformin plus sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitor </h4> <p>Four trials compared M+S combination therapy with metformin plus a SGLT‐2 inhibitor (<a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>). Three trials administered glimepiride in doses of 1 mg/day to 8 mg/day (<a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>), and one trial administered glipizide in doses of 5 mg/day to 20 mg/day (<a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>). All trials administered various SGLT‐2 inhibitors: dapagliflozin in doses of 2.5 mg/day to 10 mg/day (<a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>), ertugliflozin in doses of 15 mg/day (<a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>), canagliflozin in doses of 100 mg/day to 300 mg/day (<a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>), and empagliflozin in doses of 25 mg/day (<a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>). Metformin was given in doses of 1000 mg/day to 1500 mg/day or more. </p> <section id="CD012368-sec-0212"> <h5 class="title">Primary outcomes</h5> <section id="CD012368-sec-0213"> <h6 class="title">All‐cause mortality</h6> <p>Four trials reported that a total of 32 participants died: in the M+S group 13/2107 (0.6%) participants died compared with 19/3027 (0.6%) participants in the metformin plus SGLT‐2 inhibitor group (RR 0.96, 95% CI 0.44 to 2.09; P = 0.91; 4 trials; 5134 participants; very low‐certainty evidence; <a href="./references#CD012368-fig-0079" title="">Analysis 8.1</a>). The 95% prediction interval ranged between 0.17 and 5.30. </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. We could not perform sensitivity analysis according to trials with low risk of selection bias because all trials were evaluated as low risk of selection bias. Sensitivity analysis excluding long trials did not substantially change the effect estimate (RR 0.72, 95% CI 0.30 to 1.76; P = 0.47; 3 trials; 4320 participants). One trial reported data for 104 weeks (<a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>). We could not perform sensitivity analysis excluding large trials because all trials randomised fewer than 1000 participants to each intervention group. We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> <p>TSA showed that 1.04% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 0%. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> <section id="CD012368-sec-0214"> <h6 class="title">Health‐related quality of life</h6> <p>None of the included trials reported on this outcome.</p> </section> <section id="CD012368-sec-0215"> <h6 class="title">Serious adverse effects</h6> <p>Four trials reported that a total of 690 participants experienced a serious adverse event: in the M+S group 315/2107 (15.5%) participants had a serious adverse event compared with 375/3027 (12.4%) participants in the metformin plus SGLT‐2 inhibitor group (RR 1.02, 95% CI 0.76 to 1.37; P = 0.90; 4 trials; 5134 participants; very low‐certainty evidence; <a href="./references#CD012368-fig-0080" title="">Analysis 8.2</a>). The 95% prediction interval ranged between 0.30 and 3.51. </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. We could not perform sensitivity analysis according to trials with low risk of selection bias because all trials were evaluated as low risk of selection bias. Sensitivity analysis excluding long trials did not substantially change the effect estimate (RR 0.93, 95% CI 0.35 to 2.49; P = 0.88; 2 trials; 2775 participants). We could not perform sensitivity analysis excluding large trials because all trials randomised fewer than 1000 participants to each intervention group. We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> <p>TSA showed that 12.4% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 78%. The TSA‐adjusted 95% CI was 0.31 to 3.36. </p> </section> </section> <section id="CD012368-sec-0216"> <h5 class="title">Secondary outcomes</h5> <section id="CD012368-sec-0217"> <h6 class="title">Cardiovascular mortality</h6> <p>Three trials reported that a total of 10 participants died due to cardiovascular disease: in the M+S group 4/1327 (0.3%) participants died compared with 6/2262 (0.3%) participants in the metformin plus SGLT‐2 inhibitor group (RR 1.22, 95% CI 0.33 to 4.41; P = 0.77; 3 trials; 3589 participants; very low‐certainty evidence; <a href="./references#CD012368-fig-0081" title="">Analysis 8.3</a>). Calculation of the 95% prediction interval did not provide a meaningful estimate. </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. We could not perform sensitivity analysis according to trials with low risk of selection bias because all trials were evaluated as low risk of selection bias. Sensitivity analysis excluding long trials did not substantially change the effect estimate (RR 1.02, 95% CI 0.25 to 4.18; P = 0.98; 2 trials; 2775 participants). We could not perform sensitivity analysis excluding large trials because all trials randomised fewer than 1000 participants to each intervention group. We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> <p>TSA showed that 0.36% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 0%. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> <section id="CD012368-sec-0218"> <h6 class="title">Non‐fatal myocardial infarction</h6> <p>Two trials reported that a total of 15 participants experienced a non‐fatal myocardial infarction: in the M+S group 7/890 (0.8%) participants had a non‐fatal myocardial infarction compared with 8/1374 (0.6%) participants in the metformin plus SGLT‐2 inhibitor group (RR 1.43, 95% CI 0.49 to 4.18; P = 0.52; 2 trials; 2264 participants; very low‐certainty evidence; <a href="./references#CD012368-fig-0082" title="">Analysis 8.4</a>). </p> <p>We could not perform sensitivity analyses due to lack of data.</p> <p>TSA showed that 0.46% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 0%. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> <section id="CD012368-sec-0219"> <h6 class="title">Heart failure</h6> <p>Three trials reported that a total of four participants developed heart failure: in the M+S group 4/1670 (0.2%) participants developed heart failure compared with 0/2139 participant in the metformin plus SGLT‐2 inhibitor group (Peto OR 9.21, 95% CI 1.26 to 67.24; P = 0.03; 3 trials; 3809 participants; <a href="./references#CD012368-fig-0083" title="">Analysis 8.5</a>). </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. We could not perform sensitivity analysis according to trials with low risk of selection bias because all trials were evaluated as low risk of selection bias. Sensitivity analysis excluding long trials did not substantially change the effect estimate but widened the CI (Peto OR 11.84, 95% CI 0.68 to 205.34; P = 0.09; 2 trials; 2264 participants). We could not perform sensitivity analysis excluding large trials because all trials randomised fewer than 1000 participants to each intervention group. We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> <p>None of the participants in the comparator group (metformin plus SGLT‐2 inhibitor) developed heart failure. TSA could therefore not be performed as it was not possible to calculate an event rate in the comparator group. However, applying 0.5 events in each of the trials in the comparator group showed that 10.9% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 0%. The TSA‐adjusted 95% CI did not provide a meaningful estimate. </p> </section> <section id="CD012368-sec-0220"> <h6 class="title">Non‐fatal stroke</h6> <p>Two trials reported that a total of 10 participants experienced a non‐fatal stroke: in the M+S group 3/919 (0.3%) participants had a non‐fatal stroke compared with 7/1856 (0.4%) participants in the metformin plus SGLT‐2 inhibitor group (RR 0.87, 95% CI 0.22 to 3.34; P = 0.83; 2 trials; 2775 participants; very low‐certainty evidence; <a href="./references#CD012368-fig-0084" title="">Analysis 8.6</a>). </p> <p>We could not perform sensitivity analyses due to lack of data.</p> <p>TSA showed that 0.37% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 0%. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> <section id="CD012368-sec-0221"> <h6 class="title">Amputation of lower extremity</h6> <p><a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a> reported one amputation of lower extremity in 437 (0.2%) participants in the M+S group compared with one amputation in 888 (0.1%) participants in the metformin plus SGLT‐2 inhibitor group (very low‐certainty evidence, <a href="./references#CD012368-fig-0085" title="">Analysis 8.7</a>). </p> </section> <section id="CD012368-sec-0222"> <h6 class="title">Blindness or severe vision loss</h6> <p>None of the included trials reported on this outcome.</p> </section> <section id="CD012368-sec-0223"> <h6 class="title">End‐stage renal disease</h6> <p>None of the included trials reported on this outcome.</p> </section> <section id="CD012368-sec-0224"> <h6 class="title">Non‐serious adverse events</h6> <p>Three trials reported that a total of 2284 participants had non‐serious adverse events: in the M+S group 1139/1670 (68.2%) participants experienced a non‐serious adverse event compared with 1145/2139 (53.5%) participants in the metformin plus SGLT‐2 inhibitor group (RR 1.27, 95% CI 1.01 to 1.59; P = 0.04; 3 trials; 3809 participants; <a href="./references#CD012368-fig-0086" title="">Analysis 8.8</a>; in favour of metformin plus SGLT‐2 inhibitor). The 95% prediction interval ranged between 0.07 and 23.77. None of the trials provided a detailed definition of this outcome measure. </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. We could not perform sensitivity analysis according to trials with low risk of selection bias because all trials were evaluated as low risk of selection bias. Sensitivity analysis excluding long trials did not substantially change the direction of the effect estimate (RR 1.38, 95% CI 1.06 to 1.80; P = 0.02; 2 trials; 2264 participants). We included one trial with a duration of intervention longer than 104 weeks of treatment in the analysis because they reported data for non‐serious adverse events after 52 weeks of treatment (<a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>). We could not perform sensitivity analysis excluding large trials because all trials randomised fewer than 1000 participants to each intervention group. We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> <p>TSA showed that 6.2% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 96%. The TSA‐adjusted 95% CI was 0.53 to 3.01. </p> </section> <section id="CD012368-sec-0225"> <h6 class="title">Hypoglycaemia</h6> <p>Three trials reported that a total of 603 participants experienced mild or moderate hypoglycaemia: in the M+S group 514/1670 (30.8%) participants had a mild or moderate hypoglycaemic episode compared with 89/1639 (5.4%) participants in the metformin plus SGLT‐2 inhibitor group (RR 5.60, 95% CI 2.38 to 13.14; P &lt; 0.001; 3 trials; 3309 participants; <a href="./references#CD012368-fig-0087" title="">Analysis 8.9</a>; in favour of metformin plus SGLT‐2 inhibitor). Calculation of the 95% prediction interval did not provide a meaningful estimate. </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. We could not perform sensitivity analysis according to trials with low risk of selection bias because all trials were evaluated as low risk of selection bias. We could not perform sensitivity analysis excluding long trials due to lack of data. We could not perform sensitivity analysis excluding large trials because all trials randomised fewer than 1000 participants to each intervention group. We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> <p>TSA showed that 0.44% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 93%. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> <p>Four trials reported that a total of 38 participants had serious hypoglycaemia: in the M+S group 30/2107 (1.4%) participants had a serious hypoglycaemic episode compared with 8/3027 (0.3%) participants in the metformin plus SGLT‐2 inhibitor group (RR 6.16, 95% CI 2.92 to 12.97; P &lt; 0.001; 4 trials; 5134 participants; <a href="./references#CD012368-fig-0088" title="">Analysis 8.10</a>; in favour of metformin plus SGLT‐2 inhibitor). The 95% prediction interval ranged between 1.20 and 31.58. For one of the trials included in the meta‐analysis, the number of serious hypoglycaemic events was unclear due to varied reporting (<a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>). We contacted the trial authors for clarification but did not receive a reply. To be sure to have included all serious hypoglycaemic events, we extracted the highest number of serious hypoglycaemic events reported. </p> <p>Because all trials were published in English, we could not perform sensitivity analyses according to publication status or language of publication. We could not perform sensitivity analysis according to trials with low risk of selection bias because all trials were evaluated as low risk of selection bias. Sensitivity analysis excluding long trials did not substantially change the effect estimate (RR 6.39, 95% CI 2.89 to 14.12; P &lt; 0.001; 2 trials; 2775 participants). We could not perform sensitivity analysis excluding large trials because all trials randomised fewer than 1000 participants to each intervention group. We could not perform sensitivity analysis excluding trials funded by a pharmaceutical company because all trials received funding from a pharmaceutical company. </p> <p>TSA showed that 0.56% of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued. Diversity was 0%. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR had been accrued, we could not calculate the TSA‐adjusted 95% CI. </p> </section> <section id="CD012368-sec-0226"> <h6 class="title">Socioeconomic effects</h6> <p>One trial performed three economic analyses of trial data using the Cardiff Diabetes Model (<a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>). One economic analysis aimed to assess the cost‐effectiveness of SGLT‐2 inhibitor compared with sulphonylurea when added to metformin for treatment of people in the UK with diabetes mellitus inadequately controlled on metformin alone. There was a mean incremental benefit of 0.47 quality‐adjusted life years (95% CI 0.42 to 0.67), calculated for dapagliflozin plus metformin, the incremental cost‐effectiveness ratio point estimate was GBP 2671 per quality‐adjusted life year. </p> <p>Another economic analysis aimed to assess the cost‐effectiveness of SGLT‐2 inhibitor compared with sulphonylurea when added to metformin for treatment of Nordic people with diabetes mellitus inadequately controlled on metformin alone. The mean lifetime gain in quality‐adjusted life years for metformin plus dapagliflozin compared to M+S was 0.25 in Denmark, 0.27 in Finland, 0.24 in Norway and 0.28 in Sweden. The cost per quality‐adjusted life year gained was EUR 7944 in Denmark, EUR 5424 in Finland, EUR 4769 in Norway and EUR 6093 in Sweden. </p> <p>The third economic analysis aimed to assess the cost‐effectiveness of SGLT‐2 inhibitor compared with sulphonylurea when added to metformin for treatment of Spanish people with diabetes mellitus inadequately controlled on metformin alone. Dapagliflozin was a cost‐effective option compared with sulphonylureas and resulted in a cost per quality‐adjusted life year gained of EUR 3560. </p> </section> </section> <section id="CD012368-sec-0227"> <h5 class="title">Additional explorative outcomes</h5> <section id="CD012368-sec-0228"> <h6 class="title">Weight</h6> <p>Three trials reported weight change (MD 4.4 kg, 95% CI 4.1 to 4.8; P &lt; 0.001; 3 trials; 3294 participants; <a href="./references#CD012368-fig-0089" title="">Analysis 8.11</a>; in favour of metformin plus SGLT‐2 inhibitor). The 95% prediction interval ranged between 2.7 kg and 7.3 kg. </p> <p><b>HbA1c</b> </p> <p>Four trials reported HbA1c (random MD 0.1%, 95% CI −0.1 to 0.2; P = 0.26; fixed MD 0.1%, 95% CI 0.02 to 0.1; P = 0.005; 4 trials; 4182 participants; <a href="./references#CD012368-fig-0090" title="">Analysis 8.12</a>; in favour of metformin plus SGLT‐2 inhibitor). There was substantial heterogeneity, probably caused by various durations of intervention. For one trial (<a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a>), we extracted data after 52 weeks of treatment showing benefit of sulphonylurea treatment, whereas for the remaining trials we extracted data after 104 weeks or more showing benefit of SGLT‐2 inhibitor treatment. Furthermore, heterogeneity could have been caused by various sulphonylureas (glipizide and glimepiride) administered in various doses (1 mg/day to 8 mg/day) and various SGLT‐2 inhibitors (dapagliflozin, ertugliflozin, canagliflozin, empagliflozin). </p> </section> </section> </section> <section id="CD012368-sec-0229"> <h4 class="title">Subgroup analyses</h4> <p>We only performed subgroup analyses on M+S combination therapy versus the combination of metformin plus DPP‐4 inhibitor and metformin plus thiazolidinediones (see above). The remaining combination comparators did not include enough trials to perform subgroup analyses. </p> <p>We performed subgroup analyses for the comparison of M+S versus metformin plus thiazolidinediones dividing trials into studies investigating rosiglitazone or pioglitazone; see <a href="./references#CD012368-fig-0047" title="">Analysis 5.1</a> to <a href="./references#CD012368-fig-0060" title="">Analysis 5.14</a>. </p> <p>We performed subgroup analyses on trials with a long duration (two years and more) versus trials with a short duration (shorter than two years); see <a href="./references#CD012368-fig-0061" title="">Analysis 6.1</a> to <a href="./references#CD012368-fig-0071" title="">Analysis 6.11</a>. </p> <p>We did not perform a subgroup analysis on trials including obese participants (BMI ≥ 30) versus trials including non‐obese participants (BMI &lt; 30) due to similar BMIs among the included trials. </p> </section> <section id="CD012368-sec-0230"> <h4 class="title">Sensitivity analyses</h4> <p>We planned to perform sensitivity analyses for the following factors.</p> <p> <ul id="CD012368-list-0017"> <li> <p>Published trials</p> </li> <li> <p>Language of publication</p> </li> <li> <p>Analysis restricted to trials with low risk of selection bias</p> </li> <li> <p>Long trials (trials with duration of intervention longer than 104 weeks excluded)</p> </li> <li> <p>Large trials (trials with more than 1000 participants randomised to each intervention group excluded). </p> </li> <li> <p>Source of funding (trials funded by a pharmaceutical company excluded).</p> </li> </ul> </p> <p>We did not perform sensitivity analysis on diagnostic criteria (often not reported), country (mostly performed in multiple countries) and imputation. </p> </section> <section id="CD012368-sec-0231"> <h4 class="title">Assessment of reporting bias</h4> <p>We did not draw funnel plots due to limited number of trials for a particular outcome (maximum N = 8). </p> </section> <section id="CD012368-sec-0232"> <h4 class="title">Ongoing trials</h4> <p>We identified nine ongoing RCTs, which potentially will provide data of interest for this review ( <a href="./references#CD012368-bbs2-0097" title="EUCTR2011‐003335‐63‐IT . Effects of liraglutide on ß‐cell function in type 2 diabetic patients with secondary failure to oral hypoglycemic agents. A randomized, controlled, parallel groups, open‐label, phase II study. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐003335‐63‐IT (accessed 28 February 2018). ">EUCTR2011‐003335‐63‐IT</a>; <a href="./references#CD012368-bbs2-0098" title="EUCTR2012‐000152‐34‐IT . Evaluation of the effect of treatment with DPP‐4 inhibitor on endothelial function versus sulphonylurea on markers of oxidative stress and inflammation and platelet function in patients with diabetes mellitus type 2 in primary failure with metformin and with HbA1c values below 8, 5%. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012‐000152‐34‐IT (accessed 28 February 2018). ">EUCTR2012‐000152‐34‐IT</a>; <a href="./references#CD012368-bbs2-0099" title="JPRN‐UMIN000008815 . The effect of DPP‐4 inhibitor on pancreatic beta cell function and renal function in type 2 diabetic patients. upload.umin.ac.jp/cgi‐open‐bin/ctr_e/ctr_view.cgi?recptno=R000010271 (accessed 28 February 2018). ">JPRN‐UMIN000008815</a>; <a href="./references#CD012368-bbs2-0100" title="MarxN , RosenstockJ , KahnSE , ZinmanB , KasteleinJJ , LachinJM , et al. Design and baseline characteristics of the cardiovascular outcome trial of linagliptin versus glimepiride in type 2 diabetes (CAROLINA(R)). Diabetes &amp; Vascular Disease Research2015;12(3):164‐74. NCT01243424 . CAROLINA: Cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01243424 (accessed 28 February 2018). ">NCT01243424</a>; <a href="./references#CD012368-bbs2-0101" title="NCT01794143 . A comparative effectiveness study of major glycemia‐lowering medications for treatment of type 2 diabetes (GRADE). clinicaltrials.gov/ct2/show/NCT01794143 (accessed 28 February 2018). NathanDM , BuseJB , KahnSE , Krause‐SteinraufH , LarkinME , StatenM , et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care2013;36(8):2254‐61. ">NCT01794143</a>; <a href="./references#CD012368-bbs2-0102" title="NCT02142309 . Glycemic durability after metformin failure (AMAZING). clinicaltrials.gov/ct2/show/NCT02142309 (accessed 28 February 2018). ">NCT02142309</a>; <a href="./references#CD012368-bbs2-0103" title="NCT02730377 . Efficacy in controlling glycaemia with Victoza® (liraglutide) as add‐on to metformin vs. OAD's as add‐on to metformin after up to 104 weeks of treatment in subjects with type 2 diabetes (LIRA‐PRIME). clinicaltrials.gov/ct2/show/NCT02730377 (accessed 28 February 2018). ">NCT02730377</a>; <a href="./references#CD012368-bbs2-0104" title="NCT02769481 . Safety and efficacy of bexagliflozin compared to glimepiride as add‐on therapy to metformin in type 2 diabetes subjects. clinicaltrials.gov/ct2/show/NCT02769481 (accessed 28 February 2018). ">NCT02769481</a>; <a href="./references#CD012368-bbs2-0105" title="NCT03332771 . Efficacy and safety of sotagliflozin versus glimepiride and placebo in subjects with type 2 diabetes mellitus that are taking metformin monotherapy (SOTA‐GLIM). clinicaltrials.gov/ct2/show/NCT03332771 (accessed 9 March 2018). ">NCT03332771</a>). The ongoing trials will include about 15,147 participants. All ongoing trials assessed one or more outcomes of interest for our review. </p> </section> <section id="CD012368-sec-0233"> <h4 class="title">Studies awaiting classification</h4> <p>We classified two trials as 'studies awaiting classification'. One trial (<a href="./references#CD012368-bbs2-0095" title="Müller‐WielandD , KellererM , CyprykK , SkripovaD , RohwedderK , JohnssonE , et al. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2018;20(11):2598‐607. NCT02471404 . Efficacy and safety of dapagliflozin and dapagliflozin plus saxagliptin in combination with metformin in type 2 diabetes patients compared with sulphonylurea. clinicaltrials.gov/ct2/show/NCT02471404 (accessed 28 February 2018). ">Müller‐Wieland 2018</a>), was only published shortly before the publication of this review and one trial (<a href="./references#CD012368-bbs2-0096" title="NCT02564926 . Foxiga Korea local phase 4 study (BEYOND). clinicaltrials.gov/ct2/show/NCT02564926 (accessed 28 February 2018). ">NCT02564926</a>), was submitted in January 2019 but results are not yet publicly available. Both trials compared M+S with metformin plus SGLT‐2 inhibitors. The trials included 1484 participants. Neither trial reports outcomes relevant for <a href="./full#CD012368-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012368-sec-0234" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012368-sec-0234">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012368-sec-0326">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012368-sec-0234"></div> <section id="CD012368-sec-0235"> <h3 class="title" id="CD012368-sec-0235">Summary of main results</h3> <p>This Cochrane Review investigated the effects of M+S combination therapy compared with metformin plus another pharmacological glucose‐lowering intervention, placebo or metformin monotherapy in people with T2DM. We included 32 trials with a total of 28,746 randomised participants. We judged all trials to have unclear or high risk of bias in one or more 'Risk of bias' domains. The amount of evidence on patient‐important outcomes was limited. The use of M+S neither revealed a clear advantage nor a disadvantage for the outcome measures specified in the 'Summary of findings' table of this review. However, there were fewer hypoglycaemic episodes when comparing M+S with all other metformin plus another glucose‐lowering combination therapies. In two cases (M+S versus metformin plus placebo, M+S versus metformin plus DPP‐4 inhibitor), hypoglycaemia was reduced in the comparator groups and at the same time HbA1c was improved in the M+S group (<a href="#CD012368-tbl-0004">Table 3</a>). In three cases (M+S versus metformin plus thiazolidinedione, M+S versus metformin plus glinide, M+S versus metformin plus SGLT‐2 inhibitor), there were both improved HbA1c values and fewer hypoglycaemic episodes in the comparator groups (<a href="#CD012368-tbl-0004">Table 3</a>). One has to take into account that the risk of hypoglycaemia increases with low glucose level targets which may not apply to the majority of elderly people with diabetes (<a href="./references#CD012368-bbs2-0109" title="American Diabetes Association. Standards of medical care in diabetes ‐ 2019. care.diabetesjournals.org/content/diacare/suppl/2018/12/17/42.Supplement_1.DC1/DC_42_S1_Combined_FINAL.pdf (accessed 16 February 2019). ">ADA 2019</a>). </p> <div class="table" id="CD012368-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Overview of HbA1c and hypoglycaemia across comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Better HbA1c for M+S</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Better HbA1c for comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Less hypoglycaemia for M+S</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Less hypoglycaemia for comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>M+S vs metformin + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b>: mild or moderate episodes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>M+S vs metformin + GLP‐1 agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b>: mild or moderate episodes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>M+S vs metformin + DPP‐4 inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b>: mild or moderate and serious episodes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>M+S vs metformin + thiazolidinedione</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b>: mild or moderate and serious episodes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>M+S vs metformin + glinide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b>: mild or moderate episodes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>M+S vs metformin + SGLT‐2 inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b>: mild or moderate and serious episodes </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>DPP4‐I</b> : dipeptidyl‐peptidase 4; <b>GLP‐1</b> : glucagon‐like peptide‐1 agonist; <b>HbA1c</b> : glycosylated haemoglobin A1c; <b>M+S</b> : metformin + sulphonylurea; <b>SGLT‐2</b>: sodium‐glucose transport 2 </p> </div> </div> </section> <section id="CD012368-sec-0236"> <h3 class="title" id="CD012368-sec-0236">Overall completeness and applicability of evidence</h3> <p>We conducted an extensive search for trials, including publications in all languages, and tried to obtain additional data on all trials. Handsearching of systematic reviews and reference lists identified two additional trials to be included (<a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>). Handsearching of manufacturers' websites identified eight additional references to be included. For all trials, we contacted one or more trial authors to obtain supplemental information on 'Risk of bias' domains and outcomes. In addition, we asked trial authors about any additional information about the retrieved trial(s) and to specify whether further trials existed that we may had missed. Six trial investigators of 10 trials either just confirmed a question or provided additional data that could be implemented for the 'Risk of bias' assessment or the meta‐analyses of outcomes (<a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a>; <a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). For all trials, we identified contact information for one or more authors. </p> <p>The diagnosis of T2DM was primary established using the European Association for the Study of Diabetes (EASD), World Health Organization (WHO) and American Diabetes Association (ADA) definitions. Nineteen trials did not specify how they established diagnosis of T2DM (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a>; <a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a>; <a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>; <a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a>; <a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a>; <a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a>; <a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a>; <a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a>). The included trials used different types of sulphonylureas; 16 trials administered a second‐generation sulphonylurea and 16 trials administered a third‐generation sulphonylurea. </p> <p>A potential selection bias within the trials may exist as more healthy and motivated people are expected to participate in a clinical trial. However, one Cochrane systematic review observed that clinical outcomes in people participating in RCTs are comparable to outcomes in comparable individuals outside RCTs (<a href="./references#CD012368-bbs2-0209" title="VistGE , BryantD , SomervilleL , BirminghemT , OxmanAD . Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.MR000009.pub4] ">Vist 2008</a>). </p> </section> <section id="CD012368-sec-0237"> <h3 class="title" id="CD012368-sec-0237">Quality of the evidence</h3> <p>None of the 32 included trials in our review was classified as having low risk of bias in all 'Risk of bias' domains. The description of randomisation and allocation in the included trials was insufficient in eight trials (<a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a>; <a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a>; <a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>). Eleven trials had insufficient reporting of one or more outcomes of relevance for our review and, therefore, we classified them as having high risk of bias for selective outcome reporting bias (<a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a>; <a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a>; <a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a>; <a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a>; <a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a>; <a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a>; <a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a>; <a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a>; <a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a>; <a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a>; <a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a>). We were able to assess one or more of our predefined outcomes in all the included trials. </p> <p>For all the comparisons, we judged the certainty of the evidence to be low or very low mainly because of very limited data, various risk of bias and imprecision. </p> <p>Most trials received financial funding from the pharmaceutical industry. It is known that trials receiving funding or provision of free drugs or devices from a pharmaceutical company show more favourable results and conclusions compared to trials sponsored by other sources (<a href="./references#CD012368-bbs2-0171" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>). </p> </section> <section id="CD012368-sec-0238"> <h3 class="title" id="CD012368-sec-0238">Potential biases in the review process</h3> <p>We were unable to draw funnel plots to assess small‐study bias due to lack of data. If more data had been available and more meta‐analyses could have been performed, we would have been able to investigate heterogeneity in more detail. </p> <p>We were dealing with a substantially heterogeneous group of trials. Our meta‐analyses, when performed, were limited by the inability to use individual participant data to assess whether distinct clinical characteristics may have influenced the effect estimates of the interventions. We explored heterogeneity by performing sensitivity and subgroup analyses. However, due to a limited number of trials we only performed subgroup analyses on M+S versus metformin plus DPP‐4 inhibitor and M+S versus metformin plus thiazolidinedione. Many of the included trials were not designed or powered to detect our predefined patient‐important outcomes. </p> <p>Most of the included trials had a relatively small number of participants and the information sizes in the meta‐analyses were equally small. This increases the risk of unrealistic estimates of the intervention effects due to bias (systematic errors) and chance (random errors) (<a href="./references#CD012368-bbs2-0211" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>; <a href="./references#CD012368-bbs2-0218" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. ">Wood 2008</a>). We have attempted to address systematic errors. We contacted all trial authors for clarification if one of the bias domains was not adequately reported. To reduce the risk of random errors, we conducted TSA on all predefined outcomes, whenever possible. </p> <p>Several trials were published in more than one publication, which made it difficult for us to separate the primary publication from companion papers for some trials (for details, see <a href="./references#CD012368-bbs1-0001" title="">Included studies</a>). </p> <p>We included trials with a minimum duration of 52 weeks to detect clinically relevant differences for the predefined outcomes. Unfortunately, the reporting of patient‐relevant outcomes in the included trials was poor. </p> <p>Two review authors carried out data extraction. However, the review authors extracting the data were not blinded as to which trial they were extracting data from. </p> </section> <section id="CD012368-sec-0239"> <h3 class="title" id="CD012368-sec-0239">Agreements and disagreements with other studies or reviews</h3> <p>In the search for additional trials we checked other reviews, systematic reviews and meta‐analyses (<a href="./references#CD012368-bbs2-0115" title="AmateJM , Lopez‐CuadradoT , AlmendroN , BouzaC , Saz‐ParkinsonZ , Rivas‐RuizR , et al. Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta‐analysis. International Journal of Clinical Practice2015;69(3):292‐304. ">Amate 2015</a>; <a href="./references#CD012368-bbs2-0116" title="AndersenSE , ChristensenM . Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta‐analysis. British Journal of Clinical Pharmacology2016;82(5):1291‐302. ">Andersen 2016</a>; <a href="./references#CD012368-bbs2-0117" title="AylsworthA , DeanZ , VanNormanC , Nkemdirim OkereA . Dapagliflozin for the treatment of type 2 diabetes mellitus. Annals of Pharmacotherapy2014;48(9):1202‐8. ">Aylsworth 2014</a>; <a href="./references#CD012368-bbs2-0121" title="BelseyJ , KrishnarajahG . Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta‐analysis. Diabetes, Obesity &amp; Metabolism2008;10 Suppl 1:1‐7. ">Belsey 2008</a>; <a href="./references#CD012368-bbs2-0124" title="ChanSP , ColagiuriS . Systematic review and meta‐analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Research and Clinical Practice2015;110(1):75‐81. ">Chan 2015</a>; <a href="./references#CD012368-bbs2-0127" title="DaiX , WangH , JingZ , FuP . The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta‐analysis. Current Medical Research and Opinion2014;30(9):1777‐86. ">Dai 2014</a>; <a href="./references#CD012368-bbs2-0134" title="ForoutanN , MuratovS , LevineM . Safety and efficacy of dipeptidyl peptidase‐4 inhibitors vs sulfonylurea in metformin‐based combination therapy for type 2 diabetes mellitus: systematic review and meta‐analysis. Clinical and Investigative Medicine, Medecine Clinique et Experimentale2016;39(2):E48‐62. ">Foroutan 2016</a>; <a href="./references#CD012368-bbs2-0135" title="GengJ , YuH , MaoY , ZhangP , ChenY . Cost effectiveness of dipeptidyl peptidase‐4 inhibitors for type 2 diabetes. Pharmaco Economics2015;33(6):581‐97. ">Geng 2015</a>; <a href="./references#CD012368-bbs2-0136" title="GoringS , HawkinsN , WygantG , RoudautM , TownsendR , WoodI , et al. Dapagliflozin compared with other oral anti‐diabetes treatments when added to metformin monotherapy: a systematic review and network meta‐analysis. Diabetes, Obesity &amp; Metabolism2014;16(5):433‐42. ">Goring 2014</a>; <a href="./references#CD012368-bbs2-0138" title="GuS , DengJ , ShiL , MuY , DongH . Cost‐effectiveness of saxagliptin vs glimepiride as a second‐line therapy added to metformin in type 2 diabetes in China. Journal of Medical Economics2015;18(10):808‐20. ">Gu 2015</a>; <a href="./references#CD012368-bbs2-0140" title="GuthrieRM . Clinical use of dipeptidyl peptidase‐4 and sodium‐glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Postgraduate Medicine2015;127(5):463‐79. ">Guthrie 2015</a>; <a href="./references#CD012368-bbs2-0145" title="HershonKS . Options for empagliflozin in combination therapy in type 2 diabetes mellitus. International Journal of General Medicine2016;9:155‐72. ">Hershon 2016</a>; <a href="./references#CD012368-bbs2-0153" title="HouL , ZhaoT , LiuY , ZhangY . Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: a meta‐analysis. Experimental and Therapeutic Medicine2015;9(4):1528‐36. ">Hou 2015</a>; <a href="./references#CD012368-bbs2-0164" title="KueckerCM , VivianEM . Patient considerations in type 2 diabetes ‐ role of combination dapagliflozin‐metformin XR. Diabetes, Metabolic Syndrome and Obesity: targets and therapy2016;9:25‐35. ">Kuecker 2016</a>; <a href="./references#CD012368-bbs2-0169" title="Lim2015 . What's next after metformin? Focus on sulphonylurea: add‐on or combination therapy. Pharmacy Practice2015;13(3):606. ">Lim 2015</a>; <a href="./references#CD012368-bbs2-0170" title="LiuX , XiaoQ , ZhangL , YangQ , LiuX , XuL , et al. The long‐term efficacy and safety of DPP‐IV inhibitors monotherapy and in combination with metformin in 18,980 patients with type‐2 diabetes mellitus‐‐a meta‐analysis. Pharmacoepidemiology and Drug Safety2014;23(7):687‐98. ">Liu 2014</a>; <a href="./references#CD012368-bbs2-0172" title="MaruthurNM , TsengE , HutflessS , WilsonLM , Suarez‐CuervoC , BergerZ , et al. Diabetes medications as monotherapy or metformin‐based combination therapy for type 2 diabetes: a systematic review and meta‐analysis. Annals of Internal Medicine2016;164(11):740‐51. [DOI: 10.7326/M15‐2650] ">Maruthur 2016</a>; <a href="./references#CD012368-bbs2-0176" title="MearnsES , SobierajDM , WhiteCM , SaulsberryWJ , KohnCG , DolehY , et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta‐analysis. PloS one2015;10(4):e0125879. ">Mearns 2015</a>; <a href="./references#CD012368-bbs2-0178" title="MishrikyBM , CummingsDM , TanenbergRJ . The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add‐on therapy to metformin in patients with type 2 diabetes: a systematic review and meta‐analysis. Diabetes Research and Clinical Practice2015;109(2):378‐88. ">Mishriky 2015</a>; <a href="./references#CD012368-bbs2-0179" title="MonamiM , LamannaC , MarchionniN , MannucciE . Comparison of different drugs as add‐on treatments to metformin in type 2 diabetes: a meta‐analysis. Diabetes Research and Clinical Practice2008;79(2):196‐203. ">Monami 2008</a>; <a href="./references#CD012368-bbs2-0185" title="PhungOJ , ScholleJM , TalwarM , ColemanCI . Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA2010;303(14):1410‐8. ">Phung 2010</a>; <a href="./references#CD012368-bbs2-0186" title="PhungOJ , SobierajDM , EngelSS , RajpathakSN . Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta‐analysis. Diabetes, Obesity &amp; Metabolism2014;16(5):410‐7. ">Phung 2014</a>; <a href="./references#CD012368-bbs2-0191" title="RosenstockJ , MarxN , KahnSE , ZinmanB , KasteleinJJ , LachinJM , et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active‐comparator CAROLINA trial. Diabetes &amp; Vascular Disease Research2013;10(4):289‐301. ">Rosenstock 2013</a>; <a href="./references#CD012368-bbs2-0202" title="SharmaM , BeckleyN , NazarethI , PetersenI . Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta‐analysis. BMJ Open2017;7(10):e017260. ">Sharma 2017</a>; <a href="./references#CD012368-bbs2-0208" title="Varvaki RadosD , Catani PintoL , Reck RemontiL , Bauermann LeitaoC , GrossJL . The association between sulfonylurea use and all‐cause and cardiovascular mortality: a meta‐analysis with trial sequential analysis of randomized clinical trials. PLoS Medicine2016;13(4):e1001992. ">Varvaki 2016</a>; <a href="./references#CD012368-bbs2-0210" title="WangF , HeY , ZhangR , ZengQ , ZhaoX . Combination therapy of metformin plus dipeptidyl peptidase‐4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients. Medicine (Baltimore)2017;96(36):e7638. ">Wang 2017</a>; <a href="./references#CD012368-bbs2-0212" title="WhalenK , MillerS , OngeES . The role of sodium‐glucose co‐transporter 2 inhibitors in the treatment of type 2 diabetes. Clinical Therapeutics2015;37(6):1150‐66. ">Whalen 2015</a>; <a href="./references#CD012368-bbs2-0219" title="Zhou2015 . The benefits and risks of DPP4‐inhibitors vs sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial. International Journal of Clinical Practice2016;70(2):132‐41. ">Zhou 2015</a>; <a href="./references#CD012368-bbs2-0220" title="ZintzarasE , MiligkosM , ZiakasP , BalkEM , MademtzoglouD , DoxaniC , et al. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta‐analysis. Clinical Therapeutics2014;36(10):1443‐53. ">Zintzaras 2014</a>). Because we primarily intended to investigate patient‐important outcomes we only included trials with a minimum duration of intervention of 52 weeks. However, all but three reviews (<a href="./references#CD012368-bbs2-0136" title="GoringS , HawkinsN , WygantG , RoudautM , TownsendR , WoodI , et al. Dapagliflozin compared with other oral anti‐diabetes treatments when added to metformin monotherapy: a systematic review and network meta‐analysis. Diabetes, Obesity &amp; Metabolism2014;16(5):433‐42. ">Goring 2014</a>; <a href="./references#CD012368-bbs2-0191" title="RosenstockJ , MarxN , KahnSE , ZinmanB , KasteleinJJ , LachinJM , et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active‐comparator CAROLINA trial. Diabetes &amp; Vascular Disease Research2013;10(4):289‐301. ">Rosenstock 2013</a>; <a href="./references#CD012368-bbs2-0208" title="Varvaki RadosD , Catani PintoL , Reck RemontiL , Bauermann LeitaoC , GrossJL . The association between sulfonylurea use and all‐cause and cardiovascular mortality: a meta‐analysis with trial sequential analysis of randomized clinical trials. PLoS Medicine2016;13(4):e1001992. ">Varvaki 2016</a>), included trials with a duration of intervention less than 52 weeks or did not describe the duration of intervention in the included trials. Furthermore, all but seven reviews (<a href="./references#CD012368-bbs2-0115" title="AmateJM , Lopez‐CuadradoT , AlmendroN , BouzaC , Saz‐ParkinsonZ , Rivas‐RuizR , et al. Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta‐analysis. International Journal of Clinical Practice2015;69(3):292‐304. ">Amate 2015</a>; <a href="./references#CD012368-bbs2-0134" title="ForoutanN , MuratovS , LevineM . Safety and efficacy of dipeptidyl peptidase‐4 inhibitors vs sulfonylurea in metformin‐based combination therapy for type 2 diabetes mellitus: systematic review and meta‐analysis. Clinical and Investigative Medicine, Medecine Clinique et Experimentale2016;39(2):E48‐62. ">Foroutan 2016</a>; <a href="./references#CD012368-bbs2-0145" title="HershonKS . Options for empagliflozin in combination therapy in type 2 diabetes mellitus. International Journal of General Medicine2016;9:155‐72. ">Hershon 2016</a>; <a href="./references#CD012368-bbs2-0172" title="MaruthurNM , TsengE , HutflessS , WilsonLM , Suarez‐CuervoC , BergerZ , et al. Diabetes medications as monotherapy or metformin‐based combination therapy for type 2 diabetes: a systematic review and meta‐analysis. Annals of Internal Medicine2016;164(11):740‐51. [DOI: 10.7326/M15‐2650] ">Maruthur 2016</a>; <a href="./references#CD012368-bbs2-0191" title="RosenstockJ , MarxN , KahnSE , ZinmanB , KasteleinJJ , LachinJM , et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active‐comparator CAROLINA trial. Diabetes &amp; Vascular Disease Research2013;10(4):289‐301. ">Rosenstock 2013</a>; <a href="./references#CD012368-bbs2-0208" title="Varvaki RadosD , Catani PintoL , Reck RemontiL , Bauermann LeitaoC , GrossJL . The association between sulfonylurea use and all‐cause and cardiovascular mortality: a meta‐analysis with trial sequential analysis of randomized clinical trials. PLoS Medicine2016;13(4):e1001992. ">Varvaki 2016</a>; <a href="./references#CD012368-bbs2-0210" title="WangF , HeY , ZhangR , ZengQ , ZhaoX . Combination therapy of metformin plus dipeptidyl peptidase‐4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients. Medicine (Baltimore)2017;96(36):e7638. ">Wang 2017</a>), focused on outcomes such as glycaemic control, weight, lipids etc. One review (<a href="./references#CD012368-bbs2-0191" title="RosenstockJ , MarxN , KahnSE , ZinmanB , KasteleinJJ , LachinJM , et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active‐comparator CAROLINA trial. Diabetes &amp; Vascular Disease Research2013;10(4):289‐301. ">Rosenstock 2013</a>), and one systematic review (<a href="./references#CD012368-bbs2-0208" title="Varvaki RadosD , Catani PintoL , Reck RemontiL , Bauermann LeitaoC , GrossJL . The association between sulfonylurea use and all‐cause and cardiovascular mortality: a meta‐analysis with trial sequential analysis of randomized clinical trials. PLoS Medicine2016;13(4):e1001992. ">Varvaki 2016</a>), only included trials with a duration of intervention of 52 weeks and more, and focused on patient‐important outcomes. These reviews did not suggest an increased risk of cardiovascular events, all‐cause mortality or cardiovascular mortality, comparing M+S with metformin plus another glucose‐lowering drug. Several of the reviews and systematic reviews investigated exclusively M+S vs metformin plus a DPP‐4 inhibitor (<a href="./references#CD012368-bbs2-0115" title="AmateJM , Lopez‐CuadradoT , AlmendroN , BouzaC , Saz‐ParkinsonZ , Rivas‐RuizR , et al. Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta‐analysis. International Journal of Clinical Practice2015;69(3):292‐304. ">Amate 2015</a>; <a href="./references#CD012368-bbs2-0134" title="ForoutanN , MuratovS , LevineM . Safety and efficacy of dipeptidyl peptidase‐4 inhibitors vs sulfonylurea in metformin‐based combination therapy for type 2 diabetes mellitus: systematic review and meta‐analysis. Clinical and Investigative Medicine, Medecine Clinique et Experimentale2016;39(2):E48‐62. ">Foroutan 2016</a>; <a href="./references#CD012368-bbs2-0138" title="GuS , DengJ , ShiL , MuY , DongH . Cost‐effectiveness of saxagliptin vs glimepiride as a second‐line therapy added to metformin in type 2 diabetes in China. Journal of Medical Economics2015;18(10):808‐20. ">Gu 2015</a>; <a href="./references#CD012368-bbs2-0153" title="HouL , ZhaoT , LiuY , ZhangY . Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: a meta‐analysis. Experimental and Therapeutic Medicine2015;9(4):1528‐36. ">Hou 2015</a>; <a href="./references#CD012368-bbs2-0178" title="MishrikyBM , CummingsDM , TanenbergRJ . The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add‐on therapy to metformin in patients with type 2 diabetes: a systematic review and meta‐analysis. Diabetes Research and Clinical Practice2015;109(2):378‐88. ">Mishriky 2015</a>; <a href="./references#CD012368-bbs2-0202" title="SharmaM , BeckleyN , NazarethI , PetersenI . Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta‐analysis. BMJ Open2017;7(10):e017260. ">Sharma 2017</a>; <a href="./references#CD012368-bbs2-0210" title="WangF , HeY , ZhangR , ZengQ , ZhaoX . Combination therapy of metformin plus dipeptidyl peptidase‐4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients. Medicine (Baltimore)2017;96(36):e7638. ">Wang 2017</a>; <a href="./references#CD012368-bbs2-0219" title="Zhou2015 . The benefits and risks of DPP4‐inhibitors vs sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial. International Journal of Clinical Practice2016;70(2):132‐41. ">Zhou 2015</a>). One systematic review and meta‐analysis compared M+S with other metformin combination therapies as one group (<a href="./references#CD012368-bbs2-0208" title="Varvaki RadosD , Catani PintoL , Reck RemontiL , Bauermann LeitaoC , GrossJL . The association between sulfonylurea use and all‐cause and cardiovascular mortality: a meta‐analysis with trial sequential analysis of randomized clinical trials. PLoS Medicine2016;13(4):e1001992. ">Varvaki 2016</a>). To our knowledge, our review is the first to investigate patient‐important outcomes in long‐term trials (defined as 52 weeks and more) looking at M+S compared to metformin plus another glucose‐lowering interventions separately. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012368-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Trial flow diagram  AHRQ: Agency for Healthcare Research and Quality; DPP4‐I: dipeptidyl‐peptidase 4 inhibitor; GLP1‐A: glucagon‐like peptide 1 analogue; M+S: metformin + sulphonylurea; SGLT2‐I: sodium‐glucose co‐transporter 2 inhibitor" data-id="CD012368-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Trial flow diagram<br/> <b>AHRQ</b> : Agency for Healthcare Research and Quality; <b>DPP4‐I</b> : dipeptidyl‐peptidase 4 inhibitor; <b>GLP1‐A</b> : glucagon‐like peptide 1 analogue; <b>M+S</b> : metformin + sulphonylurea; <b>SGLT2‐I</b>: sodium‐glucose co‐transporter 2 inhibitor </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/full#CD012368-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials)." data-id="CD012368-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/full#CD012368-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial ((blank cells indicate that the particular outcome was not measured in some trials)" data-id="CD012368-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial ((blank cells indicate that the particular outcome was not measured in some trials) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/full#CD012368-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 1 All‐cause mortality." data-id="CD012368-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 2 Serious adverse events." data-id="CD012368-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 2 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 3 Cardiovascular mortality." data-id="CD012368-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 3 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 4 Non‐fatal myocardial infarction." data-id="CD012368-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 4 Non‐fatal myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 5 Heart failure." data-id="CD012368-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 5 Heart failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 6 Non‐serious adverse events." data-id="CD012368-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 6 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 7 Mild/moderate hypoglycaemia." data-id="CD012368-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 7 Mild/moderate hypoglycaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 8 Serious hypoglycaemia." data-id="CD012368-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 8 Serious hypoglycaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 9 Weight change." data-id="CD012368-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 9 Weight change. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 10 Change in HbA1c." data-id="CD012368-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Metformin plus sulphonylurea vs metformin plus placebo, Outcome 10 Change in HbA1c. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 1 All‐cause mortality." data-id="CD012368-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 2 Serious adverse events." data-id="CD012368-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 2 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 3 Cardiovascular mortality." data-id="CD012368-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 3 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 4 Non‐fatal myocardial infarction." data-id="CD012368-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 4 Non‐fatal myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 5 Heart failure." data-id="CD012368-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 5 Heart failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 6 End‐stage renal disease." data-id="CD012368-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 6 End‐stage renal disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 7 Non‐serious adverse events." data-id="CD012368-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 7 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 8 Mild/moderate hypoglycaemia." data-id="CD012368-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 8 Mild/moderate hypoglycaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 9 Serious hypoglycaemia." data-id="CD012368-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 9 Serious hypoglycaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 10 Weight (change)." data-id="CD012368-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 10 Weight (change). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 11 Change in HbA1c." data-id="CD012368-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue, Outcome 11 Change in HbA1c. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 1 All‐cause mortality." data-id="CD012368-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 2 Serious adverse events." data-id="CD012368-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 2 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 3 Cardiovascular mortality." data-id="CD012368-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 3 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 4 Non‐fatal myocardial infarction." data-id="CD012368-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 4 Non‐fatal myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 5 Heart failure." data-id="CD012368-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 5 Heart failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 6 Non‐fatal stroke." data-id="CD012368-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 6 Non‐fatal stroke. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 7 Non‐serious adverse events." data-id="CD012368-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 7 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 8 Mild/moderate hypoglycaemia." data-id="CD012368-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 8 Mild/moderate hypoglycaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 9 Serious hypoglycaemia." data-id="CD012368-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 9 Serious hypoglycaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 10 Weight change (kg)." data-id="CD012368-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 10 Weight change (kg). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 11 Change in HbA1c." data-id="CD012368-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 11 Change in HbA1c. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 12 Fasting plasma glucose." data-id="CD012368-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 12 Fasting plasma glucose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 13 BMI." data-id="CD012368-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor, Outcome 13 BMI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor, Outcome 1 All‐cause mortality." data-id="CD012368-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor, Outcome 2 Serious adverse events." data-id="CD012368-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor, Outcome 2 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor, Outcome 3 Cardiovascular mortality." data-id="CD012368-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor, Outcome 3 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor, Outcome 4 Non‐fatal myocardial infarction." data-id="CD012368-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor, Outcome 4 Non‐fatal myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor, Outcome 5 Non‐serious adverse events." data-id="CD012368-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor, Outcome 5 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor, Outcome 6 Mild/moderate hypoglycaemia." data-id="CD012368-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor, Outcome 6 Mild/moderate hypoglycaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor, Outcome 7 Serious hypoglycaemia." data-id="CD012368-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor, Outcome 7 Serious hypoglycaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor, Outcome 8 Weight change (kg)." data-id="CD012368-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor, Outcome 8 Weight change (kg). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor, Outcome 9 Change in HbA1c (%)." data-id="CD012368-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor, Outcome 9 Change in HbA1c (%). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 1 All‐cause mortality." data-id="CD012368-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 2 Serious adverse events." data-id="CD012368-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 2 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 3 Cardiovascular mortality." data-id="CD012368-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 3 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 4 Non‐fatal myocardial infarction." data-id="CD012368-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 4 Non‐fatal myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 5 Heart failure." data-id="CD012368-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 5 Heart failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 6 Non‐fatal stroke." data-id="CD012368-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 6 Non‐fatal stroke. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 7 Amputation of lower extremity." data-id="CD012368-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 7 Amputation of lower extremity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 8 Blindness or severe vision loss." data-id="CD012368-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 8 Blindness or severe vision loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 9 End‐stage renal disease." data-id="CD012368-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 9 End‐stage renal disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-005-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-005-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 10 Non‐serious adverse events." data-id="CD012368-fig-0056" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 10 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-005-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-005-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 11 Mild/moderate hypoglycaemia." data-id="CD012368-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 11 Mild/moderate hypoglycaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-005-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-005-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 12 Serious hypoglycaemia." data-id="CD012368-fig-0058" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 12 Serious hypoglycaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-005-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-005-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 13 Weight (change)." data-id="CD012368-fig-0059" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 13 Weight (change). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-005-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-005-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 14 Change in HbA1c." data-id="CD012368-fig-0060" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5 Metformin plus sulphonylurea vs metformin plus thiazolidinedione, Outcome 14 Change in HbA1c. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-005-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 1 All‐cause mortality." data-id="CD012368-fig-0061" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 2 Serious adverse events." data-id="CD012368-fig-0062" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 2 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 3 Cardiovascular mortality." data-id="CD012368-fig-0063" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 3 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 4 Non‐fatal myocardial infarction." data-id="CD012368-fig-0064" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 4 Non‐fatal myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 5 Heart failure." data-id="CD012368-fig-0065" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 5 Heart failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 6 Non‐fatal stroke." data-id="CD012368-fig-0066" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 6 Non‐fatal stroke. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 7 Non‐serious adverse events." data-id="CD012368-fig-0067" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 7 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 8 Mild/moderate hypoglycaemia." data-id="CD012368-fig-0068" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 8 Mild/moderate hypoglycaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 9 Serious hypoglycaemia." data-id="CD012368-fig-0069" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 9 Serious hypoglycaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-006-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-006-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 10 Weight change." data-id="CD012368-fig-0070" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 10 Weight change. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-006-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-006-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 11 Change in HbA1c." data-id="CD012368-fig-0071" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6 Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention), Outcome 11 Change in HbA1c. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-006-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Metformin plus sulphonylurea vs metformin plus glinide, Outcome 1 All‐cause mortality." data-id="CD012368-fig-0072" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Metformin plus sulphonylurea vs metformin plus glinide, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Metformin plus sulphonylurea vs metformin plus glinide, Outcome 2 Serious adverse events." data-id="CD012368-fig-0073" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Metformin plus sulphonylurea vs metformin plus glinide, Outcome 2 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Metformin plus sulphonylurea vs metformin plus glinide, Outcome 3 Cardiovascular mortality." data-id="CD012368-fig-0074" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Metformin plus sulphonylurea vs metformin plus glinide, Outcome 3 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Metformin plus sulphonylurea vs metformin plus glinide, Outcome 4 Mild/moderate hypoglycaemia." data-id="CD012368-fig-0075" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Metformin plus sulphonylurea vs metformin plus glinide, Outcome 4 Mild/moderate hypoglycaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Metformin plus sulphonylurea vs metformin plus glinide, Outcome 5 Serious hypoglycaemia." data-id="CD012368-fig-0076" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Metformin plus sulphonylurea vs metformin plus glinide, Outcome 5 Serious hypoglycaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Metformin plus sulphonylurea vs metformin plus glinide, Outcome 6 Weight change." data-id="CD012368-fig-0077" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Metformin plus sulphonylurea vs metformin plus glinide, Outcome 6 Weight change. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-007-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-007-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Metformin plus sulphonylurea vs metformin plus glinide, Outcome 7 Change in HbA1c." data-id="CD012368-fig-0078" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-007-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 Metformin plus sulphonylurea vs metformin plus glinide, Outcome 7 Change in HbA1c. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-007-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 1 All‐cause mortality." data-id="CD012368-fig-0079" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 2 Serious adverse events." data-id="CD012368-fig-0080" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 2 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 3 Cardiovascular mortality." data-id="CD012368-fig-0081" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 3 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 4 Non‐fatal myocardial infarction." data-id="CD012368-fig-0082" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 4 Non‐fatal myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 5 Heart failure." data-id="CD012368-fig-0083" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 5 Heart failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 6 Non‐fatal stroke." data-id="CD012368-fig-0084" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 6 Non‐fatal stroke. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 7 Amputation of lower extremity." data-id="CD012368-fig-0085" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 7 Amputation of lower extremity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-008-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-008-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 8 Non‐serious adverse events." data-id="CD012368-fig-0086" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 8 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-008-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-008-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 9 Mild/moderate hypoglycaemia." data-id="CD012368-fig-0087" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 9 Mild/moderate hypoglycaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-008-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-008-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 10 Serious hypoglycaemia." data-id="CD012368-fig-0088" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 10 Serious hypoglycaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-008-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-008-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 11 Weight change." data-id="CD012368-fig-0089" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.11</div> <div class="figure-caption"> <p>Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 11 Weight change. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012368-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/urn:x-wiley:14651858:media:CD012368:CD012368-CMP-008-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_t/tCD012368-CMP-008-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 12 Change in HbA1c." data-id="CD012368-fig-0090" src="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.12</div> <div class="figure-caption"> <p>Comparison 8 Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor, Outcome 12 Change in HbA1c. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/media/CDSR/CD012368/image_n/nCD012368-CMP-008-12.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012368-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy compared with metformin plus another antidiabetic drug for adults with type 2 diabetes mellitus</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy compared with metformin plus another antidiabetic drug for adults with type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient:</b> people with type 2 diabetes mellitus </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> metformin + sulphonylurea </p> <p><b>Comparison:</b> metformin plus another antidiabetic drug </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Metformin + antidiabetic drug</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Metformin + sulphonylurea</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No. of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>All‐cause mortality (N)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + GLP1‐A<br/> Follow‐up: 2‐3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> (4 to 19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.15</b> (0.49 to 2.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2594 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>a1</sup> </p> <p><b>Low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + DPP4‐I<br/> Follow‐up: 1‐3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> (3 to 9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.32</b> (0.76 to 2.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,694 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + thiazolidinedione<br/> Follow‐up: 1‐5.5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> (29 to 48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.09</b> (0.85 to 1.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6654 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>c1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + nateglinide</p> <p>Follow‐up: 1‐2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>874 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>d1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participant died in each intervention group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + SGLT2‐I<br/> Follow‐up: 2‐4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> (3 to 13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> (0.44 to 2.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5134 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>e1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Cardiovascular mortality (N)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + GLP1‐A<br/> Follow‐up: 2‐3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>609 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/307 (0.3%) participants died due to cardiovascular disease in the M+S group compared with 1/302 (0.3%) participants in the M + GLP1‐A group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + DPP4‐I<br/> Follow‐up: 1‐3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> (1 to 9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.54</b> (0.63 to 3.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6874 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + thiazolidinedione<br/> Follow‐up: 1‐5.5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> (5 to 23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> (0.36 to 1.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5940 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>c2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + nateglinide</p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>446 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>d2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No cardiovascular death was reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + SGLT2‐I<br/> Follow‐up: 2‐4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> (1 to 12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.22</b> (0.33 to 4.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3589 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>e2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Serious adverse events (N)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + GLP1‐A<br/> Follow‐up: 2‐3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>114 per 1000</b> (92 to 140) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> (0.73 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2594 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + DPP4‐I<br/> Follow‐up: 1‐3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>124 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b> (120 to 146) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.07</b> (0.97 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,694 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + thiazolidinedione<br/> Follow‐up: 1‐5.5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b> (186 to 222) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> (0.93 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6654 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>c3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + nateglinide</p> <p>Follow‐up:</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>101 per 1000</b> (32 to 313) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.68</b> (0.54 to 5.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>874 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>d3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + SGLT2‐I<br/> Follow‐up: 2‐4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>124 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> (94 to 170) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> (0.76 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5134 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>e3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Non‐fatal stroke (N)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + GLP1‐A</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b><sup>a4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + DPP4‐I<br/> Follow‐up: 1‐2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> (2 to 18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.21</b> (0.74 to 6.58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5093 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + thiazolidinedione<br/> Follow‐up: 1‐4.8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> (7 to 25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.29</b> (0.67 to 2.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3123 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>c4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + nateglinide</p> <p>Follow‐up: 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>d4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No non‐fatal stroke was reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + SGLT2‐I<br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> (1 to 13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> (0.22 to 3.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2775 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>e4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction (N)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + GLP1‐A<br/> Follow‐up: 2‐3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> (1 to 16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.57</b> (0.12 to 2.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1575 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + DPP4‐I<br/> Follow‐up: 1‐3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> (2 to 10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.45</b> (0.69 to 3.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6874 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>b5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + thiazolidinedione<br/> Follow‐up: 1‐4.8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> (8 to 24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b> (0.68 to 2.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3718 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>c5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + nateglinide</p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>446 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>d5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 1 trial 2/101 (2%) participants had a non‐fatal myocardial infarction in the M+S group compared with 0/112 participant in the metformin plus nateglinide group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + SGLT2‐I<br/> Follow‐up: 2‐4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> (3 to 24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.43</b> (0.49 to 4.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2264 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>e5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Microvascular complications (N), definition: end‐stage renal disease, blindness or severe vision loss, amputation of lower extremity</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + GLP1‐A</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b><sup>a6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + DPP4‐I<br/> Follow‐up: 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 1 trial no participants had a lower‐extremity amputation, developed blindness or severe vision loss, or end‐stage renal disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + thiazolidinedione<br/> Follow‐up: 1‐4.8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3123 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>c6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials (3123 participants) reported that no participants had a lower‐extremity amputation<br/> 1 trial (95 participants) reported that no participants developed blindness or severe vision loss, or end‐stage renal disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + nateglinide</p> <p>Follow‐up: 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>d6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No microvascular complications were reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M + SGLT2‐I<br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1325 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>e6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 1 trial 1/437 (0.2%) participants had an amputation of the lower extremity in the M+S group compared with 1/888 (0.1%) in the M + SGLT2‐I group </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI) </p> <p><b>CI:</b> confidence interval; <b>DPP4‐I</b> : dipeptidyl peptidase‐4 inhibitor; <b>GLP1‐A:</b> glucagon‐like peptide 1 analogue; <b>HbA1c</b> : glycosylated haemoglobin A1c; <b>M:</b> metformin; <b>M+S:</b> metformin + sulphonylurea; <b>N:</b> number; <b>N/R</b> : not reported; <b>RR:</b> risk ratio; <b>SGLT2‐I</b> : sodium‐glucose co‐transporter 2 inhibitor; <b>T</b>: thiazolidinedione </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>All‐cause mortality</b><br/> <sup>a1</sup>Downgraded by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials) ‐ see <a href="./appendices#CD012368-sec-0262">Appendix 17</a>.<br/> <sup>b1</sup>Downgraded by one level because of inconsistency (non‐consistent direction of effect) and by one level because of imprecision (CI consistent with both benefit and harm) ‐ see <a href="./appendices#CD012368-sec-0263">Appendix 18</a>.<br/> <sup>c1</sup>Downgraded by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials) ‐ see <a href="./appendices#CD012368-sec-0265">Appendix 20</a>.<br/> <sup>d1</sup>Downgraded by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials) ‐ see <a href="./appendices#CD012368-sec-0266">Appendix 21</a>.<br/> <sup>e1</sup>Downgraded by one level because of inconsistency (point estimates varied widely) and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials, low event rate) ‐ see <a href="./appendices#CD012368-sec-0267">Appendix 22</a>. </p> <p><b>Cardiovascular mortality</b><br/> <sup>a2</sup>Downgraded by two levels because of serious imprecision (small number of trials, CI consistent with both benefit and harm) ‐ see <a href="./appendices#CD012368-sec-0262">Appendix 17</a>.<br/> <sup>b2</sup>Downgraded by one level because of because of inconsistency (non‐consistent direction of effect) and by one level because of imprecision (CI consistent with both benefit and harm) ‐ see <a href="./appendices#CD012368-sec-0263">Appendix 18</a>.<br/> <sup>c2</sup>Downgraded by two levels because of serious imprecision (small number of trials, CI consistent with both benefit and harm) ‐ see <a href="./appendices#CD012368-sec-0265">Appendix 20</a>.<br/> <sup>d2</sup>Downgraded by two levels because of serious imprecision (small number of trials, unknown event rate) ‐ see <a href="./appendices#CD012368-sec-0265">Appendix 20</a>.<br/> <sup>e2</sup>Downgraded by one level because of inconsistency (point estimates varied widely) and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials, low event rate) ‐ see <a href="./appendices#CD012368-sec-0267">Appendix 22</a>. </p> <p><b>Serious adverse events</b><br/> <sup>a3</sup>Downgraded by one level because of attrition bias and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials) ‐ see <a href="./appendices#CD012368-sec-0262">Appendix 17</a>.<br/> <sup>b3</sup>Downgraded by one level because of attrition bias, by one level because of inconsistency (non‐consistent direction of effect) and by one level because of imprecision (CI consistent with both benefit and harm) ‐ see <a href="./appendices#CD012368-sec-0263">Appendix 18</a>.<br/> <sup>c3</sup>Downgraded by one level because of attrition bias, by one level because of inconsistency (non‐consistent direction of effect) and by one level because of serious imprecision (CI consistent with both benefit and harm, small number of trials) ‐ see <a href="./appendices#CD012368-sec-0265">Appendix 20</a>.<br/> <sup>d3</sup>Downgraded by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials) ‐ see <a href="./appendices#CD012368-sec-0266">Appendix 21</a>.<br/> <sup>e3</sup>Downgraded by one level because of attrition bias and inconsistency (point estimates varied widely) and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials) ‐ see <a href="./appendices#CD012368-sec-0267">Appendix 22</a>. </p> <p><b>Non‐fatal stroke</b><br/> <sup>a4</sup>No adequate data for analysis.<br/> <sup>b4</sup>Downgraded by one level because of attrition bias and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials, low event rate) ‐ see <a href="./appendices#CD012368-sec-0263">Appendix 18</a>.<br/> <sup>c4</sup>Downgraded by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials) ‐ see <a href="./appendices#CD012368-sec-0265">Appendix 20</a>.<br/> <sup>d4</sup>Downgraded by two levels of evidence because of serious imprecision (low number of trials, unknown event rate) ‐ see <a href="./appendices#CD012368-sec-0266">Appendix 21</a>.<br/> <sup>e4</sup>Downgraded by one level because of attrition bias and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials, low event rate) ‐ see <a href="./appendices#CD012368-sec-0267">Appendix 22</a>. </p> <p><b>Non‐fatal myocardial infarction</b><br/> <sup>a5</sup>Downgraded by one level because of attrition bias and by two levels because of serious imprecision (small number of trials, CI consistent with both benefit and harm) ‐ see <a href="./appendices#CD012368-sec-0262">Appendix 17</a>.<br/> <sup>b5</sup>Downgraded by one level because of attrition bias and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials, low event rate) ‐ see <a href="./appendices#CD012368-sec-0263">Appendix 18</a>.<br/> <sup>c5</sup>Downgraded by one level because of attrition bias and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials) ‐ see <a href="./appendices#CD012368-sec-0265">Appendix 20</a>.<br/> <sup>d5</sup>Downgraded by two levels because of serious imprecision (low number of trials, low event rate) ‐ see <a href="./appendices#CD012368-sec-0266">Appendix 21</a>.<br/> <sup>e15</sup>Downgraded by one level because of attrition bias and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials, low event rate) ‐ see <a href="./appendices#CD012368-sec-0267">Appendix 22</a>. </p> <p><b>Microvascular complications</b><br/> <sup>a6</sup>No adequate data for analysis.<br/> <sup>b6</sup>Downgraded by three levels because of very serious imprecision (small number of participants, one trial only, unknown event rate) ‐ see <a href="./appendices#CD012368-sec-0263">Appendix 18</a>.<br/> <sup>c6</sup>Downgraded by one level because of attrition bias and reporting bias and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials, unknown event rate) ‐ see <a href="./appendices#CD012368-sec-0265">Appendix 20</a>.<br/> <sup>d6</sup>Downgraded by two levels because of serious imprecision (low number of trials, unknown event rate) ‐ see <a href="./appendices#CD012368-sec-0266">Appendix 21</a>.<br/> <sup>e6</sup>Downgraded by one level because of attrition bias and by two levels because of serious imprecision (CI consistent with both benefit and harm, small number of trials, low event rate) ‐ see <a href="./appendices#CD012368-sec-0267">Appendix 22</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy compared with metformin plus another antidiabetic drug for adults with type 2 diabetes mellitus</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/full#CD012368-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012368-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial ID</b> </p> <p><b>(design)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description of power and sample size calculation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Screened/eligible<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysed<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Finishing trial<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised finishing trial<br/> (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up<br/> (extended follow‐up)<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0018" title="HandelsmanY , LauringB , GantzI , IredaleC , O'NeillEA , WeiZ , et al. A randomized, double‐blind, non‐inferiority trial evaluating the efficacy and safety of omarigliptin, a once‐weekly DPP‐4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion2017;33(10):1861‐8. MK‐3102‐016 . Clinical study report P016. A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). merck.com/clinical‐trials/study.html?id=3102‐016&amp;tab=access (accessed 6 March 2018). NCT01682759 . A study of the safety and efficacy of omarigliptin (MK‐3102) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin (MK‐3102‐016). clinicaltrials.gov/ct2/show/study/NCT01682759 (accessed 6 March 2018). ">Handelsman 2017</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg/day + glimepiride 1‐6 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "A sample size of ˜340 patients randomized to each treatment group was calculated to have 91% power to declare non‐inferiority for a margin of <i>δ=</i>0.35% at an overall two sided 5% alpha‐level, assuming that the true mean difference in HbA1c between omarigliptin and glimepiride is 0.0%" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>54 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin ≥ 1500 mg/day + omarigliptin 25 mg/week + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.1</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>751</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>750</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>574</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>76.4</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012368-bbs2-0019" title="HollanderP , LiuJ , HillJ , JohnsonJ , JiangZ , GolmG , et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Diabetologia2017;60:S19‐S20. HollanderP , LiuJ , HillJ , JohnsonJ , JiangZW , GolmG , et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study. Diabetes Therapy2018;9(1):193‐207. NCT01999218 . Ertugliflozin vs. glimepiride in type 2 diabetes mellitus (T2DM) participants on metformin (MK‐8835‐002). clinicaltrials.gov/ct2/show/NCT01999218 (accessed 1 March 2018). ">Hollander 2017</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg/day + glimepiride 1‐8 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Quote from publication:</b> "With a non‐inferiority margin of 3.3 mmol/mol (0.3%), and assuming a true mean difference in HbA1c of 0 mmol/mol, randomisation of approximately 1230 patients (410 patients per group, to yield a sample size of 337 per group at week 52) was estimated to provide 97% power to demonstrate non‐inferiority of a given ertugliflozin dose to glimepiride in HbA1c reduction at week 52" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>52 weeks (104 weeks)<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: metformin ≥ 1500 mg/day + ertugliflozin 5 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: metformin ≥ 1500 mg/day + ertugliflozin 15 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1326</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1037</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1045</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>78.8</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0032" title="Chilelli . Long‐term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Manuscript draft (accessed 19 March 2018). NCT00700856 . Thiazolidinediones or sulphonylureas and cardiovascular accidents intervention trial (TOSCA IT). clinicaltrials.gov/ct2/show/NCT00700856 (accessed 9 October 2017). VaccaroO , MasulliM , BonoraE , DelPratoS , GiordaCB , MaggioniAP , et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases2012;22(11):997‐1006. VaccaroO , MasulliM , BonoraE , DelPratoS , NicolucciA , RivelleseAA , et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care2012; Vol. 35, issue 12:e82. [PUBMED: 23173143] VaccaroO , MasulliM , NicolucciA , BonoraE , DelPratoS , MaggioniAP , et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinology2017;5(11):887‐97. ">Vaccaro 2017</a> </p> <p>(parallel RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 2000 mg/day + sulphonylurea (glibenclamide 5‐15 mg/day, gliclazide 30‐120 mg/day or glimepiride 2‐6 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "The study was designed to be event driven. The initial sample size calculation was based on an estimated primary endpoint rate of 3.5% per year, with the study intended to have 80% power to detect a reduction of 20% in the primary outcome in either group versus the other, based on the results of the PROACTIVE trial. On the basis of these assumptions, 652 events were needed for the primary efficacy analysis. Therefore, 4396 patients had to be enrolled and followed up for at least 4 years; assuming a trial discontinuation rate of 15%, 5172 patients needed to be recruited and randomly assigned (2586 in each treatment group). However, because of the lower than expected rate of recruitment and because the number of participants discontinuing the study was lower than initially foreseen, an approved protocol amendment (January, 2012) subsequently reduced the sample size requirement. Accordingly, 3371 patients should have been enrolled to expect the 498 endpoint events needed to detect a 20% reduction in the incidence of events with a statistical power of 80% (hazard ratio [HR] 0.80, p=0.05 [one‐sided log‐rank test]), assuming an estimated occurrence rate of the primary endpoint of 3.5% per year and a 5% loss to follow‐up. Nonetheless, nearly 9 years after the beginning of the study, the number of events needed was still not reached, and a futility analysis was done as recommended by the data and safety monitoring board" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4956</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Median follow‐up 57.3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 2000 mg/day + pioglitazone 15‐45 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.6</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3041</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3028</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2358</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>77.5</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0003" title="Dei CasA , SpigoniV , CitoM , AldigeriR , RidolfiV , MarchesiE , et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12‐month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology2017;16(1):27. [DOI: 10.1186/s12933‐017‐0503‐0] NCT01822548 . Effect of vildagliptin vs. glibenclamide on circulating endothelial progenitor cell number type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01822548 (accessed 26 June 2017). ">Dei Cas 2017</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg/day + glibenclamide 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "Sample size was calculated to achieve 80% power to reject the null hypothesis of equal mean changes in the primary endpoint when the population mean difference is 0.15 with a standard deviation of 0.2 in both groups and with a significance level (∝) of 0.05 using a two‐sided two sample equal‐variance T test (difference between the two treatments at 12 months) (software PASS‐ NCSS, USA). In addition, 40 subjects were sufficient to guarantee a delta value between 0 and 12 months in the treatment group of ˜10% (SD of pair differences 20%) with a alpha value of 5% and β = 80%" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin ≥ 1500 mg/day + vildagliptin 100 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>64</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>64</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>59</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>92.2</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012368-bbs2-0021" title="BlondeL , StenlofK , FungA , XieJ , CanovatchelW , MeiningerG . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine2016;128(4):371‐80. CefaluWT , LeiterLA , YoonK‐H , AriasP , NiskanenL , XieJ , et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet2013;382(9896):941‐50. DesaiM , MertonK , DaviesMJ , VijapurkarU , BalisD . Canagliflozin provides greater improvement in risk factors of metabolic syndrome (MetS) versus glimepiride in patients with type 2 diabetes and MetS on background metformin. Diabetologia2016;59:S340‐1. HeerspinkHJ , DesaiM , JardineM , BalisD , MeiningerG , PerkovicV . Canagliflozin slows progression of renal function decline independently of glycemic effects. Journal of the American Society of Nephrology : JASN2017;28(1):368‐75. JohnM , CerdasS , ViolanteR , DeerochanawongC , HassaneinM , SleeA , et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice2016;70(9):775‐85. Lavalle‐GonzalezFJ , EliaschewitzFG , CerdasS , Chacon MdelP , TongC , AlbaM . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research &amp; Opinion2016;32(3):427‐39. LeiterLA , LangsletG , VijapurkarU , DaviesMJ , CanovatchelW . Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Therapy2016;7(2):269‐78. LeiterLA , YoonKH , AriasP , LangsletG , XieJ , BalisDA , et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‐blind, phase 3 study. Diabetes Care2015;38(3):355‐64. NCT00968812 . Canagliflozin treatment and trial analysis‐sulfonylurea (CANTATA‐SU) SGLT2 add‐on to metformin versus glimepiride. clinicaltrials.gov/ct2/show/NCT00968812 (accessed 2 February 2017). NyirjesyP , SobelJD , FungA , MayerC , CapuanoG , WaysK , et al. Genital mycotic infections with canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion2014;30(6):1109‐19. PatelCA , BaileyRA , VijapurkarU , MeiningerG , BlondeL . A post‐hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes‐related quality measures. BMC Health Services Research2016;16(1):356. StenlofK , BlondeL , FungA , XieJ , CanovatchelW , MeiningerG . Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia2015;58:S354‐5. VanGaalL , GarveyWT , LeiterLA , VijapurkarU , ListJ , CuddihyR , et al. Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. Diabetologia2017;60(Suppl. 1):S413‐414. VercruysseF , DaviesMJ , MertonK , VijapurkarU , SimplesJ , CarrollA , et al. Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes. Diabetologia2016;59:S339. WattsNB , BilezikianJP , UsiskinK , EdwardsR , DesaiM , LawG , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism2016;101(1):157‐66. ">Leiter 2015</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg/day + glimepiride 1‐8 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Quote from publication:</b> "Sample size was calculated on the basis of the per‐protocol analysis; an estimated 277 patients per group would be needed to provide approximately 90% power to show non‐inferiority of canagliflozin to glimepiride for HbA1c lowering, with an assumed difference of 0.0% between canagliflozin and glimepiride and an assumed common SD of 1.0%. We assumed that 35% of patients would discontinue the study before week 52; therefore, about 427 patients were planned for inclusion in each group. For the body composition substudy, 46 or more patients per group would provide 90% power for the comparisons between groups in percentage of total fat and visceral adipose tissue; to assure collection of imaging at both baseline and week 52, approximately 70 patients per group were planned for inclusion" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>52 weeks (+ 52 weeks)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: metformin ≥ 1500 mg/day + canagliflozin 100 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: metformin ≥ 1500 mg/day + canagliflozin 300 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.6</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1452</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0005" title="Abad PaniaguaEJ , Casado EscribanoP , Fernández RodriguezJM , Morales EscobarFJ , Betegón NicolásL , Sánchez‐CovisaJ , et al. Cost‐effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type‐2 diabetes mellitus in Spain. Atencion Primaria2015;47(8):505‐13. [DOI: 10.1016/j.aprim.2014.11.002] CharokopouM , McEwanP , ListerS , CallanL , BergenheimK , TolleyK , et al. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine2015;32(7):890‐8. [DOI: 10.1111/dme.12772] DelPratoS , NauckM , Durán‐GarciaS , MaffeiL , RohwedderK , TheuerkaufA , et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obesity Metabolism2015;17(6):581‐90. FeniciP , SternhufvudC , CainV , MukherjeeJ , RohwedderK . Dapagliflozin added to metformin is effective in achieving combined improvements in HbA1c and weight without hypoglycaemia over 4 years. Diabetologia2015;58:S355. ForstT , RohwedderK , SuggJ , JohnssonE . Dapagliflozin decreases post‐prandial glucose without an increase in C‐peptide or insulin. Diabetes2015;64:A324. KatzA , YehH . Dapagliflozin and insulin resistance in patients with type 2 diabetes. Diabetes2015;64:A304‐5. NCT00660907 . Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients. clinicaltrials.gov/ct2/show/NCT00660907 (accessed 3 August 2017). NauckMA , DelPratoS , Duran‐GarciaS , RohwedderK , LangkildeAM , SuggJ , et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity &amp; Metabolism2014;16(11):1111‐20. NauckMA , DelPratoS , MeierJJ , Duran‐GarciaS , RohwedderK , ElzeM , et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care2011;34(9):2015‐22. ParikhS , WildingJ , JabbourS , HardyE . Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice2015;69(2):186‐98. RohwedderK , JohnssonE . Baseline fasting plasma glucose may predict response to dapagliflozin when added to metformin. Diabetologia2015;58:S349‐50. SabaleU , EkmanM , GranstromO , BergenheimK , McEwanP . Cost‐effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes2015;9(1):39‐47. StenlöfK , CainV , RohwedderK , JohnssonE . Maintenance of weight loss with dapagliflozin vs. glipizide as add‐on to metformin over 4 years. Diabetes2015;64:A27. ">Del Prato 2015</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1500‐2500 mg/day + glipizide 5‐20 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "To demonstrate non‐inferiority of dapagliflozin in comparison with glipizide as add‐on therapy to metformin for changes from baseline to week 52 in HbA1c with a non‐inferiority margin of 0.35%, assuming a standard deviation (SD) of 1.25%, and at a one‐sided significance level of 0.025, 280 evaluable patients were needed in each treatment group to provide approximately 90% power (given a true difference of zero between the 2 treatment groups). Assuming a 5% exclusion rate from the full analysis set, 295 patients per treatment group are needed for the full analysis set. Additionally, to have 90% power for the per‐protocol population and assuming a 25% exclusion rate from the per‐protocol population, 373 patients per treatment group (746 patients in total) were planned for randomization" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks (+156 weeks)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1500‐2500 mg/day + dapagliflozin 2.5‐10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.7</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>814<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>801</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>302</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>37.0</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0030" title="NCT01006603 . Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). clinicaltrials.gov/ct2/show/NCT01006603 (accessed 2 August 2017). PerlS , CookW , WeiC , OhmanP , HirshbergB . Effects of glimepiride versus saxagliptin on beta‐cell function and hypoglycemia: a post hoc analysis in older patients with type 2 diabetes inadequately controlled with metformin. Clinical Therapeutics2016;38(12):2578‐88. PerlS , CookW , WeiC , OhmanP , HirshbergB . Low beta‐cell function at baseline is associated with higher rates of hypoglycemia in response to treatment with glimepiride in elderly patients with type 2 diabetes inadequately controlled with metformin. Diabetes2015;64:A319. SchernthanerG , Durán‐GarciaS , HanefeldM , LangsletG , NiskanenL , ÖstgrenCJ , et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity &amp; Metabolism2015;17(7):630‐8. ">Schernthaner 2015</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin at any dose + glimepiride 1‐6 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "A sample size of 698 patients (349/treatment arm) was calculated for detecting superiority of saxagliptin in the primary endpoint, with a two‐sided significance level of 0.05 and 80% power. This assumed a 10% dropout rate and an odds ratio (OR) of 1.55 for achieving target HbA1c without hypoglycaemia with saxagliptin compared with glimepiride" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>957</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin at any dose + saxagliptin 5 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>720</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>718</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>574</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>79.7</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012368-bbs2-0004" title="DelPratoS , CamisascaR , WilsonC , FleckP . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity Metabolism2014;16(12):1239‐46. [DOI: doi.org/10.1111/dom.12377] DelPratoS , FleckP , WilsonC , ChaudhariP . Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity &amp; Metabolism2016;18(6):623‐7. [DOI: doi.org/10.1111/dom.12643] GordonJ , McEwanP , HurstM , PuellesJ . The cost‐effectiveness of alogliptin versus sulfonylurea as add‐on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy2016;7(4):825‐45. [DOI: 10.1007/s13300‐016‐0206‐7] NCT00856284 . Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus (ENDURE). clinicaltrials.gov/ct2/show/NCT00856284 (accessed 12 December 2016). ">Del Prato 2014</a><sup>e</sup> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg once daily or maximum tolerated dose + glipizide 5‐20 mg once daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Quote from publication:</b> "The planned randomization sample size for the study was between 815 and 897 patients per treatment arm. This ensured at least 95% power to declare non‐inferiority between either alogliptin dose (12.5 or 25 mg) and glipizide at week 104, assuming a non‐inferiority margin of 0.3%, no difference between either alogliptin dose and glipizide, a standard deviation of change from baseline of 1.2%, an evaluability rate of 60%, and a one‐sided 0.0125 significance level. The 0.0125 significance level was chosen so that, combined with similar analyses conducted at week 52, the overall one‐sided type 1 error rate for the trial was maintained at the 0.025 level" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>5789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>104 weeks (+ 2 weeks)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: metformin ≥ 1500 mg once daily or maximum tolerated dose + alogliptin 12.5 mg once daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: metformin ≥ 1500 mg once daily or maximum tolerated dose + alogliptin 25 mg once daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>885</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.7</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2639</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1089</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1392</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>52.7</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD012368-bbs2-0001" title="AhrénB , CarrMC , MurphyK , PerkinsC , RendellM , MalloryJ , et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice2017;126:230‐9. [DOI: 10.1016/j.diabres.2017.02.017] AhrénB , JohnsonSL , StewartM , CirkelDT , YangF , PerryC , et al. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care2014;37(8):2141‐8. [DOI: 10.2337/dc14‐0024] AhrénB , StewartM , CirkelD , YangF , PerryC , JohnsonS . HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met). 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21‐25; Chicago (IL). American Diabetes Assosciation, 2013. [52‐LB] DoggrellSA . Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert Review of Endocrinology and Metabolism2015;10(3):273‐6. [DOI: 10.1586/17446651.2015.995629] FisherM , PetrieMC , AmberyPD , DonaldsonJ , YeJ , McMurrayJJ . Cardiovascular safety of albiglutide in the HARMONY Programme: a meta‐analysis. Lancet Diabetes &amp; Endocrinology2015;3(9):697‐703. [DOI: 10.1016/S2213‐8587(15)00233‐8] GSK Study ID 112753. Efficacy and safety of albiglutide in treatment of type 2 diabetes. gsk‐studyregister.com/study/3736 (accessed 16 November 2016). HomePD , AhrénB , ReuschJE , RendellM , WeissmanPN , CirkelDT , et al. Three‐year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long‐term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice2017;131:49‐60. [DOI: 10.1016/j.diabres.2017.06.013] JohnsonS , AhrénB , StewartM , CirkelD , YangF , PerryC . HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin. Diabetologia2013;56:S8‐9. LeiterLA , MalloryJM , WilsonTH , ReinhardtRR . Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity &amp; Metabolism2016;18(9):930‐5. [DOI: 10.1111/dom.12679] MatthewsJE , AhrenB , YeJ , CarrMC , StewartMW . HARMONY 3 year 3 results: albiglutide vs sitagliptin, glimepiride, and placebo in patients with T2DM on metformin. 50th Annual Meeting of the European Association for the Study of Diabetes. 15‐19 September 2014. [abstract no 831] NCT00838903 . Efficacy and safety of albiglutide in treatment of type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00838903 (accessed 16 November 2016). ">Ahrén 2014</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg daily + glimepiride 2‐4 mg once daily + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Quote from publication:</b> "The planned sample size provided &gt;90% power to demonstrate superiority versus placebo and noninferiority versus sitagliptin and glimepiride (noninferiority margin = 0.3%). Superiority of albiglutide versus sitagliptin and glimepiride was tested if noninferiority was established" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>104 weeks (+ 52 weeks)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: metformin ≥ 1500 mg daily + albiglutide 30‐50 mg once weekly + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: metformin ≥ 1500 mg daily + sitagliptin 100 mg once daily + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C3: metformin ≥ 1500 mg daily + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.9</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1049</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>321</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>628</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>59.9</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0028" title="BriceR , SpencerW , Asaro‐HarrisA , ZellerC , HachT , SalsaliA , et al. Analysis of empagliflozin vs glimepiride by Quality and Outcomes Framework targets: post hoc analysis of a head‐to‐head study. Diabetic Medicine2015;32:95‐6. ChirilaC , ZhengQ , DavenportE , KaschinskiD , PfarrE , HachT , et al. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research2016;25(5):1199‐207. KhuntiK , Bingham‐GardinerP , HassanSW , ZellerC , NaderaliE , SalsaliA , et al. Efficacy and safety of empagliflozin compared with glimepiride in South Asian patients with type 2 diabetes in a head‐to‐head study. Diabetic Medicine2015;32:96. KohlerS , KaspersS , SalsaliA , ZellerC , WoerleHJ . Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM). Diabetologia2016;59:S26. NCT01167881 . Efficacy and safety of empagliflozin (BI 10773) with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT01167881 (accessed 18 July 2017). NeelandIJ , McGuireDK , EliassonB , RidderstraleM , ZellerC , WoerleHJ , et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA‐REG H2H SU Trial: a body composition sub‐study. Diabetes Therapy2015;6(4):635‐42. RidderstraleM , SvaerdR , ZellerC , KimG , WoerleHJ , BroedlUC . Rationale, design and baseline characteristics of a 4‐year (208‐week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add‐on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology2013;12:129. RidderstråleM , AndersenKR , ZellerC , KimG , WoerleHJ , BroedlUC . Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes &amp; Endocrinology2014;2(9):691‐700. ">Ridderstråle 2014</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin immediate release ≥ 1500 mg/day plus glimepiride 1‐4 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "698 patients per group were needed to provide a power of at least 95% to show non‐inferiority, based on a margin of 0.3%, for the primary endpoint at weeks 52 and 104 if the true treatment effect is 0.05% (in favour of glimepiride) and SD is 1.2%" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2637</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>648 ( 2 years)</p> <p>589 (4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.1 (2 years)</p> <p>75.5 (4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>208 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin immediate release ≥ 1500 mg/day plus empagliflozin 25 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>652 (2 years)</p> <p>610 (4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.8 (2 years)</p> <p>79.3 (4 years)</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1549</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1545</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1300 (2 years)</b> </p> <p><b>1199 (4 years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>83.9 (2 years)</b> </p> <p><b>77.4 (4 years)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0016" title="CookW , MinerviniG , BryzinskiB , HirshbergB . Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate Medicine2014;126(6):19‐32. GokeB , GallwitzB , ErikssonJ , HellqvistA , Gause‐NilssonI . Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial. International Journal of Clinical Practice2010;64(12):1619‐31. GranstromO , BergenheimK , McEwanP , SennfaltK , HenrikssonM . Cost‐effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes2012;6(2):127‐36. GökeB , GallwitzB , ErikssonJ G , HellqvistÅ , Gause‐NilssonI . Saxagliptin vs glipizide as add‐on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long‐term (52‐week) extension of a 52‐week randomised controlled trial. International Journal of Clinical Practice2013;67(4):307‐16. MintzML , MinerviniG . Saxagliptin versus glipizide as add‐on therapy to metformin: assessment of hypoglycemia. Current Medical Research &amp; Opinion2014;30(5):761‐70. NCT00575588 . 52‐week add‐on to metformin comparison of saxagliptin and sulphonylurea, with a 52‐week extension period. clinicaltrials.gov/ct2/show/NCT00575588 (accessed 10 July 2017). ">Göke 2013</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg daily + glipizide 5‐20 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "With 419 patients per treatment group, there was a 95% power to establish the non‐inferiority comparison on change from baseline to week 52 HbA1c at the 5% level, assuming that the standard deviation of change from baseline HbA1c was 1.1%, with a non‐inferiority limit set at 0.35% and a zero true difference between the two randomised treatments. The sample size assumed that 35% of randomised patients would be excluded from the PP analysis set" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks (+ 52 weeks)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin ≥ 1500 mg daily + saxagliptin 5 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.6</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>858</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>852</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>312</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>36.4</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0022" title="MaffioliP , FogariE , D’AngeloA , PerroneT , DerosaG . Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology &amp; Hepatology2013;25(9):1113‐22. ">Maffioli 2013</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 2550 mg/day plus glibenclamide 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "Considering a difference of at least 10% as clinically significant compared with the baseline and an α error of 0.05, the actual sample size was adequate to obtain a power higher than 0.80 to detect a significant between‐group difference in variables related to ultrasonography parameters" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 2550 mg/day plus pioglitazone 30 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>170</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>160</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>160</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>94.1</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD012368-bbs2-0024" title="BlondeL , Russell‐JonesD . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1‐5 studies. Diabetes, Obesity &amp; Metabolism2009;11 Suppl 3:26‐34. BodeBW , BrettJ , FalahatiA , PratleyRE . Comparison of the efficacy and tolerability profile of liraglutide, a once‐daily human GLP‐1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. American Journal of Geriatric Pharmacotherapy2011;9(6):423‐33. BuseJB , GarberA , RosenstockJ , SchmidtWE , BrettJH , VidebaekN , et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism2011;96(6):1695‐702. DaviesMJ , ChubbBD , SmithIC , ValentineWJ . Cost‐utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabetic Medicine2012;29(3):313‐20. FonsecaVA , DevriesJH , HenryRR , DonsmarkM , ThomsenHF , PlutzkyJ . Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications2014;28(3):399‐405. HegedusL , MosesAC , ZdravkovicM , LeThiT , DanielsGH . GLP‐1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP‐1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism2011;96(3):853‐60. HenryRR , BuseJB , SestiG , DaviesMJ , JensenKH , BrettJ , et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta‐analysis of the liraglutide development program. Endocrine Practice2011;17(6):906‐13. HermansenK , KolotkinRL , HammerM , ZdravkovicM , MatthewsD . Patient‐reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add‐on to metformin. Primary Care Diabetes2010;4(2):113‐7. JendleJ , NauckMA , MatthewsDR , FridA , HermansenK , DuringM , et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity &amp; Metabolism2009;11(12):1163‐72. McGillJB . Insights from the Liraglutide Clinical Development Program‐‐the liraglutide effect and action in diabetes (LEAD) studies. Postgraduate Medicine2009;121(3):16‐25. NCT00318461 . To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (LEAD‐2). clinicaltrials.gov/ct2/show/NCT00318461 (accessed 28 March 2017). NauckM , FridA , HermansenK , ShahNS , TankovaT , MithaIH , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care2009;32(1):84‐90. NauckM , FridA , HermansenK , ThomsenAB , DuringM , ShahN , et al. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study. Diabetes, Obesity &amp; Metabolism2013;15(3):204‐12. NauckM , MarreM . Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine2009;121(3):5‐15. NiswenderK , Pi‐SunyerX , BuseJ , JensenKH , ToftAD , Russell‐JonesD , et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity &amp; Metabolism2013;15(1):42‐54. RousselR , MartinezL , VandebrouckT , DouikH , EmielP , GueryM , et al. Evaluation of the long‐term cost‐effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics2016;19(2):121‐34. TroelsJ , KishoreS , SteinbergW . Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient‐level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care2015;38(6):1058‐66. ZinmanB , SchmidtWE , MosesA , LundN , GoughS . Achieving a clinically relevant composite outcome of an HbA1c of. Diabetes, Obesity &amp; Metabolism2012;14(1):77‐82. ">Nauck 2013</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1500‐2000 mg/day + glimepiride 1‐4 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><b>Quote from publication:</b> "Sample size calculations were based on showing A1C and body weight differences of 0.5 and 3%, respectively, after 6 months of treatment. The assumed standard deviation for A1C and the coefficient of variance for weight were 1.2 and 3%, respectively. The combined power (calculated as the product of the marginal powers for A1C and weight) was at least 85%" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>1662</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>26 weeks (+ 18 months)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: metformin 1500‐2000 mg/day + liraglutide 0.6 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: metformin 1500‐2000 mg/day + liraglutide 1.2 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C3: metformin 1500‐2000 mg/day + liraglutide 1.8 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C4: metformin 1500‐2000 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.4</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1091</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1059</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>529</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>48.5</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0013" title="GallwitzB , GuzmanJ , DottaF , GuerciB , SimóR , BassonBR , et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open‐label, randomised controlled trial. Lancet2012;379(9833):2270‐8. KazdaC , GallwitzB , SimóR , GuzmánJR , KrausP , NicolayC , et al. The European exenatide study of long‐term exenatide vs glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity &amp; Metabolism2009;11(12):1131‐7. NCT00359762 . Exenatide versus glimepiride in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00359762 (accessed 6 July 2017). SchernthanerG , Rosas‐GuzmanJ , DottaF , GuerciB , SimoR , FestaA , et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. Diabetes, Obesity &amp; Metabolism2015;17(7):689‐98. SimoR , GuerciB , SchernthanerG , GallwitzB , Rosas‐GuzmanJ , DottaF , et al. Long‐term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology2015;14(116):1‐13. ">Gallwitz 2012a</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin median dose 2000 mg/day + glimepiride mean dose 2.01 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "We calculated sample size on the basis of the non‐inferiority test of exenatide versus glimepiride, an expected mean baseline HbA1c concentration of 8.2%, a 1 year patient accrual, maximum follow‐up of 3 years, dropout rate of 15% per year (for reasons other than treatment failure), and a 58% event rate in each group after 1 year. With these assumptions, 527 patients per study group would provide about a 90% power to conclude non‐inferiority of exenatide" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Max. follow‐up 3 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin median dose 2000 mg/day + exenatide mean dose 17.35 μg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>488</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.2</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1029</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>973</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>727</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>71.1</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0014" title="GallwitzB , RosenstockJ , EmserA , vonEynattenM , WoerleHJ . Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c. International Journal of Clinical Practice2013;67(4):317‐21. GallwitzB , RosenstockJ , PatelS , vonEynattenM , HehnkeU , MehlburgerL , et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial. Diabetes, Obesity &amp; Metabolism2015;17(3):276‐84. GallwitzB , RosenstockJ , RauchT , BhattacharyaS , PatelS , vonEynattenM , et al. 2‐year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double‐blind, non‐inferiority trial. Lancet2012;380(9840):475‐83. JohansenOE , BoehmBO , GrillV , TorjesenPA , BhattacharyaS , PatelS , et al. C‐peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2‐year double‐blind, randomized, controlled study. Diabetes Care2014;37(1):e11‐2. JohansenOE , NeubacherD , vonEynattenM , PatelS , WoerleHJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre‐specified, prospective, and adjudicated meta‐analysis of a phase 3 programme. Cardiovascular Diabetology2012;11:3. NCT00622284 . Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00622284 (accessed 7 July 2017). RosenstockJ , MarxN , NeubacherD , SeckT , PatelS , WoerleHJ , et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient‐level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology2015;14:57. ">Gallwitz 2012b</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg/day + glimepiride 1‐4 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "On the assumption of an SD of change in HbA1c from baseline of 1.3%, a sample size of 707 participants per treatment group was needed for 90% power to show non‐inferiority through a 97.5% CI for treatment difference in the adjusted mean change from baseline to endpoint of &lt; 0.35% HbA1c at the level of α=0.0125 (one‐sided)" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>104 weeks (+ 1 week)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin ≥ 1500 mg/day + linagliptin 5 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>587</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1552</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1519</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1191</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>77</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0010" title="DerosaG , PutignanoP , BossiAC , BonaventuraA , QuerciF , FranzettiIG , et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. European Journal of Pharmacology2011;666(1‐3):251‐6. ">Derosa 2011a</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1000‐2000 mg/day + glimepiride 6 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "Considering as clinically significant a difference of at least the 10% compared to the baseline and an alpha error of 0.05, the actual sample size was adequate to obtain a power higher than 0.80 for all measured variable" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1000‐2000 mg/day + exenatide 20 μg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.2</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>111</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>101</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>101</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>91.0</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0011" title="DerosaG , CiceroAF , FogariE , D'AngeloA , BianchiL , MaffioliP . Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and Metabolic Research2011;43(7):505‐12. ">Derosa 2011b</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1700 ± 850 mg/day + glibenclamide 5‐15 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "Considering as clinically significant a difference of at least the 10% compared to the baseline and an alpha error of 0.05, the actual sample size was adequate to obtain a power higher than 0.80 for all measured variables" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1700 ± 850 mg/day + pioglitazone 15‐45 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.1</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>201</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>194</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>194</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>96.5</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0027" title="PetricaL , VladA , PetricaM , JianuCD , GluhovschiG , GadaleanF , et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice2011;94(1):22‐32. ">Petrica 2011</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1700 mg/day plus glimepiride 4 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>1 year</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1700 mg/day plus pioglitazone 30 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.2</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>78</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>68</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>68</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>87.2</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0009" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , RagonesiPD , QuerciF , et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology &amp; Therapeutics2010;12(3):233‐40. ">Derosa 2010</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1500 ± 500 mg/day + glibenclamide 15 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1500 ± 500 mg/day + exenatide 20 μg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.7</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>128</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>116</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>116</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>90.6</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0023" title="AhrenB , FoleyJE , DejagerS , AkachaM , ShaoQ , HeimannG , et al. Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities?. Diabetes Therapy2014;5(2):459‐69. AhrenB , FoleyJE , FerranniniE , MatthewsDR , ZinmanB , DejagerS , et al. Changes in prandial glucagon levels after a 2‐year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care2010;33(4):730‐2. AhrenB , MathieuC , BaderG , SchweizerA , FoleyJE . Efficacy of vildagliptin versus sulfonylureas as add‐on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia2014;57(7):1304‐7. BaderG , GeransarP , SchweizerA . Vildagliptin more effectively achieves a composite endpoint of HbA1c &lt; 7 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice2013;100(3):e78‐81. EudraCT2004‐004559‐21 . A multicenter, randomized, double‐blind, active controlled study to compare the long‐term effect (up to 5 years) of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐004559‐21/IT (accessed 11 March 2017). FerranniniE , FonsecaV , ZinmanB , MatthewsD , AhrénB , ByiersS , et al. Fifty‐two‐week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity &amp; Metabolism2009;11(2):157‐66. MatthewsDR , DejagerS , AhrenB , FonsecaV , FerranniniE , CouturierA , et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obesesity &amp; Metabolism2010;12(9):780‐9. NCT00106340 . Vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes. clinicaltrials.gov/ct2/show/NCT00106340 (accessed 11 March 2017). ">Matthews 2010</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg twice a day + glimepiride 2‐6 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "With 3120 patients randomized (i.e. 1560 patients per treatment arm) and an overall 20% discontinuation rate, the study had 96% power to show non‐inferiority of vildagliptin compared with glimepiride (one‐sided α level of 0.0125, assuming a non‐inferiority margin of 0.3% HbA1c and a standard deviation of 1.25%)" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>approx. 6000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>953</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin ≥ 1500 mg twice a day + vildagliptin 50 mg twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.6</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3118</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2994</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1947</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>62.4</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0012" title="FilozofC , GautierJF . A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study. Diabetic Medicine2010;27(3):318‐26. ">Filozof 2010</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1500 mg/day plus gliclazide 80‐320 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "Eight hundred patients (400 per group) were required to demonstrate non‐inferiority of vildagliptin to gliclazide in HbA1c reduction, with a one‐sided α level of 0.025 at the end of the study with 92% power (assuming a true difference of 0.1% in favour of gliclazide, standard deviation of HbA1c reduction at week 52 of 1.25 units and discontinuation rate of 20% over the 52‐week period)" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1500 mg/day plus vildagliptin 100 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>407</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1007</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>779</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>819</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>81.3</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0031" title="KrobotKJ , FerranteSA , DaviesMJ , SeckT , MeiningerGE , Williams‐HermanD , et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre‐specified analysis adjusting for the most recently measured HbA(1c) value. Current Medical Research and Opinion2012;28(8):1281‐7. NCT00094770 . An investigational drug study in patients with type 2 diabetes mellitus (0431‐024). clinicaltrials.gov/ct2/show/study/NCT00094770 (accessed 14 July 2017). NauckMA , MeiningerG , ShengD , TerranellaL , SteinPP . Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabetes, Obesity &amp; Metabolism2007;9(2):194‐205. OmmenES , XuL , O'NeillEA , GoldsteinBJ , KaufmanKD , EngelSS . Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Therapy2015;6(1):29‐40. SeckT , NauckM , ShengD , SungaS , DaviesMJ , SteinPP , et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study. International Journal of Clinical Practice2010;64(5):562‐76. SeckTL , EngelSS , Williams‐HermanDE , SiskCM , GolmGT , WangH , et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice2011;93(1):e15‐7. ShankarRR , XuL , GolmGT , O'NeillEA , GoldsteinBJ , KaufmanKD , et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice2015;69(6):626‐31. Williams‐HermanD , RoundE , SwernAS , MusserB , DaviesMJ , SteinPP , et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders2008;8:14. ">Seck 2010</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin ≥ 1500 mg/day plus glipizide 5‐20 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin ≥ 1500 mg/day plus sitagliptin 100 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.4</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1172</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1135</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>519</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>44.3</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0020" title="GSK Study ID BRL‐049653/231. BRL‐049653/231‐RECORD: rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. gsk‐studyregister.com/study/7631 (accessed 1 April 2017). HomePD , JonesNP , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine2007;24(6):626‐34. HomePD , KahnSE , JonesNP , NoronhaD , Beck‐NielsenH , VibertiG . Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53(9):1838‐45. HomePD , PocockSJ , Beck‐NielsenH , CurtisPS , GomisR , HanefeldM , et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet2009;373(9681):2125‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , DargieH , et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia2005;48(9):1726‐35. HomePD , PocockSJ , Beck‐NielsenH , GomisR , HanefeldM , JonesNP , et al. Rosiglitazone evaluated for cardiovascular outcomes‐‐an interim analysis. New England Journal of Medicine2007;357(1):28‐38. JonesNP , CurtisPS , HomePD . Cancer and bone fractures in observational follow‐up of the RECORD study. Acta Diabetologica2015;52(3):539‐46. KomajdaM , CurtisP , HanefeldM , Beck‐NielsenH , PocockSJ , ZambaniniA , et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology2008;7:10. KomajdaM , McMurrayJJ , Beck‐NielsenH , GomisR , HanefeldM , PocockSJ , et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal2010;31(7):824‐31. LopesRD , DickersonS , HafleyG , BurnsS , Tourt‐UhligS , WhiteJ , et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal2013;166(2):208‐16. MacDonaldMR , PetrieMC , HomePD , KomajdaM , JonesNP , Beck‐NielsenH , et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care2011;34(6):1394‐6. MahaffeyKW , HafleyG , DickersonS , BurnsS , Tourt‐UhligS , WhiteJ , et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal2013;166(2):240‐9. NCT00379769 . Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). clinicaltrials.gov/ct2/show/NCT00379769 (accessed 1 April 2017). ">Home 2009</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin up to 2550 mg/day + glibenclamide (or equivalent for different preparations) up to 15 mg/day or gliclazide up to 240 mg/day or glimepiride up to 4 mg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "For the non‐inferiority hypothesis, 4000 participants followed for a median time of 6 years were needed to give 99% power, provided that the active control group had an 11% event rate per year, allowing 2% annual loss to follow‐up. Blinded overall event tracking showed the event rate during the study was well below this rate. Therefore, endpoint sweeps were implemented to identify any missed events. An in‐depth review of a sample of individual records showed very few missed events" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Mean follow‐up: 5.5 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin up to 2550 mg/day + rosiglitazone up to 8 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>939</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.1</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2228</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2222</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1845</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>83.0</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012368-bbs2-0007" title="DerosaG , MaffioliP , SalvadeoSA , FerrariI , GravinaA , MereuR , et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism2009;58(8):1059‐66. ">Derosa 2009a</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 850 mg/day + glimepiride 2‐6 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Quote from publication:</b> "Considering as clinically significant a difference of at least 10% compared with the baseline and an α error of 0.05, the actual sample size is adequate to obtain a power higher than 0.80 for all variables related to glucose metabolism..." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>15 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: metformin 850‐2550 mg/day + pioglitazone 15‐45 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: metformin 1000‐3000 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>202</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>180</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>89.1</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0008" title="DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1‐year, double‐blind, randomized clinical trial. Internal Medicine (Tokyo, Japan)2007;46(22):1837‐46. DerosaG , D'AngeloA , FogariE , SalvadeoS , GravinaA , FerrariI , et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics2009;34(1):13‐23. ">Derosa 2009b</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1500‐3000 mg/day + glibenclamide 7.5‐15 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>1 year</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1500‐3000 mg/day + nateglinide 180‐360 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>248</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>233</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>233</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>94.0</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0026" title="PetricaL , PetricaM , VladA , JianuCD , GluhovschiG , IanculescuC , et al. Nephro‐ and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift2009;121(23‐24):765‐75. ">Petrica 2009</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1700 mg/day + glimepiride 4 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>1 year</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1700 mg/day plus rosiglitazone 4 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>44</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>77.3</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0025" title="GSK Study ID 101765. Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. gsk‐studyregister.com/study/2645 (accessed 28 June 2017). NCT00367055 . Rosiglitazone‐metformin combination versus metformin‐sulfonylurea combination on beta‐cell function in type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00367055 (accessed 28 June 2017). ">NCT00367055</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 2000 mg/day + gliclazide 80‐320 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>36 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 2000 mg/day + rosiglitazone 4‐8 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.1</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>89</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>62</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>62</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69.7</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0017" title="GSK Study ID AVM100264. AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. gsk‐studyregister.com/study/7254 (accessed 12 July 2017). HamannA , Garcia‐PuigJ , PaulG , DonaldsonJ , StewartM . Comparison of fixed‐dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight Individuals with type 2 diabetes inadequately controlled on metformin alone. Experimental and Clinical Endocrinology &amp; Diabetes2008;116(1):6‐13. NCT00359112 . AVANDAMET versus metformin and sulphonylurea in people with poorly controlled type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00359112 (accessed 12 July 2017). ">Hamann 2008</a> </p> <p>(non‐inferiority parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 2000 mg/day + glibenclamide 5‐15 mg/day or gliclazide 80‐320 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "The non‐inferiority margin was set at 0.4%. A sample size of 190 per treatment group was required to give a 90% probability that the upper limit of a two‐sided 95% CI for the difference in treatment means would be below 0.4% (significance level of 0.025 in a one‐sided test), assuming an SD of 1.2%. Assuming an attrition rate of 30%, 544 subjects were to be recruited" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 2000 mg/day + rosiglitazone 4‐8 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>596</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>573</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>463</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>77.7</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0029" title="CDJN608A2308 . A multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1852 (accessed 17 July 2017). CDJN608A2308 . Six month extension to a multicenter, double‐blind, randomized, parallel‐group study to evaluate the efficacy and safety of nateglinide and gliclazide in combination with metformin, in type 2 diabetes patients inadequately controlled on maximally tolerated doses of metformin alone. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1850 (accessed 17 July 2017). RisticS , Collober‐MaugeaisC , CressierF , TangP , PecherE . Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results. Diabetes, Obesity &amp; Metabolism2007;9(4):506‐11. RisticS , Collober‐MaugeaisC , PecherE , CressierF . Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine2006;23(7):757‐62. ">Ristic 2007</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin &gt; 1000 mg/day + gliclazide 80‐240 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "A planned sample size of 120 patients per treatment was considered sufficient to detect an HbA1c difference of 0.5% with 90% power, assuming a dropout rate of 15% and an SD of 1.1 (calculated for 24 weeks treatment)" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks (+6 months)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin &gt; 1000 mg/day + nateglinide 180‐540 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.2</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>262</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>213</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>206</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>78.6</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0002" title="BelcherG , SchernthanerG . Changes in liver tests during 1‐year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Medicine2005;22(8):973‐9. [DOI: 10.1111/j.1464‐5491.2005.01595.x] CharbonnelB , RodenM , UrquhartR , MarizS , JohnsD , MihmM , et al. Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide‐based regimens. Diabetologia2005;48(3):553‐60. [DOI: 10.1007/s00125‐004‐1651‐9] CharbonnelB , SchernthanerG , BrunettiP , MatthewsDR , UrquhartR , TanMH , et al. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia2005;48(6):1093‐104. [DOI: 10.1007/s00125‐005‐1751‐1] MatthewsDR , CharbonnelBH , HanefeldM , BrunettiP , SchernthanerG . Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews2005;21(2):167‐74. [DOI: 10.1002/dmrr.478] RodenM , MarizS , BrazzaleAR , PaciniG . Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in type 2 diabetes. Journal of Internal Medicine2009;265(4):476‐87. [DOI: 10.1111/j.1365‐2796.2008.02040.x] ">Charbonnel 2005</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin at pre‐study dose + gliclazide 80‐320 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "Sample size was based on demonstrating a between‐group difference of 0.35% in the change in HbA1c from baseline to week 52 (the primary efficacy variable) using a two‐sided t‐test. A total of 225 patients/group completing at least 24 weeks of the study was required, on the basis of a level of 95% power at 5% significance" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>104 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin at pre‐study dose + pioglitazone 15‐45 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.5</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>630</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>471</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>74.8</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0006" title="DerosaG , CiceroAF , GaddiAV , CiccarelliL , PiccinniMN , SalvadeoS , et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized clinical trial. Clinical Therapeutics2005;27(9):1383‐91. DerosaG , GaddiA , CiccarelliL , FogariE , GhelfiM , FerrariI , et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: a randomized, double‐blind clinical trial. Journal of International Medical Research2005;33(3):284‐94. DerosaG , GaddiAV , PiccinniMN , CiccarelliL , SalvadeoS , PerosE , et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy2005;25(5):637‐45. DerosaG , GaddiAV , PiccinniMN , SalvadeoS , CiccarelliL , FogariE , et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity &amp; Metabolism2006;8(2):197‐205. ">Derosa 2005</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 1500 mg/day plus glimepiride 2 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quote from publication:</b> "The study power was a priori calculated by using the World Wide Web‐available power calculator of the university of California, Los Angeles, Department of statistics (Los Angeles, CA)" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1500 mg/day plus rosiglitazone 4 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>99</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>96.0</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012368-bbs2-0015" title="CDJN608AUS07 . Multicenter, randomized, double‐blind, active controlled trial to compare the efficacy and safety of 104 weeks of nateglinide plus metformin vs glyburide plus metformin in drug naive subjects with type 2 diabetes mellitus who have inadequate control with diet and exercise. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1497 (accessed 16 March 2017). GerichJ , RaskinP , Jean‐LouisL , PurkayasthaD , BaronMA . PRESERVE‐beta: two‐year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care2005;28(9):2093‐9. SchwarzSL , GerichJE , MarcellariA , Jean‐LouisL , PurkayasthaD , BaronMA . Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naive elderly patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2008;10(8):652‐60. ">Gerich 2005</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin 500‐2000 mg/day + glyburide 1.25‐15 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>104 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 500‐2000 mg/day + nateglinide 180‐540 mg/day + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.4</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>428</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>406</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>263</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>61.4</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><i>Grand total</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All interventions</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>12,863</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="3" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All c</i> <i>omparators</i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>15,883</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All interventions and c</i> <i>omparators</i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>28,746</i> </b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>‐ denotes not reported</p> <p><sup>a</sup>Follow‐up under randomised conditions until end of trial (= duration of intervention + follow‐up post‐intervention or identical to duration of intervention); extended follow‐up refers to follow‐up of participants once the original trial was terminated as specified in the power calculation.<br/> <sup>b</sup>The trial was conducted over 104 weeks in two 52‐week phases; the primary and secondary hypotheses were pre‐specified for testing at week 52 (phase A); treatment was continued for another 52 weeks (phase B) to evaluate longer‐term safety and efficacy.<br/> <sup>c</sup>The median duration of therapy was 12 (IQR 11–13) months, 12 (11–12) months for vildagliptin and 12 (7–13) months for glibenclamide.<br/> <sup>d</sup>Two participants did not take the drug.<br/> <sup>e</sup>The primary efficacy endpoint was the change in HbA1c from baseline to week 52 and to week 104. </p> <p><b>C</b> : comparator; <b>CI</b> : confidence interval; <b>FPG</b> : fasting plasma glucose; <b>HbA1c</b> : glycosylated haemoglobin A1c; <b>I</b> : intervention; <b>IQR</b> : interquartile range; <b>PP</b> : per protocol; <b>RCT</b> : randomised controlled trial; <b>SD</b>: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/full#CD012368-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012368-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Overview of trials (trial arms), comparators, intervention and number of randomised participants</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Drug class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trials (trial arms) (N)<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metformin + comparator: randomised participants (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Metformin + sulphonylurea: randomised participants (N)<sup>b</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thiazolidinediones</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p><b>Total</b> :<b>11 (11)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pioglitazone 15‐45 mg: 1541</p> <p>Pioglitazone 15‐45 mg: 102</p> <p>Pioglitazone 15‐45 mg: 69</p> <p>Pioglitazone: 15‐45 mg: 317</p> <p>Pioglitazone 30 mg: 86</p> <p>Pioglitazone 30 mg: 39</p> <p>Rosiglitazone 4 mg: 22</p> <p>Rosiglitazone 4 mg: 50</p> <p>Rosiglitazone 4‐8 mg: 45</p> <p>Rosiglitazone 4‐8 mg: 294</p> <p>Rosiglitazone up to 8 mg: 1120</p> <p><b>Total</b> :<b>3685</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glimepiride/glibenclamide/gliclazide: 1500</p> <p>Glibenclamide: 99</p> <p>Glimepiride: 66</p> <p>Gliclazide: 313</p> <p>Glibenclamide: 84</p> <p>Glimepiride: 39</p> <p>Glimepiride: 22</p> <p>Glimepiride: 49</p> <p>Gliclazide: 44</p> <p>Glibenclamide/gliclazide: 302</p> <p>Glibenclamide/gliclazide/glimepiride: 1108</p> <p><b>Total</b> :<b>3626</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DPP‐4 inhibitors</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p><b>Total</b> : <b>10 (11)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alogliptin 12.5 mg: 880</p> <p>Alogliptin 25 mg: 885</p> <p>Linagliptin 5 mg: 777</p> <p>Omarigliptin 25 mg: 376</p> <p>Saxagliptin 5 mg: 360</p> <p>Saxagliptin 5 mg: 428</p> <p>Sitagliptin 100 mg: 313</p> <p>Sitagliptin 100 mg: 588</p> <p>Vildagliptin 50 mg: 1562</p> <p>Vildagliptin 100 mg: 40</p> <p>Vildagliptin 100 mg: 513</p> <p><b>Total</b> : <b>6722</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glipizide: 874<br/> (Glipizide: 874) </p> <p>Glimepiride: 775</p> <p>Glimepiride: 375</p> <p>Glimepiride: 360</p> <p>Glipizide: 430</p> <p>Glimepiride: 317</p> <p>Glipizide: 584</p> <p>Glimepiride: 1556</p> <p>Glibenclamide: 24</p> <p>Gliclazide: 494</p> <p><b>Total</b> : <b>5789</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GLP‐1 agonists</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p><b>Total</b> : <b>5 (7)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albiglutide 30‐50 mg: 315</p> <p>Exenatide 17.35 µg: 515</p> <p>Exenatide 20 µg: 57</p> <p>Exenatide 20 µg: 63</p> <p>Liraglutide 0.6 mg: 242</p> <p>Liraglutide 1.2 mg: 241</p> <p>Liraglutide 1.8 mg: 242</p> <p><b>Total</b> : <b>1675</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glimepiride: 317</p> <p>Glimepiride: 514</p> <p>Glimepiride: 54</p> <p>Glibenclamide: 65</p> <p>Glimepiride: 244</p> <p>(Glimepiride: 244)</p> <p>(Glimepiride: 244)</p> <p><b>Total</b> : <b>1194</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SGLT‐2 inhibitors</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p>1</p> <p><b>Total</b> : <b>4 (6)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canagliflozin 100 mg: 483</p> <p>Canagliflozin 300 mg: 485</p> <p>Dapagliflozin 2.5‐10 mg: 406</p> <p>Empagliflozin 25 mg: 769</p> <p>Ertugliflozin 5 mg: 448</p> <p>Ertugliflozin 15 mg: 441</p> <p><b>Total</b> : <b>3032</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glimepiride: 484</p> <p>(Glimepiride: 484)</p> <p>Glipizide: 408</p> <p>Glimepiride: 780</p> <p>Glimepiride: 437</p> <p>(Glimepiride: 437)</p> <p><b>Total</b> : <b>2109</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Glinides</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> <p>1</p> <p>1</p> <p><b>Total</b> : <b>3 (3)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nateglinide 180‐360 mg: 124</p> <p>Nateglinide 180‐540 mg: 133</p> <p>Nateglinide 180‐540 mg: 219</p> <p><b>Total</b> : <b>476</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glibenclamide: 124</p> <p>Gliclazide: 129</p> <p>Glyburide: 209</p> <p><b>Total</b> : <b>462</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metformin monotherapy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> <p>1</p> <p>1</p> <p><b>Total</b> :<b>3 (3)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metformin ≥1500 mg: 104</p> <p>Metformin 1500‐2000 mg: 122</p> <p>Metformin 1000‐3000 mg: 67</p> <p><b>Total</b> : <b>293</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(Glimepiride: 317)</p> <p>(Glimepiride: 244)</p> <p>(Glimepiride: 66)</p> <p>(Total: 627)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Total number of unique included trials was 32 with 41 trial arms.<br/> <sup>b</sup>Numbers of randomised participants for metformin combination therapy do not add up correctly because several trials had one intervention with several comparator groups, the intervention group may therefore appear in several drug classes and is characterised by parentheses; combination therapy data for metformin monotherapy are shown for illustrative purposes. </p> <p><b>DPP4‐I</b> : dipeptidyl‐peptidase 4; <b>GLP‐1</b> : glucagon‐like peptide‐1 agonist; <b>SGLT‐2</b>: sodium‐glucose transport 2 </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Overview of trials (trial arms), comparators, intervention and number of randomised participants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/full#CD012368-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012368-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Overview of HbA1c and hypoglycaemia across comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Better HbA1c for M+S</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Better HbA1c for comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Less hypoglycaemia for M+S</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Less hypoglycaemia for comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>M+S vs metformin + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b>: mild or moderate episodes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>M+S vs metformin + GLP‐1 agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b>: mild or moderate episodes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>M+S vs metformin + DPP‐4 inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b>: mild or moderate and serious episodes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>M+S vs metformin + thiazolidinedione</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b>: mild or moderate and serious episodes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>M+S vs metformin + glinide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b>: mild or moderate episodes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>M+S vs metformin + SGLT‐2 inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yes</b>: mild or moderate and serious episodes </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><b>DPP4‐I</b> : dipeptidyl‐peptidase 4; <b>GLP‐1</b> : glucagon‐like peptide‐1 agonist; <b>HbA1c</b> : glycosylated haemoglobin A1c; <b>M+S</b> : metformin + sulphonylurea; <b>SGLT‐2</b>: sodium‐glucose transport 2 </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Overview of HbA1c and hypoglycaemia across comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/full#CD012368-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012368-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Metformin plus sulphonylurea vs metformin plus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>771</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.59, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>771</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.08, 5.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>771</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.96, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mild/moderate hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>771</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.93 [0.71, 21.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Serious hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.37 [1.35, 5.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Change in HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐1.07, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Metformin plus sulphonylurea vs metformin plus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012368-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.49, 2.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.73, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.12, 2.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.10, 2.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 End‐stage renal disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mild/moderate hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.24 [2.05, 5.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Serious hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.16, 6.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Weight (change) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.54 [3.62, 7.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Change in HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.15, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Metformin plus sulphonylurea vs metformin plus GLP‐1 analogue</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012368-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11694</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.76, 2.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.72, 2.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.14, 7.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11694</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.97, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.97, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.61, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.63, 3.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6810</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.63, 3.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.69, 3.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6810</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.69, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10691</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.47, 2.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.33, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>782</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.00 [0.73, 49.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Non‐fatal stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5093</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [0.74, 6.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5029</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [0.74, 6.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [1.03, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6810</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.04, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>782</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.82, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mild/moderate hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.42 [4.77, 11.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9051</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.67 [4.32, 10.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>39.09 [7.69, 198.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Serious hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10691</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.04 [3.31, 19.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9051</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.66 [3.10, 24.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.46 [1.10, 37.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [1.71, 2.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [1.71, 2.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.27, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Change in HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.13, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.14, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.25, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Fasting plasma glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 BMI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Metformin plus sulphonylurea vs metformin plus DPP‐4 inhibitor</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012368-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mild/moderate hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Serious hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Change in HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Metformin plus sulphonylurea vs metformin plus long‐acting DPP‐4 inhibitor</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012368-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Metformin plus sulphonylurea vs metformin plus thiazolidinedione</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.85, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.86, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.42, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.93, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.81, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.83, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.36, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.30, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.14, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.68, 2.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.93 [0.12, 71.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.66, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.43, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.41, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.31, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Non‐fatal stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.67, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.67, 2.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Amputation of lower extremity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Blindness or severe vision loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 End‐stage renal disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6024</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.44, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.92, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.82, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mild/moderate hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6059</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.63 [2.98, 4.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.76 [2.81, 5.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.78 [1.93, 11.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Serious hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.98 [0.34, 46.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.37, 3.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>24.68 [3.34, 182.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Weight (change) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6877</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐2.75, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2865</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.96 [‐4.77, 2.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐1.36, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Change in HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.04, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Rosiglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.02, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4080</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.04, 0.34]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Metformin plus sulphonylurea vs metformin plus thiazolidinedione</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012368-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.85, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.85, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.14, 6.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.93, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.93, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.32, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.36, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.38, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.68, 2.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.66, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.93 [0.12, 71.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.43, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.43, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.06, 15.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Non‐fatal stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6024</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.44, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.39, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.48, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mild/moderate hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6059</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.63 [2.98, 4.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.73 [2.95, 4.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.39, 10.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Serious hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.98 [0.34, 46.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.61 [0.14, 149.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.93 [0.12, 71.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6877</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐2.75, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.49 [‐4.79, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐2.15, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Change in HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.04, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Trials with long duration (≥ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5896</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.04, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Trials with short duration (&lt; 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.02, 0.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Metformin plus sulphonylurea vs metformin plus thiazolidinedione (subgroups duration of intervention)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012368-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Metformin plus sulphonylurea vs metformin plus glinide</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.54, 5.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mild/moderate hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serious hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [‐0.06, 2.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change in HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [‐0.64, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Metformin plus sulphonylurea vs metformin plus glinide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012368-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.44, 2.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.76, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.33, 4.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.49, 4.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3809</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.21 [1.26, 67.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Non‐fatal stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.22, 3.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Amputation of lower extremity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3809</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.01, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mild/moderate hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.60 [2.38, 13.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Serious hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.16 [2.92, 12.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.41 [4.05, 4.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Change in HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.07, 0.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Metformin plus sulphonylurea vs metformin plus SGLT‐2 inhibitor</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012368.pub2/references#CD012368-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012368.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012368-note-0013">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012368-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012368-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012368-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD012368-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012368-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012368-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012368\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012368\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012368\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012368\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012368\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012368\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012368\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012368\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012368\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012368\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012368\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012368\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012368\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012368\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012368\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012368\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012368\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012368\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012368.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012368.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012368.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012368.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012368.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729484847"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012368.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729484851"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012368.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eddf72a55bd65',t:'MTc0MDcyOTQ4NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 